Antibodies that bind to C1S and uses thereof

Abstract

Embodiments provided herein relate to antibodies and compositions that bind to C1s, as well as methods of producing the disclosed antibodies and uses of the provided antibodies and compositions for treating C1s-mediated diseases and disorders.

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Application No. 63 / 590,980, filed October 17, 2023, U.S. Provisional Application No. 63 / 501,807, filed May 12, 2023, U.S. Provisional Application No. 63 / 485,765, filed February 17, 2023, and U.S. Provisional Application No. 63 / 384,537, filed November 21, 2022, each of which is incorporated by reference herein in its entirety.

[0002] Electronic Sequence Listing Reference This application contains a Sequence Listing that has been submitted electronically in XML format and is incorporated herein by reference in its entirety. The Sequence Listing is titled "DIN002WOsequencelisting.xml", was created on November 17, 2023, and is 495,158 bytes in size.

[0003] The field of the invention is immunology, in particular therapeutic antibodies and the treatment of diseases with such antibodies. [Background technology]

[0004] The complement system is a well-known effector mechanism of the innate immune response, providing protection against pathogens and other harmful agents as well as recovery from injury. Complement activation by autoantibodies and alloantibodies can cause damage to normal cells or rejection of transplanted tissue. The complement pathway is composed of numerous proteins typically present in the body in an inactive form. Complement consists of the alternative, classical, and lectin pathways and is important for immune defense. The classical complement pathway is triggered by activation of the first component of complement, called the C1 complex, which consists of the C1q, C1r, and C1s proteins. Upon binding of C1 to immune complexes or other activators, the C1s component, a diisopropylfluorophosphate (DFP)-sensitive serine protease, cleaves complement components C4 and C2 to initiate activation of the classical complement pathway. Binding of C1 to the antigen-antibody complex involves cleaving the proenzyme C1s to activate the C1s enzyme and ultimately triggering the formation of the pore-forming membrane attack complex (MAC), which is involved in the destruction of neuromuscular junctions. The classical complement pathway appears to play a role in many diseases and disorders.

[0005] For example, stimulimab (TNT009), sold as EnJaymo®, is an antibody that inhibits C1s to treat hemolysis in adults with cold agglutination disease.

[0006] However, stimulimab binds to both the active form of C1s and the inactive zymogen proC1s, and due to the lack of specificity of stimulimab for either form of C1s, very high doses of stimulimab must be administered to overcome circulating levels of proC1s, which may limit the clinical use of stimulimab.

[0007] Myasthenia gravis (MG) is a rare, chronic autoimmune disease caused by autoantibodies targeting proteins at the neuromuscular junction, resulting in impaired neurotransmission and muscle fatigue and weakness. The most common autoantibodies in myasthenia gravis are proposed to induce pathology through three distinct mechanisms, including targeting nicotinic acetylcholine receptors (AChRs) and activating the complement system. Treatments for MG lack efficacy.

[0008] Thus, there is a need in the art for compounds that treat complement classical pathway-mediated diseases or disorders that have specificity for activated forms of complement proteins. The embodiments provided herein meet these needs, as well as others. Summary of the Invention

[0009] In some embodiments, an antibody or antigen-binding fragment thereof that binds to the activated form of C1s is provided. In some embodiments, an antibody or antigen-binding fragment thereof that specifically binds to the activated form of C1s is provided. In some embodiments, the antibody or antigen-binding fragment thereof is as provided herein.

[0010] In some embodiments, variants of antibodies or antigen-binding fragments thereof are provided, wherein the variants have between 1 and 10 substitutions, deletions, or insertions.

[0011] In some embodiments, variants of antibodies or antigen-binding fragments thereof are provided, wherein the variants have between 1 and 10 conservative substitutions.

[0012] In some embodiments, a recombinant antibody or antigen-binding fragment thereof is provided, wherein the recombinant antibody or antigen-binding fragment thereof binds to C1s. In some embodiments, the recombinant antibody or antigen-binding fragment thereof is an antibody or antigen-binding fragment thereof described herein.

[0013] In some embodiments, an isolated nucleic acid molecule is provided. In some embodiments, the isolated nucleic acid molecule encodes an antibody or antigen-binding fragment thereof, a heavy chain variable region, a light chain variable region, a heavy chain, a light chain, or a combination thereof. In some embodiments, the antibody or antigen-binding fragment thereof, the heavy chain variable region, the light chain variable region, the heavy chain, or the light chain is as provided herein.

[0014] In some embodiments, an expression vector is provided. In some embodiments, the expression vector comprises a nucleic acid molecule as provided herein.

[0015] In some embodiments, a host cell is provided. In some embodiments, the host cell comprises a nucleic acid molecule or an expression vector as provided herein. In some embodiments, the host cell comprises a nucleic acid molecule as provided herein. In some embodiments, the host cell comprises an expression vector as provided herein.

[0016] In some embodiments, an antibody or antigen-binding fragment thereof is provided, wherein the antibody or antigen-binding fragment thereof is produced by a host cell.

[0017] In some embodiments, a pharmaceutical composition is provided. In some embodiments, the pharmaceutical composition comprises an antibody or antigen-binding fragment thereof as provided herein.

[0018] In some embodiments, methods for producing a polypeptide comprising a heavy chain variable region or a light chain variable region are provided. In some embodiments, the method includes (a) growing a host cell provided herein under conditions such that the host cell expresses a polypeptide comprising the heavy chain variable region or the light chain variable region, and (b) purifying the polypeptide comprising the heavy chain variable region or the light chain variable region. In some embodiments, the heavy chain variable region is as provided herein. In some embodiments, the light chain variable region is as provided herein.

[0019] In some embodiments, methods for producing an antibody or an antigen-binding fragment of the antibody are provided. In some embodiments, the antibody or antigen-binding fragment thereof binds to human C1s. In some embodiments, the method includes (a) growing a host cell provided herein under conditions wherein the host cell expresses one or more polypeptides comprising an immunoglobulin heavy chain variable region and / or an immunoglobulin light chain variable region, thereby producing the antibody or antigen-binding fragment of the antibody, and (b) purifying the antibody or antigen-binding fragment of the antibody.

[0020] In some embodiments, methods are provided for treating a subject having a C1s-mediated disorder, hi some embodiments, the methods comprise administering to the subject an antibody or antigen-binding fragment thereof as provided herein, or a pharmaceutical composition as provided herein.

[0021] In some embodiments, an antibody or antigen-binding fragment thereof, or a pharmaceutical composition is provided, wherein the antibody or antigen-binding fragment thereof, or pharmaceutical composition is used in the treatment of a C1s-mediated disorder. In some embodiments, the antibody or antigen-binding fragment thereof is as provided herein. In some embodiments, the pharmaceutical composition is as provided herein. In some embodiments, the C1s-mediated disorder is as provided herein. In some embodiments, the C1s-mediated disorder is hemolysis, cold agglutinin disease, immune thrombocytopenia (ITP), myasthenia gravis, glomerulopathy, atypical hemolytic uremic syndrome, antiphospholipid syndrome, graft rejection, chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN), dermatomyositis, or anti-MAG neuropathy. In some embodiments, the condition may be caused by stroke or spinal cord injury.

[0022] In some embodiments, an antibody or antigen-binding fragment thereof, or a pharmaceutical composition is provided, wherein the antibody or antigen-binding fragment thereof, or the pharmaceutical composition is used as a medicament. In some embodiments, the antibody or antigen-binding fragment thereof is as provided herein. In some embodiments, the pharmaceutical composition is as provided herein.

[0023] In some embodiments, there is provided a use of an antibody or antigen-binding fragment thereof, or a pharmaceutical composition, wherein the use is for treating a C1s-mediated disorder. In some embodiments, the antibody or antigen-binding fragment thereof is as provided herein. In some embodiments, the pharmaceutical composition is as provided herein. In some embodiments, the C1s-mediated disorder is as provided herein. [Brief explanation of the drawings]

[0024] [Figure 1] The amino acid sequence of hProC1s RQ is shown, where the underlined portion indicates the expressed protein secretion signal sequence (first 19 amino acids), the bolded portion indicates the sequence in which arginine 437 is changed to glutamine, and the italicized region indicates the spacer and 10 histidine residues used for protein purification (last 19 amino acids). [Figure 2A] Figure 1 shows binding of hProC1s RQ and human C1s to antibodies disclosed herein. Figure 2 shows binding to antibody 4011g and derivatives. [Figure 2B] Figure 1 shows binding of hProC1s RQ and human C1s to antibodies disclosed herein. Figure 2 shows binding to antibody 5L3g and derivatives. [Figure 2C] Figure 1 shows binding of hProC1s RQ and human C1s to antibodies disclosed herein. Figure 2 shows binding to antibody 191g and derivatives. [Figure 3] As disclosed herein, shows inhibition of the Wieslab classical complement pathway assay in 1% human serum by antibodies IgG4-MAB17, IgG4-MAB4, and IgG4-MAB9. [Figure 4A] 1 shows antibody-mediated inhibition of complement-mediated hRBC lysis in 25% human serum by antibodies IgG4-MAB17, IgG4-MAB4, and IgG4-MAB9 described herein. [Figure 4B] 1 shows antibody-mediated inhibition of complement-mediated hRBC lysis in 25% human serum by antibodies 191g, MAB4, and MAB9 described herein. [Figure 4C] 1 shows antibody-mediated inhibition of complement-mediated hRBC lysis in 25% human serum by antibodies MAB2 (US20220380483A1) and MAB9 described herein. [Figure 5] As disclosed herein, antibody-mediated inhibition of C3b deposition on hRBCs by antibodies IgG4-MAB17, IgG4-MAB4, and IgG4-MAB9 is shown. [Figure 6] 1 shows the mean antibody concentrations following a single IV dose of 3 or 30 mg / kg body weight (mpk) of antibodies IgG4-MAB17, IgG4-MAB4, and IgG4-MAB9 over time in cynomolgus monkeys, as disclosed herein. [Figure 7] The concentration of IgG4-MAB39 in serum diluted by the dilution factor required to obtain 50% lysate of infected sheep RBCs (CH50) is shown. Serum was obtained from cynomolgus monkeys treated with a single subcutaneous dose of 20 mg / kg body weight (mpk) of IgG4-MAB39. The concentration of IgG4-MAB39 in CH50 was monitored over time for up to 30 days. [Figure 8]We demonstrate the effect of complement classical pathway inhibition with IgG4-MAB39 on neuromuscular junction function using a preclinical cell-based model of myasthenia gravis. Human induced pluripotent stem cell (iPSC)-derived motor neurons and skeletal muscle cells were cocultured in a two-chambered microfluidic device with neurons in one chamber and muscle cells in the second. Serum (10% concentration) from AChR+ MG patients (n=3) supplemented with complement-preserved pooled normal human serum (1%) was added to the skeletal muscle cell reservoir in the absence or presence of IgG4-MAB39 or the anti-C5 antibody regenerated ravulizumab (from a published patent). The motor neuron chamber received a 2 Hz electrical stimulus for 2 minutes, and skeletal muscle contraction was monitored in real time. The muscle contraction fatigue index score was calculated based on the area under the curve (AUC) of the region of interest (ROI) divided by the tetanic response from that muscle (maximum ROI trace height x duration of simulation). IgG4-MAB39 reduced muscle contraction fatigue index scores in serum from AChR+MG patients, indicating improved neurotransmission, neuromuscular junction functionality, and muscle contraction. The response profile of IgG-MAB39 was similar to that of the anti-C5 antibody recombinant ravulizumab. IgG4-MAB39 improved impaired neurotransmission in a physiologically relevant in vitro model of AChR+MG. This finding provides a scientific rationale for targeting the classical complement pathway in AChR+MG. [Figure 9] 1 shows dose-dependent complete inhibition of the classical pathway using MAB39 and its preclinical precursor MAB9 in the Wieslab assay. [Figure 10] Shows dose-dependent complete inhibition of the classical pathway using MAB39 and its preclinical precursor MAB9 in an antibody-sensitive sheep erythrocyte lysis assay. [Figure 11] Figure 1 shows bacterial survival (%) of Neisseria meningitidis in complement-containing serum and anti-capsule antibody with heat inactivation, anti-C7 antibody, ravulizumab, or MAB39. DETAILED DESCRIPTION OF THE INVENTION

[0025] Provided herein are binding proteins, e.g., antibodies or fragments thereof, that selectively bind to C1s and have reduced binding to the zymogen proC1s. In some embodiments, the antibodies inhibit activation of the classical complement pathway and can be used in methods for treating complement-mediated disorders, including, but not limited to, those provided herein. In some embodiments, the selectivity of C1s over proC1s can be used to reduce or prevent target-mediated clearance of therapeutic antibodies, thus requiring lower doses and less frequent administration of the antibody.

[0026] Before describing the present compositions and methods, it is understood that the scope of this invention is not limited to the particular processes, compositions, or methodologies described herein, as these may vary. It is also understood that the terminology used herein is for the purpose of describing particular versions or embodiments, and is not intended to limit the scope of the invention. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the methods or systems described herein, the preferred methods, devices, and materials are described herein.

[0027] The following explanations of terms and methods are provided to better describe the present disclosure and to guide those of ordinary skill in the art in the practice of the present disclosure.

[0028] One of skill in the art, given the amino acid sequence of a variable region of a binding molecule (e.g., an antibody) described herein, can determine the CDR sequences therein by these rules or any other rules used to define CDRs, such as IMGT, Kabat, Chothia, or Contact, and web-based tools are available for determining CDRs within such variable regions based on any well-known rules. Such tools include those found at www.abysis.org / abysis / sequence_input / key_annotation / key_annotation.cgi and www.novoprolabs.com / tools / cdr.

[0029] Thus, the disclosure herein of a set of three CDRs of a heavy or light chain variable region based on one CDR rule is considered to correspond to the same set of CDRs determined by other rules, which may be referred to as "conventional equivalents" or "conventional equivalent CDRs."

[0030] As used herein, "comprising" means "including," and the singular forms "a," "an," or "the" include plural references unless the context clearly dictates otherwise. For example, a reference to "comprising a therapeutic agent" includes one or more such therapeutic agents. The term "or" refers to a single element of the alternative elements described, unless the context clearly dictates otherwise. For example, the phrase "A or B" refers to A alone or B alone. The phrase "A, B, or a combination thereof" refers to A alone, B alone, or a combination of A and B. Similarly, "one or more of A and B" refers to a combination of A, B, or both A and B. The phrase "A and B" refers to a combination of A and B. Furthermore, the various elements, features, and steps described herein, as well as other known equivalents of such elements, features, or steps, can be mixed and matched by those skilled in the art to perform methods in accordance with the principles described herein. Of the various elements, features, and steps, some are specifically included, while others are specifically excluded in certain instances.

[0031] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below. The materials, methods, and examples are illustrative only and are not intended to be limiting. All references cited herein are incorporated by reference in their entirety.

[0032] As used herein, the term "antibody" refers to any form of antibody that exhibits the desired biological activity. It is therefore used in the broadest sense and specifically covers, but is not limited to, monoclonal antibodies (including full-length monoclonal antibodies), polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), humanized antibodies, fully human antibodies, chimeric antibodies, and camelized single-domain antibodies. A "parent antibody" is an antibody obtained by exposing the immune system to an antigen before modifying the antibody for its intended use, such as humanizing an antibody for use as a human therapeutic antibody.

[0033] As used herein, unless otherwise indicated, "antibody fragment" or "antigen-binding fragment" refers to an antigen-binding fragment of an antibody, i.e., an antibody fragment that retains the ability to specifically bind to the antigen bound by the full-length antibody, e.g., a fragment that retains one or more CDR regions. Antibody-binding fragments include, but are not limited to, Fab, Fab', F(ab')2, and Fv fragments, diabodies, linear antibodies, single-chain antibody molecules such as sc-Fv, nanobodies (single-domain antibodies) formed from antibody fragments, and polyclonal antibodies.

[0034] A "Fab fragment" is a fragment of one light chain and one heavy chain C H 1 and variable region. The heavy chain of a Fab molecule cannot form disulfide bonds with another heavy chain molecule.

[0035] The "Fc" region contains the C H 2 and C H The two heavy chain fragments contain two or more disulfide bonds and a C H The three domains are held together by hydrophobic interactions.

[0036] A "Fab' fragment" contains one light chain and one V H Domain and C HA portion or fragment of one heavy chain containing one domain, C H 1 Domain and C H Also included is the region between the two domains, which allows interchain disulfide bond formation between the two heavy chains of the two Fab' fragments to form the F(ab')2 molecule.

[0037] "F(ab')2 fragment" contains C H 1 Domain and C H It contains two light chains and two heavy chains with a portion of the constant region between the two domains, which allows the formation of an interchain disulfide bond between the two heavy chains. Thus, an F(ab')2 fragment is composed of two Fab' fragments held together by disulfide bonds between the two heavy chains.

[0038] The "Fv region" comprises the variable regions from both the heavy and light chains, but lacks the constant regions.

[0039] The term "single chain Fv" or "scFv" antibody refers to the V of an antibody. H Domain and V L Fv refers to an antibody fragment containing V domains, where these domains are present in a single polypeptide chain. Generally, an Fv polypeptide is an antibody fragment containing V domains. H Domains and V L The scFv further comprises a polypeptide linker between the domains that enables the scFv to form the desired structure for antigen binding. For a review of scFvs, see Pluckthun (1994) The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds. Springer-Verlag, New York, pp. 269-315. See also International Patent Application Publication No. WO 88 / 01649 and U.S. Patent Nos. 4,946,778 and 5,260,203.

[0040] A "single domain antibody" is an immunologically functional immunoglobulin fragment that contains only the variable region of a heavy chain or the variable region of a light chain. H The two V domains of a bivalent domain antibody are covalently linked with a peptide linker to form a bivalent domain antibody. H The regions may target the same or different antigens.

[0041] A "bivalent antibody" contains two antigen-binding sites. In some cases, the two binding sites have the same antigen specificity. However, a bivalent antibody can be dual-specific (see below).

[0042] In certain embodiments, the monoclonal antibodies herein also include camelized single domain antibodies (see, e.g., Muyldermans et al. (2001) Trends Biochem. Sci. 26:230; Reichmann et al. (1999) J. Immunol. Methods 231:25; WO 94 / 04678; WO 94 / 25591; U.S. Patent No. 6,005,079). In one embodiment, the present invention provides a method for the synthesis of single domain antibodies by combining two V domains with modifications, such that single domain antibodies are formed. H A single domain antibody comprising a domain is provided.

[0043] As used herein, the term "diabody" refers to a small antibody fragment with two antigen-binding sites, which are separated by a light chain variable domain (V) within the same polypeptide chain. L ) linked to a heavy chain variable domain (V H ) including (V H -V L or V L -V H). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with complementary domains on another chain and generate two antigen-binding sites. Diabodies are more fully described, for example, in EP 404,097, WO 93 / 11161; and Holliger et al. (1993) Proc. Natl. Acad. Sci. USA 90:6444-6448. For a review of engineered antibody variants, see generally Holliger and Hudson (2005) Nat. Biotechnol. 23:1126-1136.

[0044] Typically, a variant antibody or antigen-binding fragment of an antibody provided herein retains at least 10% of its C1s binding activity (when compared to the modified parent antibody) when that activity is expressed on a molar basis. In some embodiments, a variant antibody (or antigen fragment thereof) or antigen-binding fragment of an antibody provided herein retains at least 20%, 50%, 70%, 80%, 90%, 95%, or 100% or more of the C1s binding affinity of the parent antibody. As described herein, the antibodies or antigen-binding fragments of the invention are also intended to include conservative or non-conservative amino acid substitutions, which may also be referred to as "conservative variants" or "functionally conservative variants" of the antibody, that do not significantly alter biological activity.

[0045] "Isolated antibody" refers to the purified state of the binding compound, and in that context means that the molecule is substantially free of other biological molecules such as nucleic acids, proteins, lipids, carbohydrates, or other substances such as cellular debris and growth medium. In general, the term "isolated" is not intended to refer to the complete absence of such materials or the absence of water, buffers, or salts, unless they are present in amounts that would substantially interfere with experimental or therapeutic uses of the binding compound as described herein.

[0046] As used herein, the term "monoclonal antibody" refers to a population of substantially homogeneous antibodies, i.e., the antibody molecules comprising the population are identical in amino acid sequence except for possible minor naturally occurring mutations and / or post-translational modifications. In contrast, conventional (polyclonal) antibody preparations typically include a large number of different antibodies with different amino acid sequences in the variable domains, particularly the CDRs, which are always specific for different epitopes. The modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous antibody population and is not to be construed as requiring production of the antibody by any particular method. For example, monoclonal antibodies for use in accordance with the present invention may be produced by the hybridoma method first described by Kohler et al. (1975) Nature 256:495, or may be produced by recombinant DNA methods (see, e.g., U.S. Pat. No. 4,816,567). "Monoclonal antibodies" may also be isolated from phage antibody libraries using the techniques described in Clackson et al. (1991) Nature 352:624-628 and Marks et al. (1991) J. Mol. Biol. 222:581-597. See also Presta (2005) J. Allergy Clin. Immunol. 116:731.

[0047] As used herein, a "chimeric antibody" is an antibody having variable domains from a first antibody and constant domains from a second antibody, where the first and second antibodies are of different species. (U.S. Patent No. 4,816,567, and Morrison et al., (1984) Proc. Natl. Acad. Sci. USA 81:6851-6855.) Typically, the variable domains are derived from an antibody from an experimental animal such as a rodent (the "parent antibody"), and the constant domain sequences are derived from a human antibody, making the resulting chimeric antibody less likely to elicit an adverse immune response in a human subject than the parent (e.g., rodent) antibody.

[0048] As used herein, the term "humanized antibody" refers to forms of antibodies that contain sequences from both human and non-human (e.g., mouse, rat) antibodies. Generally, humanized antibodies will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the framework (FR) regions are those of a human immunoglobulin. A humanized antibody may optionally comprise at least a portion of a human immunoglobulin constant region (Fc).

[0049] The term "fully human antibody" refers to an antibody that contains only human immunoglobulin protein sequences. A fully human antibody may contain mouse carbohydrate chains if produced in a mouse, a mouse cell, or a hybridoma derived from a mouse cell. Similarly, a "mouse antibody" refers to an antibody that contains only mouse immunoglobulin sequences. Alternatively, a fully human antibody may contain rat carbohydrate chains if produced in a rat, a rat cell, or a hybridoma derived from a rat cell. Similarly, a "rat antibody" refers to an antibody that contains only rat immunoglobulin sequences.

[0050] In some embodiments, a basic antibody structural unit comprises a tetramer. Each tetramer is composed of two identical pairs of polypeptide chains, each pair comprising one "light" chain (approximately 25 kDa) and one "heavy" chain (approximately 50-70 kDa). The amino-terminal portion of each chain comprises a variable region of approximately 100-110 or more amino acids primarily responsible for antigen recognition. The carboxy-terminal portion of each heavy chain may define a constant region primarily responsible for effector function. Human light chains are typically classified as kappa and lambda light chains. Heavy chains are further classified as mu, delta, gamma, alpha, or epsilon, defining the antibody isotype as IgM, IgD, IgG, IgA, and IgE, respectively. Within the light and heavy chains, the variable and constant regions are connected by a "J" region of approximately 12 or more amino acids, and heavy chains also include a "D" region of approximately 10 or more amino acids. See generally, Fundamental Immunology Ch. 7 (Paul, W., ed., 2nd ed. Raven Press, NY (1989)).

[0051] The variable regions of each light / heavy chain pair form the antibody binding site. Thus, an intact antibody generally has two binding sites. However, in bifunctional or bispecific antibodies, the two binding sites are generally not the same.

[0052] Typically, both heavy and light chain variable domains contain three hypervariable regions, also called complementarity-determining regions (CDRs), located within relatively conserved framework regions (FRs). The CDRs are usually aligned by the framework regions, enabling binding to a specific epitope. Generally, from N- to C-terminus, both light and heavy chain variable domains contain FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The assignment of amino acids to each domain is generally based on the information in Sequences of Proteins of Immunological Interest, Kabat, et al.; National Institutes of Health, Bethesda, Md.; 5 thPerformed according to Ed.; NIH Publ. No. 91-3242 (1991); Kabat (1978) Adv. Prot. Chem. 32: 1-75; Kabat, et al., (1977) J. Biol. Chem. 252: 6609-6616; Chothia, et al., (1987) J Mol. Biol. 196: 901-917 or Chothia, et al., (1989) Nature 342: 878-883.

[0053] As used herein, the term "hypervariable region" refers to the amino acid residues of an antibody responsible for antigen binding. The hypervariable region comprises amino acid residues from the "complementarity determining regions" or "CDRs" (i.e., residues 24-34 (CDRL1), 50-56 (CDRL2), and 89-97 (CDRL3) from the light chain variable domain, and residues 31-35 (CDRH1), 50-65 (CDRH2), and 95-102 (CDRH3) from the heavy chain variable domain; see Kabat et al. (1991) Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md.) and / or those residues from the "hypervariable loops" (i.e., residues 26-32 (CDRL1), 50-52 (CDRL2), and 91-96 (CDRL3) in the light chain variable domain, and residues 26-32 (CDRH1), 53-55 (CDRH2), and 96-101 (CDRH3) in the heavy chain variable domain; Chothia and Lesk (1987) J. Mol. Biol. 196:901-917). CDRs may also be referred to according to the IMGT system for identifying CDRs as described in Lefranc MP. Unique database numbering system for immunogenetic analysis. Immunol Today (1997) 18:509. As used herein, the term "framework" or "FR" residues refers to variable domain residues other than the hypervariable region residues defined herein as CDRs. The CDRs provide the majority of contact residues for the binding of an antibody to an antigen or epitope. The CDRs of interest are derived from donor antibody variable heavy and light chain sequences and can include analogs of the native CDRs, which analogs share or retain the same antigen-binding specificity and / or neutralizing ability as the donor antibody from which they are derived.

[0054] As used herein, "specific binding" or "immunospecific binding" or "immunospecifically binds" refers to an antibody binding to a given antigen with much higher affinity than to another antigen(s) (e.g., selectively binding to the activated form of complement component C1s compared to inactive C1s, which can also be referred to as proC1s zymogen). In some embodiments, the antibody binds to a given antigen with much higher affinity than another antigen(s) (e.g., selectively binding to the activated form of complement component C1s compared to inactive C1s, which can also be referred to as proC1s zymogen). -7 The dissociation constant (K D ) binds a given antigen, and such K D is the K for binding to a nonspecific antigen (e.g., BSA, casein, or another nonspecific polypeptide). D is at least twice as large as

[0055] The phrases "antibody recognizing C1s" and "antibody specific for C1s" are used herein interchangeably with the term "antibody that immunospecifically binds to C1s." In some embodiments, the antibody specifically or preferentially binds to C1s, such as the activated form of C1s, over other proteins, such as, but not limited to, the inactivated form of C1s (proC1s). The degree of specificity required for an anti-C1s antibody may depend on the intended use of the antibody and, in any event, is defined by its suitability for use for its intended purpose. In some embodiments, the antibody or binding compound derived from the antigen-binding site of the antibody of the contemplated methods binds to its antigen (the activated form of C1s) with an affinity at least 2-fold greater, at least 10-fold greater, at least 20-fold greater, or at least 100-fold greater than its affinity to any other antigen, including, but not limited to, inactive C1s.

[0056] Methods for determining mAb specificity and affinity by competitive inhibition are described in Harlow, et al., Antibodies: A Laboratory Manual (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1988), Colligan et al., eds., Current Protocols in Immunology, Greene Publishing Assoc. and Wiley Interscience, NY, (1992, 1993), and Muller, Meth. Enzymol. 92:589 601 (1983), which are incorporated herein by reference in their entireties.

[0057] The term "homolog" refers to a protein sequence having 40% to 100% sequence identity to a reference sequence. The percent identity between two peptide chains can be determined by pairwise alignment using the default settings of the AlignX module in Vector NTI v.9.0.0 (Invitrogen Corp., Carlsbad, CA) or other suitable alignment software, such as BLAST. In some embodiments, the antibody or antigen-binding fragment thereof has at least 50, 60, 70, 80, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99% homology or identity to a sequence described herein. In some embodiments, the antibody has conservative substitutions compared to the sequences described herein. Exemplary conservative substitutions are shown in Table 1 and are within the scope of the disclosed subject matter. Conservative substitutions may be present in the framework region or antigen-binding site, as long as they do not adversely affect the properties of the antibody. Substitutions may be made to improve antibody properties, such as stability and affinity. Conservative substitutions produce molecules with functional and chemical properties similar to those molecules to which such modifications are made. Exemplary amino acid substitutions are shown in the table below. [Table 1]

[0058] In some embodiments, variants of the proteins and peptides provided herein are provided. In some embodiments, the variants comprise substitutions, deletions, or insertions. In some embodiments, the variants comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 (e.g., 1-10) substituents. As described herein, the substituents can include conservative substituents. In some embodiments, the substituents are non-conservative. In some embodiments, the variants comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 (e.g., 1-10) substituents. In some embodiments, the variants comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 (e.g., 1-10) substituents. In some embodiments, the variants comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 (e.g., 1-10) substituents. In some embodiments, the substitutions, deletions, or insertions are present in the CDRs provided herein. In some embodiments, the substitutions, deletions, or insertions are absent from the CDRs provided herein.

[0059] The term "combination" as used herein means that the described agents can be administered together to an animal or subject in an admixture either simultaneously as a single agent or sequentially as a single agent in any order.

[0060] The term "epitope" is meant to refer to that portion of any molecule that can be recognized and bound by an antibody at one or more of the antigen-binding regions of the Ab. Epitopes generally consist of chemically active surface groupings of molecules, such as amino acids or sugar side chains, and have specific three-dimensional structural characteristics as well as specific charge characteristics.

[0061] An "expression vector" refers to a vector containing a recombinant polynucleotide comprising an expression control sequence operably linked to a nucleotide sequence to be expressed. An expression vector contains sufficient cis-acting elements for expression; other elements for expression can be supplied by the host cell or in an in vitro expression system. Expression vectors include all those known in the art, such as cosmids, plasmids (e.g., naked or contained in liposomes), and viruses (e.g., Sendai virus, lentivirus, retrovirus, adenovirus, and adeno-associated virus) that incorporate the recombinant polynucleotide.

[0062] In some embodiments, the antibody is a monoclonal antibody that binds to C1s. The sequence of active C1s is as follows (SEQ ID NO:258): residues 1-15 (SEQ ID NO:259) make up the signal peptide that is cleaved during translation, and residues 16-688 (SEQ ID NO:260) make up the mature protein, as shown below: (SEQ ID NO: 258), MWCIVLFSLLAWVYA (SEQ ID NO: 259), (SEQ ID NO: 260).

[0063] The difference between inactive C1s and active C1s is that inactive proC1s is cleaved at the peptide bond between R437 and I438 and undergoes a conformational change. The two fragments generated by this cleavage remain associated by a disulfide bond. Without wishing to be bound by any particular theory, proC1s is a single-chain 86,000 Da protein that is the native form of the C1s protein (e.g., a serine protease). C1s is a subunit of the C1 complex, the first complement component in the cascade known as the classical pathway of complement. ProC1s is an inactive zymogen until C1 is activated. The C1 complex binds to and is activated by an antigen-antibody complex (immune complex), which generates the C1r enzyme. The C1r enzyme in the C1 complex activates proC1s, generating the C1s enzyme. The C1 complex is a noncovalent, calcium-dependent complex of one C1q, two C1r, and two C1s molecules. C1q binds to the Fc domain of IgG or IgM through two or more of its six arms. Upon binding of multiple arms to an immune complex, two C1r proteins in the complex actively generate two proteases that cleave and activate two proC1s in the complex (Morikis, D. and Lambris, JD (2005)). This activation of proC1s is triggered by cleavage into two C1s enzyme chains with 58,000 and 28,000 dalton fragments.

[0064] In some embodiments, the antibodies provided herein do not inhibit or do not significantly inhibit the proteolytic cleavage of non-complement substrates. Examples of non-complement substrates include, but are not limited to, collagen, HMC I, HMGB1, IGFBP5, LRP6, NCL, and NPM1. Without being bound by any theory, such substrates are important in cleavage of antigens on apoptotic cells or hemostasis of bone, muscle, and connective tissue. Thus, antibodies that do not inhibit or do not significantly inhibit the proteolytic cleavage of non-complement substrates, such as those provided herein, may allow the antibody to be utilized with fewer side effects or at higher doses. In some embodiments, the non-complement substrate is collagen. In some embodiments, the non-complement substrate is HMC I. In some embodiments, the non-complement substrate is HMGB1. In some embodiments, the non-complement substrate is IGFBP5. In some embodiments, the non-complement substrate is LRP6. In some embodiments, the non-complement substrate is NCL. In some embodiments, the non-complement substrate is NPM1.

[0065] In some embodiments, the antibody comprises an Fc domain. The Fc domain can be linked to the heavy or light chain of the antibody. In some embodiments, the Fc domain comprises a mutation to extend the half-life of the antibody. In some embodiments, the Fc domain comprises a mutation as described in U.S. Pat. No. 7,670,600, which is incorporated by reference in its entirety. In some embodiments, the constant region comprises a mutation at amino acid residue 428 relative to a wild-type human IgG constant domain numbered according to the EU numbering index of Kabat ("EU numbering"). Without being bound by theory, antibodies comprising a mutation corresponding to residue 428 can have an increased half-life compared to the half-life of an IgG having a wild-type human IgG constant domain. In some embodiments, the mutation is a substitution of the native residue with threonine, leucine, phenylalanine, or serine. In some embodiments, the antibody further comprises one or more amino acid substitutions relative to the corresponding wild-type human IgG constant domain at one or more of amino acid residues 251-256, 285-290, 308-314, 385-389, and 429-436, numbered according to the Kabat EU numbering index. Particular mutations or substitutions at these positions are described in U.S. Patent No. 7,670,600, which is incorporated by reference in its entirety.

[0066] Other variants can be used in the Fc domain, such as those provided in U.S. Patent No. 8,394,925, which is incorporated by reference in its entirety. In some embodiments, the Fc region is a variant Fc region comprising amino acid substitutions at positions 428 and 434, where the amino acid substitutions are a non-wild-type leucine at position 428 and a non-wild-type serine at position 434, and the polypeptide is an antibody, where the numbering is according to the EU index of Kabat et al. In some embodiments, the Fc region comprises an S228P, L235E, M428L, or N434S substituent. In some embodiments, the Fc region comprises an M428L substituent. In some embodiments, the Fc region comprises an N434S substituent. In some embodiments, the Fc region comprises an M428L and an N434S substituent (EU numbering), which can be collectively referred to as an "LS variant" or "LS." In some embodiments, the Fc region comprises M252Y, S254T, and / or T256E substituents (EU numbering). In some embodiments, the Fc region comprises M252Y, S254T, and T256E substituents. When all three M252Y, S254T, and T256E variants are present in an Fc region, it can be referred to as "YTE" or a "YTE variant."

[0067] In some embodiments, the antibody comprises the constant region set forth below, with or without the mutations set forth in the list below: >IgG4 S228P L235E LS ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVLHEALHSHYTQKSLSLSLGK (SEQ ID NO: 261), >IgG4 S228P L235E YTE ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK (SEQ ID NO: 262).

[0068] In some embodiments, the antibody comprises a constant region described herein, wherein the C-terminal lysine (K) amino acid is deleted. In some embodiments, the antibody comprises the constant region shown below: >IgG4 S228P L235E LS-trunc ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVLHEALHSHYTQKSLSLSLG (SEQ ID NO: 263), >IgG4 S228P L235E YTE-trunc ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFEGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG (SEQ ID NO: 264).

[0069] In some embodiments, the antibody, such as the light chain, comprises a kappa constant region, such as a human constant domain, and may comprise the following sequence: RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (human kappa constant region, SEQ ID NO: 265).

[0070] As used herein, unless otherwise indicated, the term "about" is intended to mean ±5% of the value it modifies. Thus, about 100 means 95 to 105.

[0071] In some embodiments, the antibodies described herein are used to detect the presence of an antigen. The present antibodies can be used in any device or method to detect the presence of an antigen. In some embodiments, the antibodies are used to detect the activated form of C1s. In some embodiments, the antibodies are used to detect the activated form of C1s preferentially (specifically) over the inactivated form.

[0072] The term "purified" when referring to an antibody refers to an antibody that is substantially free of other materials associated with the molecule in its natural environment. For example, a purified protein is substantially free of cellular material or other proteins from the cell or tissue from which it is derived. The term refers to preparations where the isolated protein is sufficiently pure for analysis, or is at least 70%-80% (w / w) pure, at least 80%-90% (w / w) pure, 90-95% pure, and at least 95%, 96%, 97%, 98%, 99%, or 100% (w / w) pure. In some embodiments, an antibody is purified.

[0073] antibody conjugates The antibodies provided herein can also be conjugated to a chemical moiety. The chemical moiety can be, among others, a polymer, a radionuclide, or a cytotoxic agent. In some embodiments, this can be referred to as an antibody-drug conjugate. In some embodiments, the chemical moiety is a polymer that increases the half-life of the antibody molecule in the subject's body. Suitable polymers include, but are not limited to, polyethylene glycol (PEG) (e.g., PEG having a molecular weight of 2 kDa, 5 kDa, 10 kDa, 12 kDa, 20 kDa, 30 kDa, or 40 kDa), dextran, and monomethoxypolyethylene glycol (mPEG). Lee, et al., (1999) (Bioconj. Chem. 10:973-981) disclose a PEG-conjugated single-chain antibody. Wen, et al., (2001) (Bioconj. Chem. 12:545-553) disclose a conjugated antibody with PEG attached to a radioactive chelator (diethylenetriaminepentaacetic acid (DTPA)). Chemical moieties include, but are not limited to, antimitotics such as calichamicins (e.g., ozogamicin), monomethyl auristatin E, and mertansine. Other examples include, but are not limited to, biologically active antimicrotubule agents, alkylating agents, and DNA minor groove binding agents. Further examples are provided herein and below. Chemical moieties can be linked to antibodies via linking groups (maleimides), cleavable linkers such as cathepsin-cleavable linkers (valine-citrulline), and in some embodiments, one or more spacers (e.g., para-aminobenzyl carbamates).

[0074] The antibodies and antibody fragments of the invention also comprise: 99 Tc, 90 Y, 111 In, 32 P, 14 C. 125 I, 3 H, 131 I, 11 C. 15 O. 13 N, 18 F, 35 S,51 Cr, 57 To, 226 Ra, 60 Co, 59 Fe, 57 Se, 152 EU, 67 CU, 217 Ci, 211 At, 212 Pb, 47 Sc, 109 Pd, 234 Th, and 40 K. 157 Gd, 55 Mn, 52 Tr and 56 It may be linked with a label such as Fe.

[0075] Antibodies and antibody fragments may also be used in combination with other compounds such as rare earth chelates, fluorescein and its derivatives, rhodamine and its derivatives, isothiocyanates, phycoerythrin, phycocyanin, allophycocyanin, o-phthalaldehyde, fluorescamine, 152 Fluorescent or chemiluminescent labels may be conjugated, including fluorophores such as Eu, dansyl, umbelliferone, luciferin, luminal labels, isoluminal labels, aromatic acridinium ester labels, imidazole labels, acridinium salt labels, oxalate ester labels, aequorin labels, 2,3-dihydrophthalazinedione, biotin / avidin, spin labels, and stable free radicals.

[0076] The antibody molecule may also be conjugated to cytotoxic agents such as diphtheria toxin, Pseudomonas aeruginosa exotoxin A chain, ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleuritesfoldii proteins and compounds (e.g., fatty acids), dianthin proteins, Phytoiacca americana proteins PAPI, PAPII and PAP-S, Momordica charantia inhibitor, curcin, crotin, Saponaria officinalis inhibitor, mitogenin, restrictocin, phenomycin, and neomycin.

[0077] Any of the well-known methods for conjugating the antibody molecules of the present invention to various moieties may be employed, including those described in Hunter, et al., (1962) Nature 144:945, David, et al., (1974) Biochemistry 13:1014, Pain, et al., (1981) J. Immunol. Meth. 40:219, and Nygren, J., (1982) Histochem. and Cytochem. 30:407. Methods for conjugating antibodies are conventional and well known in the art.

[0078] In some embodiments, an antibody (e.g., an anti-C1s antibody) is provided herein. In some embodiments, the antibody is a recombinant antibody that binds to C1s. In some embodiments, the antibody binds to the activated form of C1s. In some embodiments, the antibody preferentially forms the inactive form of C1s. In some embodiments, the antibody binds to the activated form of C1s with at least 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, or 200% greater affinity than the affinity for the inactive form of C1s. In some embodiments, the C1s protein is a human C1s protein, such as an activated form of C1s. In some embodiments, the antibody does not specifically bind to the inactive form of C1s protein. As used herein, the term "recombinant antibody" refers to an antibody that is not naturally occurring. In some embodiments, the term "recombinant antibody" refers to an antibody that is not isolated from a human subject. In some embodiments, the antibody binds to the activated form of C1s with at least 100-fold greater affinity than proC1s.

[0079] In some embodiments, an antibody or antigen-binding fragment thereof is provided, wherein the antibody or antibody fragment comprises a peptide selected from the following table showing the CDRs according to Kabat numbering: [Table 2-1] [Table 2-2] [Table 2-3]

[0080] The CDRs in the table above can also be referenced according to the Chothia CDRs or IMGT CDRs, which are shown in the tables below for various antibodies. [Table 3-1] [Table 3-2] [Table 3-3] [Table 4-1] [Table 4-2] [Table 4-3]

[0081] In some embodiments, the antibody comprises a variable heavy chain comprising an HCDR1 of SEQ ID NO: 128, an HCDR2 of SEQ ID NO: 129, and an HCDR3 of DEQLGGX1X2YYYYYMDX3 (SEQ ID NO: 333), wherein: X1 is N, T, I, Q, L, K, or R; X2 is Y, T, K, H, or V, and X3 is V or A.

[0082] In some embodiments, X1 is N, T, I, Q, L, K, or R, X2 is Y, and X3 is V. In some embodiments, X1 is N, T, I, Q, L, K, or R, X2 is Y, and X3 is A. In some embodiments, X1 is N, T, I, Q, L, K, or R, X2 is T, and X3 is V. In some embodiments, X1 is N, T, I, Q, L, K, or R, X2 is T, and X3 is A. In some embodiments, X1 is N, T, I, Q, L, K, or R, X2 is K, and X3 is V. In some embodiments, X1 is N, T, I, Q, L, K, or R, X2 is K, and X3 is A.

[0083] In some embodiments, X1 is N, T, I, Q, L, K, or R, X2 is H, and X3 is V. In some embodiments, X1 is N, T, I, Q, L, K, or R, X2 is H, and X3 is A. In some embodiments, X1 is N, T, I, Q, L, K, or R, X2 is V, and X3 is V. In some embodiments, X1 is N, T, I, Q, L, K, or R, X2 is V, and X3 is A. In some embodiments, X1 is N, X2 is Y, and X3 is A. In some embodiments, X1 is N, T, I, Q, L, K, or R, X2 is T, and X3 is V. In some embodiments, X1 is N, T, I, Q, L, K, or R, X2 is T, and X3 is A. In some embodiments, X1 is N, T, I, Q, L, K, or R, X2 is K, and X3 is V. In some embodiments, X1 is N, T, I, Q, L, K, or R, X2 is K, and X3 is A.

[0084] In some embodiments, X1 is N, T, I, Q, L, K, or R, X2 is H, and X3 is V. In some embodiments, X1 is N, T, I, Q, L, K, or R, X2 is H, and X3 is A. In some embodiments, X1 is N, T, I, Q, L, K, or R, X2 is V, and X3 is V. In some embodiments, X1 is N, T, I, Q, L, K, or R, X2 is V, and X3 is A. In some embodiments, X1 is not N. In some embodiments, X1 is not T. In some embodiments, X1 is not I. In some embodiments, X1 is not Q. In some embodiments, X1 is not L. In some embodiments, X1 is not K. In some embodiments, X1 is not R.

[0085] In some embodiments, an antibody is provided, the antibody comprising a variable light chain LCDR1 of SEQ ID NO: 106, an LCDR2 of SEQ ID NO: 107, and X4QX5X6X7X8PLX9 (SEQ ID NO: 332), wherein: X4 is L or F; X5 is Y or T; X6 is N, K, A, H, or R; X7 is S, Q, I, or A; X8 is Y, V, or H, and X9 is T, G, K, R, I or A.

[0086] In some embodiments, X4 is L, X5 is Y or T, X6 is N, K, A, H, or R, X7 is S, Q, I, or A, X8 is Y, V, or H, and X9 is T, G, K, R, I, or A. In some embodiments, X4 is F, X5 is Y or T, X6 is N, K, A, H, or R, X7 is S, Q, I, or A, X8 is Y, V, or H, and X9 is T, G, K, R, I, or A. In some embodiments, X4 is L or F, X5 is Y, X6 is N, K, A, H, or R, X7 is S, Q, I, or A, X8 is Y, V, or H, and X9 is T, G, K, R, I, or A. In some embodiments, X4 is L or F, X5 is T, X6 is N, K, A, H, or R, X7 is S, Q, I, or A, X8 is Y, V, or H, and X9 is T, G, K, R, I, or A. In some embodiments, X4 is L or F, X5 is Y or T, X6 is N, X7 is S, Q, I, or A, X8 is Y, V, or H, and X9 is T, G, K, R, I, or A. In some embodiments, X4 is L or F, X5 is Y or T, X6 is K, X7 is S, Q, I, or A, X8 is Y, V, or H, and X9 is T, G, K, R, I, or A. In some embodiments, X4 is L or F, X5 is Y or T, X6 is A, X7 is S, Q, I, or A, X8 is Y, V, or H, and X9 is T, G, K, R, I, or A. In some embodiments, X4 is L or F, X5 is Y or T, X6 is H, X7 is S, Q, I, or A, X8 is Y, V, or H, and X9 is T, G, K, R, I, or A. In some embodiments, X4 is L or F, X5 is Y or T, X6 is R, X7 is S, Q, I, or A, X8 is Y, V, or H, and X9 is T, G, K, R, I, or A.In some embodiments, X4 is L or F, X5 is Y or T, X6 is N, K, A, H, or R, X7 is S, X8 is Y, V, or H, and X9 is T, G, K, R, I, or A. In some embodiments, X4 is L or F, X5 is Y or T, X6 is N, K, A, H, or R, X7 is Q, X8 is Y, V, or H, and X9 is T, G, K, R, I, or A. In some embodiments, X4 is L or F, X5 is Y or T, X6 is N, K, A, H, or R, X7 is I, X8 is Y, V, or H, and X9 is T, G, K, R, I, or A. In some embodiments, X4 is L or F, X5 is Y or T, X6 is N, K, A, H, or R, X7 is A, X8 is Y, V, or H, and X9 is T, G, K, R, I, or A. In some embodiments, X4 is L or F, X5 is Y or T, X6 is N, K, A, H, or R, X7 is S, Q, I, or A, X8 is Y, and X9 is T, G, K, R, I, or A. In some embodiments, X4 is L or F, X5 is Y or T, X6 is N, K, A, H, or R, X7 is S, Q, I, or A, X8 is V, and X9 is T, G, K, R, I, or A. In some embodiments, X4 is L or F, X5 is Y or T, X6 is N, K, A, H, or R, X7 is S, Q, I, or A, X8 is H, and X9 is T, G, K, R, I, or A. In some embodiments, X4 is L or F, X5 is Y or T, X6 is N, K, A, H, or R, X7 is S, Q, I, or A, X8 is Y, V, or H, and X9 is T. In some embodiments, X4 is L or F, X5 is Y or T, X6 is N, K, A, H, or R, X7 is S, Q, I, or A, X8 is Y, V, or H, and X9 is G.In some embodiments, X4 is L or F, X5 is Y or T, X6 is N, K, A, H, or R, X7 is S, Q, I, or A, X8 is Y, V, or H, and X9 is K. In some embodiments, X4 is L or F, X5 is Y or T, X6 is N, K, A, H, or R, X7 is S, Q, I, or A, X8 is Y, V, or H, and X9 is R. In some embodiments, X4 is L or F, X5 is Y or T, X6 is N, K, A, H, or R, X7 is S, Q, I, or A, X8 is Y, V, or H, and X9 is I. In some embodiments, X4 is L or F, X5 is Y or T, X6 is N, K, A, H, or R, X7 is S, Q, I, or A, X8 is Y, V, or H, and X9 is A.

[0087] In some embodiments, an antibody is provided, the antibody comprising a variable heavy chain having an HCDR1 of SEQ ID NO: 128, an HCDR2 of SEQ ID NO: 129, and an HCDR3 of DEQLGGX1X2YYYYYMDX3 (SEQ ID NO: 333), where X1 is N, T, I, Q, L, K, or R, X2 is Y, T, K, H, or V, and X3 is V or A; and an LCDR1 of SEQ ID NO: 106. and a variable light chain comprising an HCDR2 of SEQ ID NO: 107, and an LCDR3 having the amino acid sequence of X4QX5X6X7X8PLX9 (SEQ ID NO: 332), where X4 is L or F, X5 is Y or T, X6 is N, K, A, H, or R, X7 is S, Q, I, or A, X8 is Y, V, or H, and X9 is T, G, K, R, I, or A. In some embodiments, the HCDR3 and LCDR3 variables are as described above.

[0088] In some embodiments, the antibody comprises a variable light chain and a variable heavy chain as described for MAB21, MAB22, MAB23, MAB24, MAB25, MAB26, MAB27, MAB28, MAB29, MAB30, MAB51, MAB52, MAB53, MAB54, MAB55, MAB56, MAB57, MAB58, MAB59, or MAB60, wherein HCDR3 comprises the amino acid sequence of SEQ ID NO: 333 and LCDR3 comprises the amino acid sequence of SEQ ID NO: 332, as described herein. In some embodiments, the antibody comprises a variable light chain and a variable heavy chain that are independently at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of those set forth for the VL and VH of MAB21, MAB22, MAB23, MAB24, MAB25, MAB26, MAB27, MAB28, MAB29, MAB30, MAB51, MAB52, MAB53, MAB54, MAB55, MAB56, MAB57, MAB58, MAB59, or MAB60, as described herein, wherein HCDR3 comprises the amino acid sequence of SEQ ID NO: 333 and LCDR3 comprises the amino acid sequence of SEQ ID NO: 332, as described herein.

[0089] In some embodiments, the antibody does not comprise the HCDR3 of EQLGGNYYYYYYMDV and / or the LCDR3 of LQYNSYPLT. In some embodiments, when the antibody comprises the HCDR3 of EQLGGNYYYYYYMDV, the antibody does not comprise the LCDR3 of LQYNSYPLT.

[0090] In some embodiments, the antibody comprises an HCDR1 of SEQ ID NO: 61, an HCDR2 of SEQ ID NO: 62, and a DX 10 X 11 X 12 YX 13 X 14 DX 15 (SEQ ID NO: 329), wherein X 10 is E, Q, or N, and X 11 is T, E, S, or N, and X 12 is D or Q, and X 13 is A or G, and X14 is L, W, F, or Y, and X 15 is Y, E, L, N, F, or W. In some embodiments, X 10 is E. In some embodiments, X 10 is Q. In some embodiments, X 10 is N. In some embodiments, X 11 is T. In some embodiments, X 11 is E. In some embodiments, X 11 is S. In some embodiments, X 11 is N. In some embodiments, X 12 is D. In some embodiments, X 12 is D. In some embodiments, X 13 is A. In some embodiments, X 13 is G. In some embodiments, X 14 is L. In some embodiments, X 14 is W. In some embodiments, X 14 is F. In some embodiments, X 14 is Y. In some embodiments, X 15 is Y. In some embodiments, X 15 is E. In some embodiments, X 15 is L. In some embodiments, X 15 is N. In some embodiments, X 15 is F. In some embodiments, X 15 is W.

[0091] In some embodiments, the antibody comprises an LCDR1 of SEQ ID NO: 64, an LCDR2 of SEQ ID NO: 65, and X 16 X 17 X 18 EDX 19 X 20 X 21 X 22 (SEQ ID NO: 328), wherein X 16is Q, E, K, or H, and X 17 is Q or H, and X 18 is Y or H, and X 19 is L or Y, and X 20 is P or I, and X 21 is L or P, and X 22 is T or V. In some embodiments, X 16 is Q. In some embodiments, X 16 is E. In some embodiments, X 16 is K. In some embodiments, X 16 is H. In some embodiments, X 17 is Q. In some embodiments, X 17 is H. In some embodiments, X 18 is Y. In some embodiments, X 18 is H. In some embodiments, X 19 is L. In some embodiments, X 19 is Y. In some embodiments, X 20 is P. In some embodiments, X 20 is I. In some embodiments, X 21 is L. In some embodiments, X 21 is P. In some embodiments, X 22 is T. In some embodiments, X 22 is V.

[0092] In some embodiments, an antibody is provided, wherein the antibody comprises a variable heavy chain having an HCDR1 of SEQ ID NO: 61, an HCDR2 of SEQ ID NO: 62, and an HCDR3 of SEQ ID NO: 329, as described herein, and a variable light chain comprising an LCDR1 of SEQ ID NO: 63, an LCDR2 of SEQ ID NO: 64, and an LCDR3 having the amino acid sequence of SEQ ID NO: 328, as described herein.

[0093] In some embodiments, the antibody comprises a variable light chain and a variable heavy chain as described for MAB1, MAB2, MAB3, MAB4, MAB5, MAB6, MAB7, MAB8, MAB9, MAB10, MAB31, MAB32, MAB33, MAB34, MAB35, MAB36, MAB38, MAB39, or MAB40, wherein HCDR3 comprises the amino acid sequence of SEQ ID NO: 329 and LCDR3 comprises the amino acid sequence of SEQ ID NO: 328, as described herein. In some embodiments, the antibody comprises a variable light chain and a variable heavy chain that are independently at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of those set forth for the VL and VH of MAB1, MAB2, MAB3, MAB4, MAB5, MAB6, MAB7, MAB8, MAB9, MAB10, MAB31, MAB32, MAB33, MAB34, MAB35, MAB36, MAB38, MAB39, or MAB40, as described herein, wherein HCDR3 comprises the amino acid sequence of SEQ ID NO: 329 and LCDR3 comprises the amino acid sequence of SEQ ID NO: 328, as described herein.

[0094] In some embodiments, VH and VL are provided where HCDR3 is DETDYALDY and LCDR3 is not QQYEDLPLT. In some embodiments, SEQ ID NO: 329 is not DETDYALDY. In some embodiments, SEQ ID NO: 328 is not QQYEDLPLT.

[0095] In some embodiments, the antibody comprises an HCDR1 of SEQ ID NO: 82, an HCDR2 of SEQ ID NO: 83, and X 23 GX 24 X 25 X 26 X 27 PX 28 X 29 X 30(SEQ ID NO: 330), wherein X23 is E or K, X24 is L or E, X25 is A or G, X26 is G or W, X27 is R, V, L, I, or F, X28 is F, Y, or T, X29 is D or Y, and X30 is A, V, L, S, H, or I. In some embodiments, X23 is E. In some embodiments, X24 is L. In some embodiments, X25 is A. In some embodiments, X26 is G. In some embodiments, X27 is R. In some embodiments, X27 is V. In some embodiments, X27 is L. In some embodiments, X27 is I. In some embodiments, X27 is F. In some embodiments, X28 is F. In some embodiments, X28 is Y. In some embodiments, X29 is D. In some embodiments, X30 is S or L.

[0096] In some embodiments, the antibody comprises an LCDR1 of SEQ ID NO: 85, an LCDR2 of SEQ ID NO: 86, and X 31 QX 32 X 33 SX 34 X 35 X 36 X 37(SEQ ID NO: 331), wherein X31 is Q or V, X32 is Y, A, V, or H, X33 is N, P, S, or R, X34 is Y, L, or P, X35 is S, K, V, A, D, or R, X36 is W or L, and X37 is T or L. In some embodiments, X31 is Q. In some embodiments, X31 is V. In some embodiments, X32 is Y. In some embodiments, X32 is A. In some embodiments, X32 is V. In some embodiments, X32 is H. In some embodiments, X33 is N. In some embodiments, X33 is P. In some embodiments, X33 is S. In some embodiments, X33 is R. In some embodiments, X34 is Y. In some embodiments, X34 is L. In some embodiments, X34 is P. In some embodiments, X35 is S. In some embodiments, X35 is K. In some embodiments, X35 is V. In some embodiments, X35 is A. In some embodiments, X35 is D. In some embodiments, X35 is R. In some embodiments, X36 is W. In some embodiments, X36 is L. In some embodiments, X37 is T. In some embodiments, X37 is L.

[0097] In some embodiments, an antibody is provided, wherein the antibody comprises a variable heavy chain having an HCDR1 of SEQ ID NO: 82, an HCDR2 of SEQ ID NO: 83, and an HCDR3 of SEQ ID NO: 330, as described herein, and a variable light chain comprising an LCDR1 of SEQ ID NO: 84, an LCDR2 of SEQ ID NO: 85, and an LCDR3 having the amino acid sequence of SEQ ID NO: 331, as described herein.

[0098] In some embodiments, the antibody comprises a variable light chain and a variable heavy chain as described for MAB11, MAB12, MAB13, MAB14, MAB15, MAB16, MAB17, MAB18, MAB19, MAB20, MAB41, MAB42, MAB43, MAB44, MAB45, MAB46, MAB47, MAB48, MAB49, or MAB50, and wherein HCDR3 comprises the amino acid sequence of SEQ ID NO: 330 and LCDR3 comprises the amino acid sequence of SEQ ID NO: 331, as described herein. In some embodiments, the antibody comprises a variable light chain and a variable heavy chain that are independently at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of those set forth for the VL and VH of MAB11, MAB12, MAB13, MAB14, MAB15, MAB16, MAB17, MAB18, MAB19, MAB20, MAB41, MAB42, MAB43, MAB44, MAB45, MAB46, MAB47, MAB48, MAB49, or MAB50, as described herein, wherein HCDR3 comprises the amino acid sequence of SEQ ID NO: 330 and LCDR3 comprises the amino acid sequence of SEQ ID NO: 331, as described herein.

[0099] In some embodiments, VH and VL are provided where HCDR3 is EGLAGRPFDS and LCDR3 is not QQYNSYSWTY. In some embodiments, SEQ ID NO: 330 is not EGLAGRPFDS. In some embodiments, SEQ ID NO: 331 is not QQYNSYSWTY.

[0100] In some embodiments, the antibody or antibody-binding fragment thereof comprises a heavy or light chain CDR as set forth in the tables above. In some embodiments, the antibody or antibody-binding fragment thereof comprises a light chain LCDR having the sequence of SEQ ID NO: 64, 65, 66, 68, 71, 75, 77, 79, 81, 85, 86, 87, 89, 92, 94, 95, 97, 99, 101, 102, 106, 107, 108, 110, 112, 113, 115, 118, 119, 121, 123, 133, 134, 147, 148, 159, 160, or a combination thereof. In some embodiments, the antibody or antibody binding fragment thereof is selected from the group consisting of SEQ ID NOs: 61, 62, 63, 67, 69, 70, 72, 73, 74, 76, 78, 80, 82, 83, 84, 88, 90, 91, 93, 96, 98, 100, 103, 104, 105, 109, 111, 114, 116, 117, 120, 122, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 19 , 129, 130, 131, 132, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 161, 162, 163, 164, 165, 166, 167, or a combination thereof.

[0101] In some embodiments, the heavy chain HCDRs are selected from the group consisting of SEQ ID NOs: 61, 62, 63, 67, 69, 70, 72, 73, 74, 76, 78, 80, 82, 83, 84, 88, 90, 91, 93, 96, 98, 100, 103, 104, 105, 109, 111, 114, 116, 117, 120, 122, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 23 9, 130, 131, 132, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 161, 162, 163, 164, 165, 166, and 167.

[0102] It is understood that the CDRs referred to in the embodiments throughout this specification are interchangeable with CDRs characterized in different formats such as Chothia and IMGT as shown in the table above.

[0103] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 64, LCDR2 has the sequence of SEQ ID NO: 65, and LCDR3 has the sequence of SEQ ID NO: 66.

[0104] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 64, LCDR2 has the sequence of SEQ ID NO: 65, and LCDR3 has the sequence of SEQ ID NO: 68.

[0105] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 64, LCDR2 has the sequence of SEQ ID NO: 65, and LCDR3 has the sequence of SEQ ID NO: 71.

[0106] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 64, LCDR2 has the sequence of SEQ ID NO: 65, and LCDR3 has the sequence of SEQ ID NO: 75.

[0107] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 64, LCDR2 has the sequence of SEQ ID NO: 65, and LCDR3 has the sequence of SEQ ID NO: 77.

[0108] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 64, LCDR2 has the sequence of SEQ ID NO: 65, and LCDR3 has the sequence of SEQ ID NO: 79.

[0109] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 64, LCDR2 has the sequence of SEQ ID NO: 65, and LCDR3 has the sequence of SEQ ID NO: 81.

[0110] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 85, LCDR2 has the sequence of SEQ ID NO: 86, and LCDR3 has the sequence of SEQ ID NO: 87.

[0111] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 85, LCDR2 has the sequence of SEQ ID NO: 86, and LCDR3 has the sequence of SEQ ID NO: 89.

[0112] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 85, LCDR2 has the sequence of SEQ ID NO: 86, and LCDR3 has the sequence of SEQ ID NO: 92.

[0113] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 85, LCDR2 has the sequence of SEQ ID NO: 86, and LCDR3 has the sequence of SEQ ID NO: 94.

[0114] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 85, LCDR2 has the sequence of SEQ ID NO: 86, and LCDR3 has the sequence of SEQ ID NO: 95.

[0115] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 85, LCDR2 has the sequence of SEQ ID NO: 86, and LCDR3 has the sequence of SEQ ID NO: 97.

[0116] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 85, LCDR2 has the sequence of SEQ ID NO: 86, and LCDR3 has the sequence of SEQ ID NO: 99.

[0117] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 85, LCDR2 has the sequence of SEQ ID NO: 86, and LCDR3 has the sequence of SEQ ID NO: 101.

[0118] In some embodiments, the antibody or antibody-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 85, LCDR2 has the sequence of SEQ ID NO: 86, and LCDR3 has the sequence of SEQ ID NO: 102.

[0119] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 106, LCDR2 has the sequence of SEQ ID NO: 107, and LCDR3 has the sequence of SEQ ID NO: 108.

[0120] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 106, LCDR2 has the sequence of SEQ ID NO: 107, and LCDR3 has the sequence of SEQ ID NO: 110.

[0121] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 106, LCDR2 has the sequence of SEQ ID NO: 107, and LCDR3 has the sequence of SEQ ID NO: 112.

[0122] In some embodiments, the antibody or antibody-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 106, LCDR2 has the sequence of SEQ ID NO: 107, and LCDR3 has the sequence of SEQ ID NO: 113.

[0123] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 106, LCDR2 has the sequence of SEQ ID NO: 107, and LCDR3 has the sequence of SEQ ID NO: 115.

[0124] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 106, LCDR2 has the sequence of SEQ ID NO: 107, and LCDR3 has the sequence of SEQ ID NO: 118.

[0125] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 106, LCDR2 has the sequence of SEQ ID NO: 107, and LCDR3 has the sequence of SEQ ID NO: 119.

[0126] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 106, LCDR2 has the sequence of SEQ ID NO: 107, and LCDR3 has the sequence of SEQ ID NO: 121.

[0127] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 106, LCDR2 has the sequence of SEQ ID NO: 107, and LCDR3 has the sequence of SEQ ID NO: 123.

[0128] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 133, LCDR2 has the sequence of SEQ ID NO: 134, and LCDR3 has the sequence of SEQ ID NO: 66.

[0129] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 133, LCDR2 has the sequence of SEQ ID NO: 134, and LCDR3 has the sequence of SEQ ID NO: 68.

[0130] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 133, LCDR2 has the sequence of SEQ ID NO: 134, and LCDR3 has the sequence of SEQ ID NO: 71.

[0131] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 133, LCDR2 has the sequence of SEQ ID NO: 134, and LCDR3 has the sequence of SEQ ID NO: 75.

[0132] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 133, LCDR2 has the sequence of SEQ ID NO: 134, and LCDR3 has the sequence of SEQ ID NO: 77.

[0133] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 133, LCDR2 has the sequence of SEQ ID NO: 134, and LCDR3 has the sequence of SEQ ID NO: 79.

[0134] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 133, LCDR2 has the sequence of SEQ ID NO: 134, and LCDR3 has the sequence of SEQ ID NO: 81.

[0135] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 147, LCDR2 has the sequence of SEQ ID NO: 148, and LCDR3 has the sequence of SEQ ID NO: 87.

[0136] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 147, LCDR2 has the sequence of SEQ ID NO: 148, and LCDR3 has the sequence of SEQ ID NO: 89.

[0137] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 147, LCDR2 has the sequence of SEQ ID NO: 148, and LCDR3 has the sequence of SEQ ID NO: 92.

[0138] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 147, LCDR2 has the sequence of SEQ ID NO: 148, and LCDR3 has the sequence of SEQ ID NO: 94.

[0139] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 147, LCDR2 has the sequence of SEQ ID NO: 148, and LCDR3 has the sequence of SEQ ID NO: 95.

[0140] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 147, LCDR2 has the sequence of SEQ ID NO: 148, and LCDR3 has the sequence of SEQ ID NO: 97.

[0141] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 147, LCDR2 has the sequence of SEQ ID NO: 148, and LCDR3 has the sequence of SEQ ID NO: 99.

[0142] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 147, LCDR2 has the sequence of SEQ ID NO: 148, and LCDR3 has the sequence of SEQ ID NO: 101.

[0143] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 147, LCDR2 has the sequence of SEQ ID NO: 148, and LCDR3 has the sequence of SEQ ID NO: 102.

[0144] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 159, LCDR2 has the sequence of SEQ ID NO: 160, and LCDR3 has the sequence of SEQ ID NO: 108.

[0145] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 159, LCDR2 has the sequence of SEQ ID NO: 160, and LCDR3 has the sequence of SEQ ID NO: 110.

[0146] In some embodiments, the antibody or antibody-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 159, LCDR2 has the sequence of SEQ ID NO: 160, and LCDR3 has the sequence of SEQ ID NO: 112.

[0147] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 159, LCDR2 has the sequence of SEQ ID NO: 160, and LCDR3 has the sequence of SEQ ID NO: 113.

[0148] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 159, LCDR2 has the sequence of SEQ ID NO: 160, and LCDR3 has the sequence of SEQ ID NO: 115.

[0149] In some embodiments, the antibody or antibody-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 159, LCDR2 has the sequence of SEQ ID NO: 160, and LCDR3 has the sequence of SEQ ID NO: 118.

[0150] In some embodiments, the antibody or antibody-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 159, LCDR2 has the sequence of SEQ ID NO: 160, and LCDR3 has the sequence of SEQ ID NO: 119.

[0151] In some embodiments, the antibody or antibody-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 159, LCDR2 has the sequence of SEQ ID NO: 160, and LCDR3 has the sequence of SEQ ID NO: 112.

[0152] In some embodiments, the antibody or antibody-binding fragment thereof comprises a light chain variable region having LCDR1, LCDR2, and LCDR3, wherein LCDR1 has the sequence of SEQ ID NO: 159, LCDR2 has the sequence of SEQ ID NO: 160, and LCDR3 has the sequence of SEQ ID NO: 123.

[0153] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 61, HCDR2 has the sequence of SEQ ID NO: 62, and HCDR3 has the sequence of SEQ ID NO: 63.

[0154] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 61, HCDR2 has the sequence of SEQ ID NO: 62, and HCDR3 has the sequence of SEQ ID NO: 67.

[0155] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 61, HCDR2 has the sequence of SEQ ID NO: 62, and HCDR3 has the sequence of SEQ ID NO: 69.

[0156] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 61, HCDR2 has the sequence of SEQ ID NO: 62, and HCDR3 has the sequence of SEQ ID NO: 70.

[0157] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 61, HCDR2 has the sequence of SEQ ID NO: 62, and HCDR3 has the sequence of SEQ ID NO: 72.

[0158] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 61, HCDR2 has the sequence of SEQ ID NO: 62, and HCDR3 has the sequence of SEQ ID NO: 73.

[0159] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 61, HCDR2 has the sequence of SEQ ID NO: 62, and HCDR3 has the sequence of SEQ ID NO: 74.

[0160] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 61, HCDR2 has the sequence of SEQ ID NO: 62, and HCDR3 has the sequence of SEQ ID NO: 76.

[0161] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 61, HCDR2 has the sequence of SEQ ID NO: 62, and HCDR3 has the sequence of SEQ ID NO: 78.

[0162] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 61, HCDR2 has the sequence of SEQ ID NO: 62, and HCDR3 has the sequence of SEQ ID NO: 80.

[0163] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 82, HCDR2 has the sequence of SEQ ID NO: 83, and HCDR3 has the sequence of SEQ ID NO: 84.

[0164] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 82, HCDR2 has the sequence of SEQ ID NO: 83, and HCDR3 has the sequence of SEQ ID NO: 88.

[0165] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 82, HCDR2 has the sequence of SEQ ID NO: 83, and HCDR3 has the sequence of SEQ ID NO: 90.

[0166] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 82, HCDR2 has the sequence of SEQ ID NO: 83, and HCDR3 has the sequence of SEQ ID NO: 91.

[0167] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 82, HCDR2 has the sequence of SEQ ID NO: 83, and HCDR3 has the sequence of SEQ ID NO: 93.

[0168] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 82, HCDR2 has the sequence of SEQ ID NO: 83, and HCDR3 has the sequence of SEQ ID NO: 96.

[0169] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 82, HCDR2 has the sequence of SEQ ID NO: 83, and HCDR3 has the sequence of SEQ ID NO: 98.

[0170] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 82, HCDR2 has the sequence of SEQ ID NO: 83, and HCDR3 has the sequence of SEQ ID NO: 100.

[0171] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 103, HCDR2 has the sequence of SEQ ID NO: 104, and HCDR3 has the sequence of SEQ ID NO: 105.

[0172] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 103, HCDR2 has the sequence of SEQ ID NO: 104, and HCDR3 has the sequence of SEQ ID NO: 109.

[0173] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 103, HCDR2 has the sequence of SEQ ID NO: 104, and HCDR3 has the sequence of SEQ ID NO: 111.

[0174] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 103, HCDR2 has the sequence of SEQ ID NO: 104, and HCDR3 has the sequence of SEQ ID NO: 114.

[0175] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 103, HCDR2 has the sequence of SEQ ID NO: 104, and HCDR3 has the sequence of SEQ ID NO: 116.

[0176] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 103, HCDR2 has the sequence of SEQ ID NO: 104, and HCDR3 has the sequence of SEQ ID NO: 117.

[0177] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 103, HCDR2 has the sequence of SEQ ID NO: 104, and HCDR3 has the sequence of SEQ ID NO: 120.

[0178] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 103, HCDR2 has the sequence of SEQ ID NO: 104, and HCDR3 has the sequence of SEQ ID NO: 122.

[0179] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 124, HCDR2 has the sequence of SEQ ID NO: 125, and HCDR3 has the sequence of SEQ ID NO: 63.

[0180] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 124, HCDR2 has the sequence of SEQ ID NO: 125, and HCDR3 has the sequence of SEQ ID NO: 67.

[0181] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 124, HCDR2 has the sequence of SEQ ID NO: 125, and HCDR3 has the sequence of SEQ ID NO: 69.

[0182] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 124, HCDR2 has the sequence of SEQ ID NO: 125, and HCDR3 has the sequence of SEQ ID NO: 70.

[0183] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 124, HCDR2 has the sequence of SEQ ID NO: 125, and HCDR3 has the sequence of SEQ ID NO: 72.

[0184] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 124, HCDR2 has the sequence of SEQ ID NO: 125, and HCDR3 has the sequence of SEQ ID NO: 73.

[0185] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 124, HCDR2 has the sequence of SEQ ID NO: 125, and HCDR3 has the sequence of SEQ ID NO: 74.

[0186] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 124, HCDR2 has the sequence of SEQ ID NO: 125, and HCDR3 has the sequence of SEQ ID NO: 76.

[0187] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 124, HCDR2 has the sequence of SEQ ID NO: 125, and HCDR3 has the sequence of SEQ ID NO: 78.

[0188] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 124, HCDR2 has the sequence of SEQ ID NO: 125, and HCDR3 has the sequence of SEQ ID NO: 80.

[0189] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 126, HCDR2 has the sequence of SEQ ID NO: 127, and HCDR3 has the sequence of SEQ ID NO: 84.

[0190] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 126, HCDR2 has the sequence of SEQ ID NO: 127, and HCDR3 has the sequence of SEQ ID NO: 88.

[0191] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 126, HCDR2 has the sequence of SEQ ID NO: 127, and HCDR3 has the sequence of SEQ ID NO: 90.

[0192] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 126, HCDR2 has the sequence of SEQ ID NO: 127, and HCDR3 has the sequence of SEQ ID NO: 91.

[0193] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 126, HCDR2 has the sequence of SEQ ID NO: 127, and HCDR3 has the sequence of SEQ ID NO: 93.

[0194] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 126, HCDR2 has the sequence of SEQ ID NO: 127, and HCDR3 has the sequence of SEQ ID NO: 96.

[0195] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 126, HCDR2 has the sequence of SEQ ID NO: 127, and HCDR3 has the sequence of SEQ ID NO: 98.

[0196] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 126, HCDR2 has the sequence of SEQ ID NO: 127, and HCDR3 has the sequence of SEQ ID NO: 100.

[0197] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 128, HCDR2 has the sequence of SEQ ID NO: 129, and HCDR3 has the sequence of SEQ ID NO: 105.

[0198] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 128, HCDR2 has the sequence of SEQ ID NO: 129, and HCDR3 has the sequence of SEQ ID NO: 109.

[0199] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 128, HCDR2 has the sequence of SEQ ID NO: 129, and HCDR3 has the sequence of SEQ ID NO: 111.

[0200] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 128, HCDR2 has the sequence of SEQ ID NO: 129, and HCDR3 has the sequence of SEQ ID NO: 114.

[0201] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 128, HCDR2 has the sequence of SEQ ID NO: 129, and HCDR3 has the sequence of SEQ ID NO: 116.

[0202] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 128, HCDR2 has the sequence of SEQ ID NO: 129, and HCDR3 has the sequence of SEQ ID NO: 117.

[0203] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 128, HCDR2 has the sequence of SEQ ID NO: 129, and HCDR3 has the sequence of SEQ ID NO: 120.

[0204] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 128, HCDR2 has the sequence of SEQ ID NO: 129, and HCDR3 has the sequence of SEQ ID NO: 122.

[0205] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 130, HCDR2 has the sequence of SEQ ID NO: 131, and HCDR3 has the sequence of SEQ ID NO: 132.

[0206] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 130, HCDR2 has the sequence of SEQ ID NO: 131, and HCDR3 has the sequence of SEQ ID NO: 135.

[0207] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 130, HCDR2 has the sequence of SEQ ID NO: 131, and HCDR3 has the sequence of SEQ ID NO: 136.

[0208] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 130, HCDR2 has the sequence of SEQ ID NO: 131, and HCDR3 has the sequence of SEQ ID NO: 137.

[0209] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 130, HCDR2 has the sequence of SEQ ID NO: 131, and HCDR3 has the sequence of SEQ ID NO: 138.

[0210] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 130, HCDR2 has the sequence of SEQ ID NO: 131, and HCDR3 has the sequence of SEQ ID NO: 139.

[0211] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 130, HCDR2 has the sequence of SEQ ID NO: 131, and HCDR3 has the sequence of SEQ ID NO: 140.

[0212] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 130, HCDR2 has the sequence of SEQ ID NO: 131, and HCDR3 has the sequence of SEQ ID NO: 141.

[0213] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 130, HCDR2 has the sequence of SEQ ID NO: 131, and HCDR3 has the sequence of SEQ ID NO: 142.

[0214] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 130, HCDR2 has the sequence of SEQ ID NO: 131, and HCDR3 has the sequence of SEQ ID NO: 143.

[0215] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 144, HCDR2 has the sequence of SEQ ID NO: 145, and HCDR3 has the sequence of SEQ ID NO: 146.

[0216] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 144, HCDR2 has the sequence of SEQ ID NO: 145, and HCDR3 has the sequence of SEQ ID NO: 149.

[0217] In some embodiments, the antibody or antibody-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 144, HCDR2 has the sequence of SEQ ID NO: 145, and HCDR3 has the sequence of SEQ ID NO: 150.

[0218] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 144, HCDR2 has the sequence of SEQ ID NO: 145, and HCDR3 has the sequence of SEQ ID NO: 151.

[0219] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 144, HCDR2 has the sequence of SEQ ID NO: 145, and HCDR3 has the sequence of SEQ ID NO: 152.

[0220] In some embodiments, the antibody or antibody-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 144, HCDR2 has the sequence of SEQ ID NO: 145, and HCDR3 has the sequence of SEQ ID NO: 153.

[0221] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 144, HCDR2 has the sequence of SEQ ID NO: 145, and HCDR3 has the sequence of SEQ ID NO: 154.

[0222] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 144, HCDR2 has the sequence of SEQ ID NO: 145, and HCDR3 has the sequence of SEQ ID NO: 155.

[0223] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 156, HCDR2 has the sequence of SEQ ID NO: 157, and HCDR3 has the sequence of SEQ ID NO: 158.

[0224] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 156, HCDR2 has the sequence of SEQ ID NO: 157, and HCDR3 has the sequence of SEQ ID NO: 161.

[0225] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 156, HCDR2 has the sequence of SEQ ID NO: 157, and HCDR3 has the sequence of SEQ ID NO: 162.

[0226] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 156, HCDR2 has the sequence of SEQ ID NO: 157, and HCDR3 has the sequence of SEQ ID NO: 163.

[0227] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 156, HCDR2 has the sequence of SEQ ID NO: 157, and HCDR3 has the sequence of SEQ ID NO: 164.

[0228] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 156, HCDR2 has the sequence of SEQ ID NO: 157, and HCDR3 has the sequence of SEQ ID NO: 165.

[0229] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 156, HCDR2 has the sequence of SEQ ID NO: 157, and HCDR3 has the sequence of SEQ ID NO: 166.

[0230] In some embodiments, the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having HCDR1, HCDR2, and HCDR3, wherein HCDR1 has the sequence of SEQ ID NO: 156, HCDR2 has the sequence of SEQ ID NO: 157, and HCDR3 has the sequence of SEQ ID NO: 167.

[0231] In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a light chain variable region having light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 has the amino acid sequence of SEQ ID NO: 64, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 65, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO: 66; and (ii) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO: 61, the heavy chain HCDR2 has the amino acid sequence of SEQ ID NO: 62, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO: 63, or any one of the foregoing variants or conventional equivalents.

[0232] In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a light chain variable region having light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 has the amino acid sequence of SEQ ID NO: 64, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 65, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO: 68; and (ii) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the HCDR1 sequence has the amino acid sequence of SEQ ID NO: 61, the HCDR2 has the amino acid sequence of SEQ ID NO: 62, and the HCDR3 sequence has the amino acid sequence of SEQ ID NO: 67, or any one of the foregoing variants or conventional equivalents.

[0233] In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a light chain variable region having light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 has the amino acid sequence of SEQ ID NO: 64, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 65, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO: 68; and (ii) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO: 61, the heavy chain HCDR2 has the amino acid sequence of SEQ ID NO: 62, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO: 69, or any one of the foregoing variants or conventional equivalents.

[0234] In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a light chain variable region having light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 has the amino acid sequence of SEQ ID NO: 64 and the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 65; and (ii) a heavy chain variable region having heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the HCDR1 sequence has the amino acid sequence of SEQ ID NO: 61, the HCDR2 has the amino acid sequence of SEQ ID NO: 62, and the HCDR3 sequence has the amino acid sequence of SEQ ID NO: 70, or any one of the foregoing variants or conventional equivalents.

[0235] In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a light chain variable region having light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 has the amino acid sequence of SEQ ID NO: 64, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 65, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO: 71; and (ii) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the HCDR1 sequence has the amino acid sequence of SEQ ID NO: 61, the HCDR2 has the amino acid sequence of SEQ ID NO: 62, and the HCDR3 sequence has the amino acid sequence of SEQ ID NO: 72, or any one of the foregoing variants or conventional equivalents.

[0236] In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a light chain variable region having light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 has the amino acid sequence of SEQ ID NO: 64, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 65, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO: 71; and (ii) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the HCDR1 sequence has the amino acid sequence of SEQ ID NO: 61, the HCDR2 has the amino acid sequence of SEQ ID NO: 62, and the HCDR3 sequence has the amino acid sequence of SEQ ID NO: 73, or any one of the foregoing variants or conventional equivalents.

[0237] In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a light chain variable region having light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 has the amino acid sequence of SEQ ID NO: 64, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 65, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO: 75; and (ii) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the HCDR1 sequence has the amino acid sequence of SEQ ID NO: 61, the HCDR2 has the amino acid sequence of SEQ ID NO: 62, and the HCDR3 sequence has the amino acid sequence of SEQ ID NO: 74, or any one of the foregoing variants or conventional equivalents.

[0238] In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a light chain variable region having light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 has the amino acid sequence of SEQ ID NO: 64, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 65, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO: 77; and (ii) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the HCDR1 sequence has the amino acid sequence of SEQ ID NO: 61, the HCDR2 has the amino acid sequence of SEQ ID NO: 62, and the HCDR3 sequence has the amino acid sequence of SEQ ID NO: 76, or any one of the foregoing variants or conventional equivalents.

[0239] In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a light chain variable region having light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 has the amino acid sequence of SEQ ID NO: 64, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 65, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO: 79; and (ii) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the HCDR1 sequence has the amino acid sequence of SEQ ID NO: 61, the HCDR2 has the amino acid sequence of SEQ ID NO: 62, and the HCDR3 sequence has the amino acid sequence of SEQ ID NO: 78, or any one of the foregoing variants or conventional equivalents.

[0240] In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a light chain variable region having light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 has the amino acid sequence of SEQ ID NO: 64, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 65, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO: 81; and (ii) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the HCDR1 sequence has the amino acid sequence of SEQ ID NO: 61, the HCDR2 has the amino acid sequence of SEQ ID NO: 62, and the HCDR3 sequence has the amino acid sequence of SEQ ID NO: 80, or any one of the foregoing variants or conventional equivalents.

[0241] In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a light chain variable region having light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 has the amino acid sequence of SEQ ID NO: 85, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 86, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO: 87; and (ii) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO: 82, the heavy chain HCDR2 has the amino acid sequence of SEQ ID NO: 83, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO: 84, or any one of the foregoing variants or conventional equivalents.

[0242] In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a light chain variable region having light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain has the amino acid sequence of SEQ ID NO: 85, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 86, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO: 89; and (ii) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO: 82, the heavy chain HCDR2 has the amino acid sequence of SEQ ID NO: 83, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO: 88, or any one of the foregoing variants or conventional equivalents.

[0243] In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a light chain variable region having light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 has the amino acid sequence of SEQ ID NO: 85, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 86, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO: 89; and (ii) a heavy chain variable region having heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO: 82, the heavy chain HCDR2 has the amino acid sequence of SEQ ID NO: 83, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO: 90, or any one of the foregoing variants or conventional equivalents.

[0244] In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a light chain variable region having light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 has the amino acid sequence of SEQ ID NO: 85, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 86, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO: 92; and (ii) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO: 82, the heavy chain HCDR2 has the amino acid sequence of SEQ ID NO: 83, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO: 91, or any one of the foregoing variants or conventional equivalents.

[0245] In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a light chain variable region having light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 has the amino acid sequence of SEQ ID NO: 85, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 86, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO: 94; and (ii) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO: 82, the heavy chain HCDR2 has the amino acid sequence of SEQ ID NO: 83, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO: 93, or any one of the foregoing variants or conventional equivalents.

[0246] In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a light chain variable region having light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 has the amino acid sequence of SEQ ID NO: 85, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 86, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO: 95; and (ii) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO: 82, the heavy chain HCDR2 has the amino acid sequence of SEQ ID NO: 83, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO: 84, or any one of the foregoing variants or conventional equivalents.

[0247] In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a light chain variable region having light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 has the amino acid sequence of SEQ ID NO: 85, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 86, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO: 97; and (ii) a heavy chain variable region having heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO: 82, the heavy chain HCDR2 has the amino acid sequence of SEQ ID NO: 83, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO: 96, or any one of the foregoing variants or conventional equivalents.

[0248] In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a light chain variable region having light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 has the amino acid sequence of SEQ ID NO: 85, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 86, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO: 99; and (ii) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO: 82, the heavy chain HCDR2 has the amino acid sequence of SEQ ID NO: 83, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO: 98, or any one of the foregoing variants or conventional equivalents.

[0249] In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a light chain variable region having light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 has the amino acid sequence of SEQ ID NO: 85, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 86, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO: 101; and (ii) a heavy chain variable region having heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO: 82, the heavy chain HCDR2 has the amino acid sequence of SEQ ID NO: 83, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO: 100, or any one of the foregoing variants or conventional equivalents.

[0250] In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a light chain variable region having light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 has the amino acid sequence of SEQ ID NO: 85, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 86, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO: 102; and (ii) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO: 82, the heavy chain HCDR2 has the amino acid sequence of SEQ ID NO: 83, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO: 100, or any one of the foregoing variants or conventional equivalents.

[0251] In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a light chain variable region having light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 has the amino acid sequence of SEQ ID NO: 106, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 107, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO: 108; and (ii) a heavy chain variable region having heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO: 103, the heavy chain HCDR2 has the amino acid sequence of SEQ ID NO: 104, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO: 105, or any one of the foregoing variants or conventional equivalents.

[0252] In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a light chain variable region having light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 has the amino acid sequence of SEQ ID NO: 106, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 107, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO: 110; and (ii) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO: 103, the heavy chain HCDR2 has the amino acid sequence of SEQ ID NO: 104, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO: 109, or any one of the foregoing variants or conventional equivalents.

[0253] In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a light chain variable region having light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 has the amino acid sequence of SEQ ID NO: 106, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 107, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO: 112; and (ii) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO: 103, the heavy chain HCDR2 has the amino acid sequence of SEQ ID NO: 104, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO: 111, or any one of the foregoing variants or conventional equivalents.

[0254] In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a light chain variable region having light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 has the amino acid sequence of SEQ ID NO: 106, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 107, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO: 113; and (ii) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO: 103, the heavy chain HCDR2 has the amino acid sequence of SEQ ID NO: 104, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO: 105, or any one of the foregoing variants or conventional equivalents.

[0255] In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a light chain variable region having light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 has the amino acid sequence of SEQ ID NO: 106, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 107, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO: 115; and (ii) a heavy chain variable region having heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO: 103, the heavy chain HCDR2 has the amino acid sequence of SEQ ID NO: 104, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO: 114, or any one of the foregoing variants or conventional equivalents.

[0256] In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a light chain variable region having light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 has the amino acid sequence of SEQ ID NO: 106, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 107, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO: 113; and (ii) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO: 103, the heavy chain HCDR2 has the amino acid sequence of SEQ ID NO: 104, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO: 116, or any one of the foregoing variants or conventional equivalents.

[0257] In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a light chain variable region having light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 has the amino acid sequence of SEQ ID NO: 106, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 107, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO: 118; and (ii) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO: 103, the heavy chain HCDR2 has the amino acid sequence of SEQ ID NO: 104, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO: 117, or any one of the foregoing variants or conventional equivalents.

[0258] In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a light chain variable region having light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 has the amino acid sequence of SEQ ID NO: 106, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 107, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO: 119; and (ii) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO: 103, the heavy chain HCDR2 has the amino acid sequence of SEQ ID NO: 104, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO: 116, or any one of the foregoing variants or conventional equivalents.

[0259] In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a light chain variable region having light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 has the amino acid sequence of SEQ ID NO: 106, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 107, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO: 121; and (ii) a heavy chain variable region having heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO: 103, the heavy chain HCDR2 has the amino acid sequence of SEQ ID NO: 104, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO: 120, or any one of the foregoing variants or conventional equivalents.

[0260] In some embodiments, the antibody or antigen-binding fragment thereof comprises: (i) a light chain variable region having light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 has the amino acid sequence of SEQ ID NO: 106, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 107, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO: 123; and (ii) a heavy chain variable region having heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO: 103, the heavy chain HCDR2 has the amino acid sequence of SEQ ID NO: 104, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO: 122, or any one of the foregoing variants or conventional equivalents.

[0261] Although the previous paragraph may refer to CDRs under the Kabat system, equivalent CDR sequences from the IMGT and CHOTHIA designations can be used.

[0262] In some embodiments, an antibody or antigen-binding fragment thereof is provided, wherein HCDR1, HCDR2, and HCDR3 are selected from SEQ ID NO:61, SEQ ID NO:62, and SEQ ID NO:63, respectively; from SEQ ID NO:124, SEQ ID NO:125, and SEQ ID NO:63, respectively; or from SEQ ID NO:130, SEQ ID NO:131, and SEQ ID NO:132, respectively; and LCDR1, LCDR2, and LCDR3 are selected from SEQ ID NO:64, SEQ ID NO:65, and SEQ ID NO:66, respectively; from SEQ ID NO:64, SEQ ID NO:65, and SEQ ID NO:66, respectively; or from SEQ ID NO:133, SEQ ID NO:134, and SEQ ID NO:66, respectively.

[0263] In some embodiments, an antibody or antigen-binding fragment thereof is provided, wherein HCDR1, HCDR2, and HCDR3 are selected from SEQ ID NO:61, SEQ ID NO:62, and SEQ ID NO:67, respectively; from SEQ ID NO:124, SEQ ID NO:125, and SEQ ID NO:67, respectively; or from SEQ ID NO:130, SEQ ID NO:131, and SEQ ID NO:135, respectively; and LCDR1, LCDR2, and LCDR3 are selected from SEQ ID NO:64, SEQ ID NO:65, and SEQ ID NO:68, respectively; from SEQ ID NO:64, SEQ ID NO:65, and SEQ ID NO:68, respectively; or from SEQ ID NO:133, SEQ ID NO:134, and SEQ ID NO:68, respectively.

[0264] In some embodiments, an antibody or antigen-binding fragment thereof is provided, wherein HCDR1, HCDR2, and HCDR3 are selected from SEQ ID NO:61, SEQ ID NO:62, and SEQ ID NO:69, respectively; from SEQ ID NO:124, SEQ ID NO:125, and SEQ ID NO:69, respectively; or from SEQ ID NO:130, SEQ ID NO:131, and SEQ ID NO:136, respectively; and LCDR1, LCDR2, and LCDR3 are selected from SEQ ID NO:64, SEQ ID NO:65, and SEQ ID NO:68, respectively; from SEQ ID NO:64, SEQ ID NO:65, and SEQ ID NO:68, respectively; or from SEQ ID NO:133, SEQ ID NO:134, and SEQ ID NO:68, respectively.

[0265] In some embodiments, an antibody or antigen-binding fragment thereof is provided, wherein HCDR1, HCDR2, and HCDR3 are selected from SEQ ID NO:61, SEQ ID NO:62, and SEQ ID NO:70, respectively; from SEQ ID NO:124, SEQ ID NO:125, and SEQ ID NO:70, respectively; or from SEQ ID NO:130, SEQ ID NO:131, and SEQ ID NO:137, respectively; and LCDR1, LCDR2, and LCDR3 are selected from SEQ ID NO:64, SEQ ID NO:65, and SEQ ID NO:71, respectively; from SEQ ID NO:64, SEQ ID NO:65, and SEQ ID NO:71, respectively; or from SEQ ID NO:133, SEQ ID NO:134, and SEQ ID NO:71, respectively.

[0266] In some embodiments, an antibody or antigen-binding fragment thereof is provided, wherein HCDR1, HCDR2, and HCDR3 are selected from SEQ ID NO:61, SEQ ID NO:62, and SEQ ID NO:72, respectively; from SEQ ID NO:124, SEQ ID NO:125, and SEQ ID NO:72, respectively; or from SEQ ID NO:130, SEQ ID NO:131, and SEQ ID NO:138, respectively; and LCDR1, LCDR2, and LCDR3 are selected from SEQ ID NO:64, SEQ ID NO:65, and SEQ ID NO:71, respectively; from SEQ ID NO:64, SEQ ID NO:65, and SEQ ID NO:71, respectively; or from SEQ ID NO:133, SEQ ID NO:134, and SEQ ID NO:71, respectively.

[0267] In some embodiments, an antibody or antigen-binding fragment thereof is provided, wherein HCDR1, HCDR2, and HCDR3 are selected from SEQ ID NO:61, SEQ ID NO:62, and SEQ ID NO:73, respectively; from SEQ ID NO:124, SEQ ID NO:125, and SEQ ID NO:73, respectively; or from SEQ ID NO:130, SEQ ID NO:131, and SEQ ID NO:139, respectively; and LCDR1, LCDR2, and LCDR3 are selected from SEQ ID NO:64, SEQ ID NO:65, and SEQ ID NO:71, respectively; from SEQ ID NO:64, SEQ ID NO:65, and SEQ ID NO:71, respectively; or from SEQ ID NO:133, SEQ ID NO:134, and SEQ ID NO:71, respectively.

[0268] In some embodiments, an antibody or antigen-binding fragment thereof is provided, wherein HCDR1, HCDR2, and HCDR3 are selected from SEQ ID NO:61, SEQ ID NO:62, and SEQ ID NO:74, respectively; from SEQ ID NO:124, SEQ ID NO:125, and SEQ ID NO:74, respectively; or from SEQ ID NO:130, SEQ ID NO:131, and SEQ ID NO:140, respectively; and LCDR1, LCDR2, and LCDR3 are selected from SEQ ID NO:64, SEQ ID NO:65, and SEQ ID NO:75, respectively; from SEQ ID NO:64, SEQ ID NO:65, and SEQ ID NO:75, respectively; or from SEQ ID NO:133, SEQ ID NO:134, and SEQ ID NO:75, respectively.

[0269] In some embodiments, an antibody or antigen-binding fragment thereof is provided, wherein HCDR1, HCDR2, and HCDR3 are selected from SEQ ID NO:61, SEQ ID NO:62, and SEQ ID NO:76, respectively; from SEQ ID NO:124, SEQ ID NO:125, and SEQ ID NO:76, respectively; or from SEQ ID NO:130, SEQ ID NO:131, and SEQ ID NO:141, respectively; and LCDR1, LCDR2, and LCDR3 are selected from SEQ ID NO:64, SEQ ID NO:65, and SEQ ID NO:77, respectively; from SEQ ID NO:64, SEQ ID NO:65, and SEQ ID NO:77, respectively; or from SEQ ID NO:133, SEQ ID NO:134, and SEQ ID NO:77, respectively.

[0270] In some embodiments, an antibody or antigen-binding fragment thereof is provided, wherein HCDR1, HCDR2, and HCDR3 are selected from SEQ ID NO:61, SEQ ID NO:62, and SEQ ID NO:78, respectively; from SEQ ID NO:124, SEQ ID NO:125, and SEQ ID NO:78, respectively; or from SEQ ID NO:130, SEQ ID NO:131, and SEQ ID NO:142, respectively; and LCDR1, LCDR2, and LCDR3 are selected from SEQ ID NO:64, SEQ ID NO:65, and SEQ ID NO:79, respectively; from SEQ ID NO:64, SEQ ID NO:65, and SEQ ID NO:79, respectively; or from SEQ ID NO:133, SEQ ID NO:134, and SEQ ID NO:79, respectively.

[0271] In some embodiments, an antibody or antigen-binding fragment thereof is provided, wherein HCDR1, HCDR2, and HCDR3 are selected from SEQ ID NO:61, SEQ ID NO:62, and SEQ ID NO:80, respectively; from SEQ ID NO:124, SEQ ID NO:125, and SEQ ID NO:80, respectively; or from SEQ ID NO:130, SEQ ID NO:131, and SEQ ID NO:143, respectively; and LCDR1, LCDR2, and LCDR3 are selected from SEQ ID NO:64, SEQ ID NO:65, and SEQ ID NO:81, respectively; from SEQ ID NO:64, SEQ ID NO:65, and SEQ ID NO:81, respectively; or from SEQ ID NO:133, SEQ ID NO:134, and SEQ ID NO:81, respectively.

[0272] In some embodiments, an antibody or antigen-binding fragment thereof is provided, wherein HCDR1, HCDR2, and HCDR3 are selected from SEQ ID NO:82, SEQ ID NO:83, and SEQ ID NO:84, respectively; from SEQ ID NO:126, SEQ ID NO:127, and SEQ ID NO:84, respectively; or from SEQ ID NO:144, SEQ ID NO:145, and SEQ ID NO:146, respectively; and LCDR1, LCDR2, and LCDR3 are selected from SEQ ID NO:85, SEQ ID NO:86, and SEQ ID NO:87, respectively; from SEQ ID NO:85, SEQ ID NO:86, and SEQ ID NO:87, respectively; or from SEQ ID NO:147, SEQ ID NO:148, and SEQ ID NO:87, respectively.

[0273] In some embodiments, an antibody or antigen-binding fragment thereof is provided, wherein HCDR1, HCDR2, and HCDR3 are selected from SEQ ID NO:82, SEQ ID NO:83, and SEQ ID NO:88, respectively; from SEQ ID NO:126, SEQ ID NO:127, and SEQ ID NO:88, respectively; or from SEQ ID NO:144, SEQ ID NO:145, and SEQ ID NO:149, respectively; and LCDR1, LCDR2, and LCDR3 are selected from SEQ ID NO:85, SEQ ID NO:86, and SEQ ID NO:89, respectively; from SEQ ID NO:85, SEQ ID NO:86, and SEQ ID NO:89, respectively; or from SEQ ID NO:147, SEQ ID NO:148, and SEQ ID NO:89, respectively.

[0274] In some embodiments, an antibody or antigen-binding fragment thereof is provided, wherein HCDR1, HCDR2, and HCDR3 are selected from SEQ ID NO:82, SEQ ID NO:83, and SEQ ID NO:90, respectively; from SEQ ID NO:126, SEQ ID NO:127, and SEQ ID NO:90, respectively; or from SEQ ID NO:144, SEQ ID NO:145, and SEQ ID NO:150, respectively; and LCDR1, LCDR2, and LCDR3 are selected from SEQ ID NO:85, SEQ ID NO:86, and SEQ ID NO:89, respectively; from SEQ ID NO:85, SEQ ID NO:86, and SEQ ID NO:89, respectively; or from SEQ ID NO:147, SEQ ID NO:148, and SEQ ID NO:89, respectively.

[0275] In some embodiments, an antibody or antigen-binding fragment thereof is provided, wherein HCDR1, HCDR2, and HCDR3 are selected from SEQ ID NO:82, SEQ ID NO:83, and SEQ ID NO:91, respectively; from SEQ ID NO:126, SEQ ID NO:127, and SEQ ID NO:91, respectively; or from SEQ ID NO:144, SEQ ID NO:145, and SEQ ID NO:151, respectively; and LCDR1, LCDR2, and LCDR3 are selected from SEQ ID NO:85, SEQ ID NO:86, and SEQ ID NO:92, respectively; from SEQ ID NO:85, SEQ ID NO:86, and SEQ ID NO:92, respectively; or from SEQ ID NO:147, SEQ ID NO:148, and SEQ ID NO:92, respectively.

[0276] In some embodiments, an antibody or antigen-binding fragment thereof is provided, wherein HCDR1, HCDR2, and HCDR3 are selected from SEQ ID NO:82, SEQ ID NO:83, and SEQ ID NO:93, respectively; from SEQ ID NO:126, SEQ ID NO:127, and SEQ ID NO:93, respectively; or from SEQ ID NO:144, SEQ ID NO:145, and SEQ ID NO:152, respectively; and LCDR1, LCDR2, and LCDR3 are selected from SEQ ID NO:85, SEQ ID NO:86, and SEQ ID NO:94, respectively; from SEQ ID NO:85, SEQ ID NO:86, and SEQ ID NO:94, respectively; or from SEQ ID NO:147, SEQ ID NO:148, and SEQ ID NO:94, respectively.

[0277] In some embodiments, an antibody or antigen-binding fragment thereof is provided, wherein HCDR1, HCDR2, and HCDR3 are selected from SEQ ID NO:82, SEQ ID NO:83, and SEQ ID NO:84, respectively; from SEQ ID NO:126, SEQ ID NO:127, and SEQ ID NO:84, respectively; or from SEQ ID NO:144, SEQ ID NO:145, and SEQ ID NO:146, respectively; and LCDR1, LCDR2, and LCDR3 are selected from SEQ ID NO:85, SEQ ID NO:86, and SEQ ID NO:95, respectively; from SEQ ID NO:85, SEQ ID NO:86, and SEQ ID NO:95, respectively; or from SEQ ID NO:147, SEQ ID NO:148, and SEQ ID NO:95, respectively.

[0278] In some embodiments, an antibody or antigen-binding fragment thereof is provided, wherein HCDR1, HCDR2, and HCDR3 are selected from SEQ ID NO:82, SEQ ID NO:83, and SEQ ID NO:96, respectively; from SEQ ID NO:126, SEQ ID NO:127, and SEQ ID NO:96, respectively; or from SEQ ID NO:144, SEQ ID NO:145, and SEQ ID NO:153, respectively; and LCDR1, LCDR2, and LCDR3 are selected from SEQ ID NO:85, SEQ ID NO:86, and SEQ ID NO:97, respectively; from SEQ ID NO:85, SEQ ID NO:86, and SEQ ID NO:97, respectively; or from SEQ ID NO:147, SEQ ID NO:148, and SEQ ID NO:97, respectively.

[0279] In some embodiments, an antibody or antigen-binding fragment thereof is provided, wherein HCDR1, HCDR2, and HCDR3 are selected from SEQ ID NO:82, SEQ ID NO:83, and SEQ ID NO:98, respectively; from SEQ ID NO:126, SEQ ID NO:127, and SEQ ID NO:98, respectively; or from SEQ ID NO:144, SEQ ID NO:145, and SEQ ID NO:154, respectively; and LCDR1, LCDR2, and LCDR3 are selected from SEQ ID NO:85, SEQ ID NO:86, and SEQ ID NO:99, respectively; from SEQ ID NO:85, SEQ ID NO:86, and SEQ ID NO:99, respectively; or from SEQ ID NO:147, SEQ ID NO:148, and SEQ ID NO:99, respectively.

[0280] In some embodiments, an antibody or antigen-binding fragment thereof is provided, wherein HCDR1, HCDR2, and HCDR3 are selected from SEQ ID NO:82, SEQ ID NO:83, and SEQ ID NO:100, respectively; from SEQ ID NO:126, SEQ ID NO:127, and SEQ ID NO:100, respectively; or from SEQ ID NO:144, SEQ ID NO:145, and SEQ ID NO:155, respectively; and LCDR1, LCDR2, and LCDR3 are selected from SEQ ID NO:85, SEQ ID NO:86, and SEQ ID NO:101, respectively; from SEQ ID NO:85, SEQ ID NO:86, and SEQ ID NO:101, respectively; or from SEQ ID NO:147, SEQ ID NO:148, and SEQ ID NO:101, respectively.

[0281] In some embodiments, an antibody or antigen-binding fragment thereof is provided, wherein HCDR1, HCDR2, and HCDR3 are selected from SEQ ID NO:82, SEQ ID NO:83, and SEQ ID NO:100, respectively; from SEQ ID NO:126, SEQ ID NO:127, and SEQ ID NO:100, respectively; or from SEQ ID NO:144, SEQ ID NO:145, and SEQ ID NO:155, respectively; and LCDR1, LCDR2, and LCDR3 are selected from SEQ ID NO:85, SEQ ID NO:86, and SEQ ID NO:102, respectively; from SEQ ID NO:85, SEQ ID NO:86, and SEQ ID NO:102, respectively; or from SEQ ID NO:147, SEQ ID NO:148, and SEQ ID NO:102, respectively.

[0282] In some embodiments, an antibody or antigen-binding fragment thereof is provided, wherein HCDR1, HCDR2, and HCDR3 are selected from SEQ ID NO:103, SEQ ID NO:104, and SEQ ID NO:105, respectively; from SEQ ID NO:128, SEQ ID NO:129, and SEQ ID NO:105, respectively; or from SEQ ID NO:156, SEQ ID NO:157, and SEQ ID NO:158, respectively; and LCDR1, LCDR2, and LCDR3 are selected from SEQ ID NO:106, SEQ ID NO:107, and SEQ ID NO:108, respectively; from SEQ ID NO:106, SEQ ID NO:107, and SEQ ID NO:108, respectively; or from SEQ ID NO:159, SEQ ID NO:160, and SEQ ID NO:108, respectively.

[0283] In some embodiments, an antibody or antigen-binding fragment thereof is provided, wherein HCDR1, HCDR2, and HCDR3 are selected from SEQ ID NO:103, SEQ ID NO:104, and SEQ ID NO:109, respectively; from SEQ ID NO:128, SEQ ID NO:129, and SEQ ID NO:109, respectively; or from SEQ ID NO:156, SEQ ID NO:157, and SEQ ID NO:161, respectively; and LCDR1, LCDR2, and LCDR3 are selected from SEQ ID NO:106, SEQ ID NO:107, and SEQ ID NO:110, respectively; from SEQ ID NO:106, SEQ ID NO:107, and SEQ ID NO:110, respectively; or from SEQ ID NO:159, SEQ ID NO:160, and SEQ ID NO:110, respectively.

[0284] In some embodiments, an antibody or antigen-binding fragment thereof is provided, wherein HCDR1, HCDR2, and HCDR3 are selected from SEQ ID NO:103, SEQ ID NO:104, and SEQ ID NO:111, respectively; from SEQ ID NO:128, SEQ ID NO:129, and SEQ ID NO:111, respectively; or from SEQ ID NO:156, SEQ ID NO:157, and SEQ ID NO:162, respectively; and LCDR1, LCDR2, and LCDR3 are selected from SEQ ID NO:106, SEQ ID NO:107, and SEQ ID NO:112, respectively; from SEQ ID NO:106, SEQ ID NO:107, and SEQ ID NO:112, respectively; or from SEQ ID NO:159, SEQ ID NO:160, and SEQ ID NO:112, respectively.

[0285] In some embodiments, an antibody or antigen-binding fragment thereof is provided, wherein HCDR1, HCDR2, and HCDR3 are selected from SEQ ID NO:103, SEQ ID NO:104, and SEQ ID NO:105, respectively; from SEQ ID NO:128, SEQ ID NO:129, and SEQ ID NO:105, respectively; or from SEQ ID NO:156, SEQ ID NO:157, and SEQ ID NO:158, respectively; and LCDR1, LCDR2, and LCDR3 are selected from SEQ ID NO:106, SEQ ID NO:107, and SEQ ID NO:113, respectively; from SEQ ID NO:106, SEQ ID NO:107, and SEQ ID NO:113, respectively; or from SEQ ID NO:159, SEQ ID NO:160, and SEQ ID NO:113, respectively.

[0286] In some embodiments, an antibody or antigen-binding fragment thereof is provided, wherein HCDR1, HCDR2, and HCDR3 are selected from SEQ ID NO:103, SEQ ID NO:104, and SEQ ID NO:114, respectively; from SEQ ID NO:128, SEQ ID NO:129, and SEQ ID NO:114, respectively; or from SEQ ID NO:156, SEQ ID NO:157, and SEQ ID NO:163, respectively; and LCDR1, LCDR2, and LCDR3 are selected from SEQ ID NO:106, SEQ ID NO:107, and SEQ ID NO:115, respectively; from SEQ ID NO:106, SEQ ID NO:107, and SEQ ID NO:115, respectively; or from SEQ ID NO:159, SEQ ID NO:160, and SEQ ID NO:115, respectively.

[0287] In some embodiments, an antibody or antigen-binding fragment thereof is provided, wherein HCDR1, HCDR2, and HCDR3 are selected from SEQ ID NO:103, SEQ ID NO:104, and SEQ ID NO:116, respectively; from SEQ ID NO:128, SEQ ID NO:129, and SEQ ID NO:116, respectively; or from SEQ ID NO:156, SEQ ID NO:157, and SEQ ID NO:164, respectively; and LCDR1, LCDR2, and LCDR3 are selected from SEQ ID NO:106, SEQ ID NO:107, and SEQ ID NO:113, respectively; from SEQ ID NO:106, SEQ ID NO:107, and SEQ ID NO:113, respectively; or from SEQ ID NO:159, SEQ ID NO:160, and SEQ ID NO:113, respectively.

[0288] In some embodiments, an antibody or antigen-binding fragment thereof is provided, wherein HCDR1, HCDR2, and HCDR3 are selected from SEQ ID NO:103, SEQ ID NO:104, and SEQ ID NO:117, respectively; from SEQ ID NO:128, SEQ ID NO:129, and SEQ ID NO:117, respectively; or from SEQ ID NO:156, SEQ ID NO:157, and SEQ ID NO:165, respectively; and LCDR1, LCDR2, and LCDR3 are selected from SEQ ID NO:106, SEQ ID NO:107, and SEQ ID NO:118, respectively; from SEQ ID NO:106, SEQ ID NO:107, and SEQ ID NO:118, respectively; or from SEQ ID NO:159, SEQ ID NO:160, and SEQ ID NO:118, respectively.

[0289] In some embodiments, an antibody or antigen-binding fragment thereof is provided, wherein HCDR1, HCDR2, and HCDR3 are selected from SEQ ID NO:103, SEQ ID NO:104, and SEQ ID NO:116, respectively; from SEQ ID NO:128, SEQ ID NO:129, and SEQ ID NO:116, respectively; or from SEQ ID NO:156, SEQ ID NO:157, and SEQ ID NO:164, respectively; and LCDR1, LCDR2, and LCDR3 are selected from SEQ ID NO:106, SEQ ID NO:107, and SEQ ID NO:119, respectively; from SEQ ID NO:106, SEQ ID NO:107, and SEQ ID NO:119, respectively; or from SEQ ID NO:159, SEQ ID NO:160, and SEQ ID NO:119, respectively.

[0290] In some embodiments, an antibody or antigen-binding fragment thereof is provided, wherein HCDR1, HCDR2, and HCDR3 are selected from SEQ ID NO:103, SEQ ID NO:104, and SEQ ID NO:120, respectively; from SEQ ID NO:128, SEQ ID NO:129, and SEQ ID NO:120, respectively; or from SEQ ID NO:156, SEQ ID NO:157, and SEQ ID NO:166, respectively; and LCDR1, LCDR2, and LCDR3 are selected from SEQ ID NO:106, SEQ ID NO:107, and SEQ ID NO:121, respectively; from SEQ ID NO:106, SEQ ID NO:107, and SEQ ID NO:121, respectively; or from SEQ ID NO:159, SEQ ID NO:160, and SEQ ID NO:121, respectively.

[0291] In some embodiments, an antibody or antigen-binding fragment thereof is provided, wherein HCDR1, HCDR2, and HCDR3 are selected from SEQ ID NO:103, SEQ ID NO:104, and SEQ ID NO:122, respectively; from SEQ ID NO:128, SEQ ID NO:129, and SEQ ID NO:122, respectively; or from SEQ ID NO:156, SEQ ID NO:157, and SEQ ID NO:167, respectively; and LCDR1, LCDR2, and LCDR3 are selected from SEQ ID NO:106, SEQ ID NO:107, and SEQ ID NO:123, respectively; from SEQ ID NO:106, SEQ ID NO:107, and SEQ ID NO:123, respectively; or from SEQ ID NO:159, SEQ ID NO:160, and SEQ ID NO:123, respectively.

[0292] In some embodiments, the antibody comprises a heavy chain variable region peptide having any of the following sequences, or a variant thereof: [Table 5-1] [Table 5-2] [Table 5-3] [Table 5-4] [Table 5-5]

[0293] In some embodiments, the antibody comprises the following heavy chain variable chain sequence: VQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISRSGSTKYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDENYALDWWGQGTLVTVSS (SEQ ID NO: 454). A variable heavy chain comprising this amino acid sequence can be paired with, for example, a variable light chain comprising the amino acid sequence of SEQ ID NO: 18 or a light chain of SEQ ID NO: 236. A variable heavy chain (VH) comprising the amino acid sequence of SEQ ID NO: 454 can be fused to a constant domain comprising a YTE or LS variant, as exemplified herein. For example, in some embodiments, the constant domain comprises the amino acid sequence of SEQ ID NO: 262 or SEQ ID NO: 261.

[0294] In some embodiments, the antibody comprises the following heavy chain sequence: VQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVSYISRSGSTKYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDENYALDWWGQGTLVT VSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCP APEFEGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG (SEQ ID NO: 455).

[0295] In some embodiments, the antibody comprises a light chain variable region peptide having any of the following sequences, or a variant thereof: [Table 6-1] [Table 6-2]

[0296] In some embodiments, the antibody or antigen-binding fragment thereof is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, and / or any variant thereof.

[0297] In some embodiments, the antibody or antigen-binding fragment thereof comprises the V of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 358, 359, 360, 361, 362, or 363H peptide or any variant thereof.

[0298] In some embodiments, the antibody or antigen-binding fragment thereof is selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343 , 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 353, 358, 359, 360, 361, 362, or 363 having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to H Contains peptides.

[0299] In some embodiments, the antibody or antigen-binding fragment thereof comprises the V of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 358, 359, 360, 361, 362, or 363 H Contains peptides.

[0300] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 1 H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO:1. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:1.H Contains peptides.

[0301] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO:3 H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO:3. H Contains peptides.

[0302] In some embodiments, the antibody or antigen-binding fragment thereof has a V that has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:3. H Contains peptides.

[0303] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO:5. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO:5. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:5. H Contains peptides.

[0304] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO:7 H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO:7. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:7. H Contains peptides.

[0305] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO:9. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO:9. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:9. H Contains peptides.

[0306] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 11. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 11. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 11. H Contains peptides.

[0307] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 13. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 13. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 13. H Contains peptides.

[0308] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 15.H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 15. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 15. H Contains peptides.

[0309] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 17 H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 17. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 17. H Contains peptides.

[0310] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 19. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 19. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 19. H Contains peptides.

[0311] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 21. HIn some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO:21. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:21. H Contains peptides.

[0312] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 23 H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO:23. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:23. H Contains peptides.

[0313] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 25. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO:25. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:25. H Contains peptides.

[0314] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 27 H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO:27.H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:27. H Contains peptides.

[0315] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO:29. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO:29. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:29. H Contains peptides.

[0316] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 31 H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 31. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 31. H Contains peptides.

[0317] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 33 H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 33. HIn some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 33. H Contains peptides.

[0318] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 35 H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 35. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 35. H Contains peptides.

[0319] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 37 H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 37. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 37. H Contains peptides.

[0320] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 39 H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO:39. HIn some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:39. H Contains peptides.

[0321] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 41 H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO:41. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:41. H Contains peptides.

[0322] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 43 H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO:43. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:43. H Contains peptides.

[0323] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 45 H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO:45. HIn some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:45. H Contains peptides.

[0324] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 47 H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO:47. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:47. H Contains peptides.

[0325] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO:49 H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO:49. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:49. H Contains peptides.

[0326] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 51 H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO:51. HIn some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:51. H Contains peptides.

[0327] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 53 H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 53. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 53. H Contains peptides.

[0328] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 55. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 55. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:55. H Contains peptides.

[0329] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 57 H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO:57. HIn some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:57. H Contains peptides.

[0330] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 59. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO:59. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:59. H Contains peptides.

[0331] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 334. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 334. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 334. H Contains peptides.

[0332] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 335. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 335. HIn some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 335. H Contains peptides.

[0333] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 336. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 336. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 336. H Contains peptides.

[0334] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 337. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 337. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 337. H Contains peptides.

[0335] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 338. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 338. HIn some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 338. H Contains peptides.

[0336] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 339. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 339. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 339. H Contains peptides.

[0337] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 340. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 340. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 340. H Contains peptides.

[0338] In some embodiments, the antibody or antigen-binding fragment thereof comprises the V of SEQ ID NO: 341. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 341. HIn some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 341. H Contains peptides.

[0339] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 342. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 342. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 342. H Contains peptides.

[0340] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 343. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 343. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 343. H Contains peptides.

[0341] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 344. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 344. HIn some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 344. H Contains peptides.

[0342] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 345. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 345. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 345. H Contains peptides.

[0343] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 346 H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 346. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 346. H Contains peptides.

[0344] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 347. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 347. HIn some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 347. H Contains peptides.

[0345] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 348. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 348. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 348. H Contains peptides.

[0346] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 349. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 349. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 349. H Contains peptides.

[0347] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 350. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 350. HIn some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 350. H Contains peptides.

[0348] In some embodiments, the antibody or antigen-binding fragment thereof comprises the V of SEQ ID NO: 351. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 351. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 351. H Contains peptides.

[0349] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 352. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 352. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 352. H Contains peptides.

[0350] In some embodiments, the antibody or antigen-binding fragment thereof comprises the V of SEQ ID NO: 353. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 353. HIn some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 353. H Contains peptides.

[0351] In some embodiments, the antibody or antigen-binding fragment thereof comprises the V of SEQ ID NO: 354. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 354. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 354. H Contains peptides.

[0352] In some embodiments, the antibody or antigen-binding fragment thereof comprises the V of SEQ ID NO: 355. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 355. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 355. H Contains peptides.

[0353] In some embodiments, the antibody or antigen-binding fragment thereof comprises the V of SEQ ID NO: 356. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 356. HIn some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 356. H Contains peptides.

[0354] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 357. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 357. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 357. H Contains peptides.

[0355] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 358. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 358. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 358. H Contains peptides.

[0356] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 359. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 359. HIn some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 359. H Contains peptides.

[0357] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 360. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 360. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 360. H Contains peptides.

[0358] In some embodiments, the antibody or antigen-binding fragment thereof comprises the V of SEQ ID NO: 361. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 361. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 361. H Contains peptides.

[0359] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 362. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 362. HIn some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 362. H Contains peptides.

[0360] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 363. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 363. H In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 363. H Contains peptides.

[0361] In some embodiments, the antibody or antigen-binding fragment thereof comprises a V of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, or 60. L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide or any variant thereof having at least 85% identity to SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, or 60. LIn some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, or 60. L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, or 60. L Contains peptides.

[0362] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO:2. L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO:2. L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:2. L Contains peptides.

[0363] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO:4 L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO:4. L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:4. L Contains peptides.

[0364] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO:6 L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO:6. L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:6. L Contains peptides.

[0365] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO:8 L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO:8. L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:8. L Contains peptides.

[0366] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 10. L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 10. L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 10. L Contains peptides.

[0367] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 12. L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 12. L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 12. L Contains peptides.

[0368] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 14. L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 14. L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 14. L Contains peptides.

[0369] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 16. L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 16. L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 16. L Contains peptides.

[0370] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 18. LIn some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 18. L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 18. L Contains peptides.

[0371] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 20 L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO:20. L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:20. L Contains peptides.

[0372] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 22. L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 22. L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:22. L Contains peptides.

[0373] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 24. L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO:24.L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:24. L Contains peptides.

[0374] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 26 L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO:26. L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:26. L Contains peptides.

[0375] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 28 L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO:28. L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:28. L Contains peptides.

[0376] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 30 L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 30. LIn some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 30. L Contains peptides.

[0377] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 32. L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 32. L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 32. L Contains peptides.

[0378] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 34. L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 34. L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 34. L Contains peptides.

[0379] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 36 L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 36. LIn some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:36. L Contains peptides.

[0380] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 38 L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 38. L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 38. L Contains peptides.

[0381] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 40 L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO:40. L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:40. L Contains peptides.

[0382] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 42. L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO:42. LIn some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:42. L Contains peptides.

[0383] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 44. L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO:44. L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:44. L Contains peptides.

[0384] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 46 L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO:46. L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:46. L Contains peptides.

[0385] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 48 L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO:48. LIn some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:48. L Contains peptides.

[0386] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 50 L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO:50. L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:50. L Contains peptides.

[0387] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 52. L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 52. L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:52. L Contains peptides.

[0388] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 54. L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO: 54. LIn some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:54. L Contains peptides.

[0389] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 56 L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO:56. L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:56. L Contains peptides.

[0390] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 58 L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO:58. L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:58. L Contains peptides.

[0391] In some embodiments, the antibody or antigen-binding fragment thereof comprises V of SEQ ID NO: 60 L In some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85% identity to SEQ ID NO:60. LIn some embodiments, the antibody or antigen-binding fragment thereof comprises a V peptide having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO:60. L Contains peptides.

[0392] In some embodiments, the antibody or antigen-binding fragment thereof has a V H Peptides and V L Contains peptides, V H The peptide comprises the sequence of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 358, 359, 360, 361, 362, or 363, or any variant thereof; L The peptide comprises the sequence of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, or 60, or any variant thereof. H Peptides and V L Contains peptides, V HThe peptides are SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346 , 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 35358, 359, 360, 361, 362, or 363, and V L The peptide has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, or 60. In some embodiments, V H The peptide comprises the sequence of SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 358, 359, 360, 361, 362, or 363; L The peptide comprises the sequence of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, or 60.

[0393] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 1, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 61, SEQ ID NO: 124, or SEQ ID NO: 130, maintains the HCDR2 sequence of SEQ ID NO: 62, SEQ ID NO: 125, or SEQ ID NO: 131, maintains the HCDR3 sequence of SEQ ID NO: 63 or SEQ ID NO: 132, maintains the LCDR1 sequence of SEQ ID NO: 64 or SEQ ID NO: 133, maintains the LCDR2 sequence of SEQ ID NO: 65 or SEQ ID NO: 134, and maintains the LCDR3 sequence of SEQ ID NO: 66.

[0394] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:3, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:61, SEQ ID NO:124, or SEQ ID NO:130, maintains the HCDR2 sequence of SEQ ID NO:62, SEQ ID NO:125, or SEQ ID NO:131, maintains the HCDR3 sequence of SEQ ID NO:67 or SEQ ID NO:135, maintains the LCDR1 sequence of SEQ ID NO:64 or SEQ ID NO:1339, maintains the LCDR2 sequence of SEQ ID NO:65 or SEQ ID NO:134, and maintains the LCDR3 sequence of SEQ ID NO:68.

[0395] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:5, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:61, SEQ ID NO:124, or SEQ ID NO:130, maintains the HCDR2 sequence of SEQ ID NO:62, SEQ ID NO:125, or SEQ ID NO:131, maintains the HCDR3 sequence of SEQ ID NO:69 or SEQ ID NO:136, maintains the LCDR1 sequence of SEQ ID NO:64 or SEQ ID NO:133, maintains the LCDR2 sequence of SEQ ID NO:65 or SEQ ID NO:134, and maintains the LCDR3 sequence of SEQ ID NO:68.

[0396] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:7, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:61, SEQ ID NO:124, or SEQ ID NO:130, maintains the HCDR2 sequence of SEQ ID NO:62, SEQ ID NO:125, or SEQ ID NO:131, maintains the HCDR3 sequence of SEQ ID NO:70 or SEQ ID NO:137, maintains the LCDR1 sequence of SEQ ID NO:64 or SEQ ID NO:133, maintains the LCDR2 sequence of SEQ ID NO:65 or SEQ ID NO:134, and maintains the LCDR3 sequence of SEQ ID NO:71.

[0397] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 9, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 61, SEQ ID NO: 124, or SEQ ID NO: 130, maintains the HCDR2 sequence of SEQ ID NO: 62, SEQ ID NO: 125, or SEQ ID NO: 131, maintains the HCDR3 sequence of SEQ ID NO: 72 or SEQ ID NO: 138, maintains the LCDR1 sequence of SEQ ID NO: 64 or SEQ ID NO: 133, maintains the LCDR2 sequence of SEQ ID NO: 65 or SEQ ID NO: 134, and maintains the LCDR3 sequence of SEQ ID NO: 71.

[0398] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 11, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 61, SEQ ID NO: 124, or SEQ ID NO: 130, maintains the HCDR2 sequence of SEQ ID NO: 62, SEQ ID NO: 125, or SEQ ID NO: 131, maintains the HCDR3 sequence of SEQ ID NO: 73 or SEQ ID NO: 139, maintains the LCDR1 sequence of SEQ ID NO: 64 or SEQ ID NO: 133, maintains the LCDR2 sequence of SEQ ID NO: 65 or SEQ ID NO: 134, and maintains the LCDR3 sequence of SEQ ID NO: 71.

[0399] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 13, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 61, SEQ ID NO: 124, or SEQ ID NO: 130, maintains the HCDR2 sequence of SEQ ID NO: 62, SEQ ID NO: 125, or SEQ ID NO: 131, maintains the HCDR3 sequence of SEQ ID NO: 74 or SEQ ID NO: 140, maintains the LCDR1 sequence of SEQ ID NO: 64 or SEQ ID NO: 133, maintains the LCDR2 sequence of SEQ ID NO: 65 or SEQ ID NO: 134, and maintains the LCDR3 sequence of SEQ ID NO: 75.

[0400] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 15, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 61, SEQ ID NO: 124, or SEQ ID NO: 130, maintains the HCDR2 sequence of SEQ ID NO: 62, SEQ ID NO: 125, or SEQ ID NO: 131, maintains the HCDR3 sequence of SEQ ID NO: 76 or SEQ ID NO: 141, maintains the LCDR1 sequence of SEQ ID NO: 64 or SEQ ID NO: 133, maintains the LCDR2 sequence of SEQ ID NO: 65 or SEQ ID NO: 134, and maintains the LCDR3 sequence of SEQ ID NO: 77.

[0401] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 17, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 61, SEQ ID NO: 124, or SEQ ID NO: 130, maintains the HCDR2 sequence of SEQ ID NO: 62, SEQ ID NO: 125, or SEQ ID NO: 131, maintains the HCDR3 sequence of SEQ ID NO: 78 or SEQ ID NO: 142, maintains the LCDR1 sequence of SEQ ID NO: 64 or SEQ ID NO: 133, maintains the LCDR2 sequence of SEQ ID NO: 65 or SEQ ID NO: 134, and maintains the LCDR3 sequence of SEQ ID NO: 79.

[0402] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 19, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 61, SEQ ID NO: 124, or SEQ ID NO: 130, maintains the HCDR2 sequence of SEQ ID NO: 62, SEQ ID NO: 125, or SEQ ID NO: 131, maintains the HCDR3 sequence of SEQ ID NO: 80 or SEQ ID NO: 143, maintains the LCDR1 sequence of SEQ ID NO: 64 or SEQ ID NO: 133, maintains the LCDR2 sequence of SEQ ID NO: 65 or SEQ ID NO: 134, and maintains the LCDR3 sequence of SEQ ID NO: 81.

[0403] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:21, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:82, SEQ ID NO:126, or SEQ ID NO:144, maintains the HCDR2 sequence of SEQ ID NO:83, SEQ ID NO:127, or SEQ ID NO:145, maintains the HCDR3 sequence of SEQ ID NO:84 or SEQ ID NO:146, maintains the LCDR1 sequence of SEQ ID NO:85 or SEQ ID NO:147, maintains the LCDR2 sequence of SEQ ID NO:86 or SEQ ID NO:148, and maintains the LCDR3 sequence of SEQ ID NO:87.

[0404] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:23, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:82, SEQ ID NO:126, or SEQ ID NO:144, maintains the HCDR2 sequence of SEQ ID NO:83, SEQ ID NO:127, or SEQ ID NO:145, maintains the HCDR3 sequence of SEQ ID NO:88 or SEQ ID NO:149, maintains the LCDR1 sequence of SEQ ID NO:85 or SEQ ID NO:147, maintains the LCDR2 sequence of SEQ ID NO:86 or SEQ ID NO:148, and maintains the LCDR3 sequence of SEQ ID NO:89.

[0405] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:25, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:82, SEQ ID NO:126, or SEQ ID NO:144, maintains the HCDR2 sequence of SEQ ID NO:83, SEQ ID NO:127, or SEQ ID NO:145, maintains the HCDR3 sequence of SEQ ID NO:90 or SEQ ID NO:150, maintains the LCDR1 sequence of SEQ ID NO:85 or SEQ ID NO:147, maintains the LCDR2 sequence of SEQ ID NO:86 or SEQ ID NO:148, and maintains the LCDR3 sequence of SEQ ID NO:89.

[0406] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:27, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:82, SEQ ID NO:126, or SEQ ID NO:144, maintains the HCDR2 sequence of SEQ ID NO:83, SEQ ID NO:127, or SEQ ID NO:145, maintains the HCDR3 sequence of SEQ ID NO:91 or SEQ ID NO:151, maintains the LCDR1 sequence of SEQ ID NO:85 or SEQ ID NO:147, maintains the LCDR2 sequence of SEQ ID NO:86 or SEQ ID NO:148, and maintains the LCDR3 sequence of SEQ ID NO:92.

[0407] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:29, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:82, SEQ ID NO:126, or SEQ ID NO:144, maintains the HCDR2 sequence of SEQ ID NO:83, SEQ ID NO:127, or SEQ ID NO:145, maintains the HCDR3 sequence of SEQ ID NO:93 or SEQ ID NO:152, maintains the LCDR1 sequence of SEQ ID NO:85 or SEQ ID NO:147, maintains the LCDR2 sequence of SEQ ID NO:86 or SEQ ID NO:148, and maintains the LCDR3 sequence of SEQ ID NO:94.

[0408] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:31, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:82, SEQ ID NO:126, or SEQ ID NO:144, maintains the HCDR2 sequence of SEQ ID NO:83, SEQ ID NO:127, or SEQ ID NO:145, maintains the HCDR3 sequence of SEQ ID NO:84 or SEQ ID NO:146, maintains the LCDR1 sequence of SEQ ID NO:85 or SEQ ID NO:147, maintains the LCDR2 sequence of SEQ ID NO:86 or SEQ ID NO:148, and maintains the LCDR3 sequence of SEQ ID NO:95.

[0409] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 33, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 82, SEQ ID NO: 126, or SEQ ID NO: 144, maintains the HCDR2 sequence of SEQ ID NO: 83, SEQ ID NO: 127, or SEQ ID NO: 145, maintains the HCDR3 sequence of SEQ ID NO: 96 or SEQ ID NO: 153, maintains the LCDR1 sequence of SEQ ID NO: 85 or SEQ ID NO: 147, maintains the LCDR2 sequence of SEQ ID NO: 86 or SEQ ID NO: 148, and maintains the LCDR3 sequence of SEQ ID NO: 97.

[0410] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:35, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:82, SEQ ID NO:126, or SEQ ID NO:144, maintains the HCDR2 sequence of SEQ ID NO:83, SEQ ID NO:127, or SEQ ID NO:145, maintains the HCDR3 sequence of SEQ ID NO:98 or SEQ ID NO:154, maintains the LCDR1 sequence of SEQ ID NO:85 or SEQ ID NO:147, maintains the LCDR2 sequence of SEQ ID NO:86 or SEQ ID NO:148, and maintains the LCDR3 sequence of SEQ ID NO:99.

[0411] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:37, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:82, SEQ ID NO:126, or SEQ ID NO:144, maintains the HCDR2 sequence of SEQ ID NO:83, SEQ ID NO:127, or SEQ ID NO:145, maintains the HCDR3 sequence of SEQ ID NO:100 or SEQ ID NO:155, maintains the LCDR1 sequence of SEQ ID NO:85 or SEQ ID NO:147, maintains the LCDR2 sequence of SEQ ID NO:86 or SEQ ID NO:148, and maintains the LCDR3 sequence of SEQ ID NO:101.

[0412] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:39, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:82, SEQ ID NO:126, or SEQ ID NO:144, maintains the HCDR2 sequence of SEQ ID NO:83, SEQ ID NO:127, or SEQ ID NO:145, maintains the HCDR3 sequence of SEQ ID NO:100 or SEQ ID NO:155, maintains the LCDR1 sequence of SEQ ID NO:85 or SEQ ID NO:147, maintains the LCDR2 sequence of SEQ ID NO:86 or SEQ ID NO:148, and maintains the LCDR3 sequence of SEQ ID NO:102.

[0413] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:41, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:103, SEQ ID NO:128, or SEQ ID NO:156, maintains the HCDR2 sequence of SEQ ID NO:104, SEQ ID NO:129, or SEQ ID NO:157, maintains the HCDR3 sequence of SEQ ID NO:105 or SEQ ID NO:158, maintains the LCDR1 sequence of SEQ ID NO:106 or SEQ ID NO:159, maintains the LCDR2 sequence of SEQ ID NO:107 or SEQ ID NO:160, and maintains the LCDR3 sequence of SEQ ID NO:108.

[0414] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:43, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:103, SEQ ID NO:128, or SEQ ID NO:156, maintains the HCDR2 sequence of SEQ ID NO:104, SEQ ID NO:129, or SEQ ID NO:157, maintains the HCDR3 sequence of SEQ ID NO:109 or SEQ ID NO:161, maintains the LCDR1 sequence of SEQ ID NO:106 or SEQ ID NO:159, maintains the LCDR2 sequence of SEQ ID NO:107 or SEQ ID NO:160, and maintains the LCDR3 sequence of SEQ ID NO:110.

[0415] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:45, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:103, SEQ ID NO:128, or SEQ ID NO:156, maintains the HCDR2 sequence of SEQ ID NO:104, SEQ ID NO:129, or SEQ ID NO:157, maintains the HCDR3 sequence of SEQ ID NO:111 or SEQ ID NO:162, maintains the LCDR1 sequence of SEQ ID NO:106 or SEQ ID NO:159, maintains the LCDR2 sequence of SEQ ID NO:107 or SEQ ID NO:160, and maintains the LCDR3 sequence of SEQ ID NO:112.

[0416] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:47, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:103, SEQ ID NO:128, or SEQ ID NO:156, maintains the HCDR2 sequence of SEQ ID NO:104, SEQ ID NO:129, or SEQ ID NO:157, maintains the HCDR3 sequence of SEQ ID NO:105 or SEQ ID NO:158, maintains the LCDR1 sequence of SEQ ID NO:106 or SEQ ID NO:159, maintains the LCDR2 sequence of SEQ ID NO:107 or SEQ ID NO:160, and maintains the LCDR3 sequence of SEQ ID NO:113.

[0417] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:49, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:103, SEQ ID NO:128, or SEQ ID NO:156, maintains the HCDR2 sequence of SEQ ID NO:104, SEQ ID NO:129, or SEQ ID NO:157, maintains the HCDR3 sequence of SEQ ID NO:114 or SEQ ID NO:163, maintains the LCDR1 sequence of SEQ ID NO:106 or SEQ ID NO:159, maintains the LCDR2 sequence of SEQ ID NO:107 or SEQ ID NO:160, and maintains the LCDR3 sequence of SEQ ID NO:115.

[0418] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:51, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:103, SEQ ID NO:128, or SEQ ID NO:156, maintains the HCDR2 sequence of SEQ ID NO:104, SEQ ID NO:129, or SEQ ID NO:157, maintains the HCDR3 sequence of SEQ ID NO:116 or SEQ ID NO:164, maintains the LCDR1 sequence of SEQ ID NO:106 or SEQ ID NO:159, maintains the LCDR2 sequence of SEQ ID NO:107 or SEQ ID NO:160, and maintains the LCDR3 sequence of SEQ ID NO:113.

[0419] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:53, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:103, SEQ ID NO:128, or SEQ ID NO:156, maintains the HCDR2 sequence of SEQ ID NO:104, SEQ ID NO:129, or SEQ ID NO:157, maintains the HCDR3 sequence of SEQ ID NO:117 or SEQ ID NO:165, maintains the LCDR1 sequence of SEQ ID NO:106 or SEQ ID NO:159, maintains the LCDR2 sequence of SEQ ID NO:107 or SEQ ID NO:160, and maintains the LCDR3 sequence of SEQ ID NO:118.

[0420] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:55, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:103, SEQ ID NO:128, or SEQ ID NO:156, maintains the HCDR2 sequence of SEQ ID NO:104, SEQ ID NO:129, or SEQ ID NO:157, maintains the HCDR3 sequence of SEQ ID NO:116 or SEQ ID NO:164, maintains the LCDR1 sequence of SEQ ID NO:106 or SEQ ID NO:159, maintains the LCDR2 sequence of SEQ ID NO:107 or SEQ ID NO:160, and maintains the LCDR3 sequence of SEQ ID NO:119.

[0421] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:57, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:103, SEQ ID NO:128, or SEQ ID NO:156, maintains the HCDR2 sequence of SEQ ID NO:104, SEQ ID NO:129, or SEQ ID NO:157, maintains the HCDR3 sequence of SEQ ID NO:120 or SEQ ID NO:166, maintains the LCDR1 sequence of SEQ ID NO:106 or SEQ ID NO:159, maintains the LCDR2 sequence of SEQ ID NO:107 or SEQ ID NO:160, and maintains the LCDR3 sequence of SEQ ID NO:121.

[0422] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:59, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:103, SEQ ID NO:128, or SEQ ID NO:156, maintains the HCDR2 sequence of SEQ ID NO:104, SEQ ID NO:129, or SEQ ID NO:157, maintains the HCDR3 sequence of SEQ ID NO:122 or SEQ ID NO:167, maintains the LCDR1 sequence of SEQ ID NO:106 or SEQ ID NO:159, maintains the LCDR2 sequence of SEQ ID NO:107 or SEQ ID NO:160, and maintains the LCDR3 sequence of SEQ ID NO:123.

[0423] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 334, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 61, SEQ ID NO: 124, or SEQ ID NO: 130, maintains the HCDR2 sequence of SEQ ID NO: 62, SEQ ID NO: 125, or SEQ ID NO: 131, maintains the HCDR3 sequence of SEQ ID NO: 63 or SEQ ID NO: 132, maintains the LCDR1 sequence of SEQ ID NO: 64 or SEQ ID NO: 133, maintains the LCDR2 sequence of SEQ ID NO: 65 or SEQ ID NO: 134, and maintains the LCDR3 sequence of SEQ ID NO: 66.

[0424] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 335, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 61, SEQ ID NO: 124, or SEQ ID NO: 130, maintains the HCDR2 sequence of SEQ ID NO: 62, SEQ ID NO: 125, or SEQ ID NO: 131, maintains the HCDR3 sequence of SEQ ID NO: 67 or SEQ ID NO: 135, maintains the LCDR1 sequence of SEQ ID NO: 64 or SEQ ID NO: 1339, maintains the LCDR2 sequence of SEQ ID NO: 65 or SEQ ID NO: 134, and maintains the LCDR3 sequence of SEQ ID NO: 68.

[0425] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 336, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 61, SEQ ID NO: 124, or SEQ ID NO: 130, maintains the HCDR2 sequence of SEQ ID NO: 62, SEQ ID NO: 125, or SEQ ID NO: 131, maintains the HCDR3 sequence of SEQ ID NO: 69 or SEQ ID NO: 136, maintains the LCDR1 sequence of SEQ ID NO: 64 or SEQ ID NO: 133, maintains the LCDR2 sequence of SEQ ID NO: 65 or SEQ ID NO: 134, and maintains the LCDR3 sequence of SEQ ID NO: 68.

[0426] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 337, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 61, SEQ ID NO: 124, or SEQ ID NO: 130, maintains the HCDR2 sequence of SEQ ID NO: 62, SEQ ID NO: 125, or SEQ ID NO: 131, maintains the HCDR3 sequence of SEQ ID NO: 70 or SEQ ID NO: 137, maintains the LCDR1 sequence of SEQ ID NO: 64 or SEQ ID NO: 133, maintains the LCDR2 sequence of SEQ ID NO: 65 or SEQ ID NO: 134, and maintains the LCDR3 sequence of SEQ ID NO: 71.

[0427] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 338, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 61, SEQ ID NO: 124, or SEQ ID NO: 130, maintains the HCDR2 sequence of SEQ ID NO: 62, SEQ ID NO: 125, or SEQ ID NO: 131, maintains the HCDR3 sequence of SEQ ID NO: 72 or SEQ ID NO: 138, maintains the LCDR1 sequence of SEQ ID NO: 64 or SEQ ID NO: 133, maintains the LCDR2 sequence of SEQ ID NO: 65 or SEQ ID NO: 134, and maintains the LCDR3 sequence of SEQ ID NO: 71.

[0428] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 339, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 61, SEQ ID NO: 124, or SEQ ID NO: 130, maintains the HCDR2 sequence of SEQ ID NO: 62, SEQ ID NO: 125, or SEQ ID NO: 131, maintains the HCDR3 sequence of SEQ ID NO: 73 or SEQ ID NO: 139, maintains the LCDR1 sequence of SEQ ID NO: 64 or SEQ ID NO: 133, maintains the LCDR2 sequence of SEQ ID NO: 65 or SEQ ID NO: 134, and maintains the LCDR3 sequence of SEQ ID NO: 71.

[0429] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 340, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 61, SEQ ID NO: 124, or SEQ ID NO: 130, maintains the HCDR2 sequence of SEQ ID NO: 62, SEQ ID NO: 125, or SEQ ID NO: 131, maintains the HCDR3 sequence of SEQ ID NO: 74 or SEQ ID NO: 140, maintains the LCDR1 sequence of SEQ ID NO: 64 or SEQ ID NO: 133, maintains the LCDR2 sequence of SEQ ID NO: 65 or SEQ ID NO: 134, and maintains the LCDR3 sequence of SEQ ID NO: 75.

[0430] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 341, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 61, SEQ ID NO: 124, or SEQ ID NO: 130, maintains the HCDR2 sequence of SEQ ID NO: 62, SEQ ID NO: 125, or SEQ ID NO: 131, maintains the HCDR3 sequence of SEQ ID NO: 76 or SEQ ID NO: 141, maintains the LCDR1 sequence of SEQ ID NO: 64 or SEQ ID NO: 133, maintains the LCDR2 sequence of SEQ ID NO: 65 or SEQ ID NO: 134, and maintains the LCDR3 sequence of SEQ ID NO: 77.

[0431] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 342, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 61, SEQ ID NO: 124, or SEQ ID NO: 130, maintains the HCDR2 sequence of SEQ ID NO: 62, SEQ ID NO: 125, or SEQ ID NO: 131, maintains the HCDR3 sequence of SEQ ID NO: 78 or SEQ ID NO: 142, maintains the LCDR1 sequence of SEQ ID NO: 64 or SEQ ID NO: 133, maintains the LCDR2 sequence of SEQ ID NO: 65 or SEQ ID NO: 134, and maintains the LCDR3 sequence of SEQ ID NO: 79.

[0432] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 343, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 61, SEQ ID NO: 124, or SEQ ID NO: 130, maintains the HCDR2 sequence of SEQ ID NO: 62, SEQ ID NO: 125, or SEQ ID NO: 131, maintains the HCDR3 sequence of SEQ ID NO: 80 or SEQ ID NO: 143, maintains the LCDR1 sequence of SEQ ID NO: 64 or SEQ ID NO: 133, maintains the LCDR2 sequence of SEQ ID NO: 65 or SEQ ID NO: 134, and maintains the LCDR3 sequence of SEQ ID NO: 81.

[0433] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 344, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 82, SEQ ID NO: 126, or SEQ ID NO: 144, maintains the HCDR2 sequence of SEQ ID NO: 83, SEQ ID NO: 127, or SEQ ID NO: 145, maintains the HCDR3 sequence of SEQ ID NO: 84 or SEQ ID NO: 146, maintains the LCDR1 sequence of SEQ ID NO: 85 or SEQ ID NO: 147, maintains the LCDR2 sequence of SEQ ID NO: 86 or SEQ ID NO: 148, and maintains the LCDR3 sequence of SEQ ID NO: 87.

[0434] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 345, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 82, SEQ ID NO: 126, or SEQ ID NO: 144, maintains the HCDR2 sequence of SEQ ID NO: 83, SEQ ID NO: 127, or SEQ ID NO: 145, maintains the HCDR3 sequence of SEQ ID NO: 88 or SEQ ID NO: 149, maintains the LCDR1 sequence of SEQ ID NO: 85 or SEQ ID NO: 147, maintains the LCDR2 sequence of SEQ ID NO: 86 or SEQ ID NO: 148, and maintains the LCDR3 sequence of SEQ ID NO: 89.

[0435] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 346, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 82, SEQ ID NO: 126, or SEQ ID NO: 144, maintains the HCDR2 sequence of SEQ ID NO: 83, SEQ ID NO: 127, or SEQ ID NO: 145, maintains the HCDR3 sequence of SEQ ID NO: 90 or SEQ ID NO: 150, maintains the LCDR1 sequence of SEQ ID NO: 85 or SEQ ID NO: 147, maintains the LCDR2 sequence of SEQ ID NO: 86 or SEQ ID NO: 148, and maintains the LCDR3 sequence of SEQ ID NO: 89.

[0436] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 347, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 82, SEQ ID NO: 126, or SEQ ID NO: 144, maintains the HCDR2 sequence of SEQ ID NO: 83, SEQ ID NO: 127, or SEQ ID NO: 145, maintains the HCDR3 sequence of SEQ ID NO: 91 or SEQ ID NO: 151, maintains the LCDR1 sequence of SEQ ID NO: 85 or SEQ ID NO: 147, maintains the LCDR2 sequence of SEQ ID NO: 86 or SEQ ID NO: 148, and maintains the LCDR3 sequence of SEQ ID NO: 92.

[0437] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 348, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 82, SEQ ID NO: 126, or SEQ ID NO: 144, maintains the HCDR2 sequence of SEQ ID NO: 83, SEQ ID NO: 127, or SEQ ID NO: 145, maintains the HCDR3 sequence of SEQ ID NO: 93 or SEQ ID NO: 152, maintains the LCDR1 sequence of SEQ ID NO: 85 or SEQ ID NO: 147, maintains the LCDR2 sequence of SEQ ID NO: 86 or SEQ ID NO: 148, and maintains the LCDR3 sequence of SEQ ID NO: 94.

[0438] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 349, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 82, SEQ ID NO: 126, or SEQ ID NO: 144, maintains the HCDR2 sequence of SEQ ID NO: 83, SEQ ID NO: 127, or SEQ ID NO: 145, maintains the HCDR3 sequence of SEQ ID NO: 84 or SEQ ID NO: 146, maintains the LCDR1 sequence of SEQ ID NO: 85 or SEQ ID NO: 147, maintains the LCDR2 sequence of SEQ ID NO: 86 or SEQ ID NO: 148, and maintains the LCDR3 sequence of SEQ ID NO: 95.

[0439] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 350, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 82, SEQ ID NO: 126, or SEQ ID NO: 144, maintains the HCDR2 sequence of SEQ ID NO: 83, SEQ ID NO: 127, or SEQ ID NO: 145, maintains the HCDR3 sequence of SEQ ID NO: 96 or SEQ ID NO: 153, maintains the LCDR1 sequence of SEQ ID NO: 85 or SEQ ID NO: 147, maintains the LCDR2 sequence of SEQ ID NO: 86 or SEQ ID NO: 148, and maintains the LCDR3 sequence of SEQ ID NO: 97.

[0440] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 351, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 82, SEQ ID NO: 126, or SEQ ID NO: 144, maintains the HCDR2 sequence of SEQ ID NO: 83, SEQ ID NO: 127, or SEQ ID NO: 145, maintains the HCDR3 sequence of SEQ ID NO: 98 or SEQ ID NO: 154, maintains the LCDR1 sequence of SEQ ID NO: 85 or SEQ ID NO: 147, maintains the LCDR2 sequence of SEQ ID NO: 86 or SEQ ID NO: 148, and maintains the LCDR3 sequence of SEQ ID NO: 99.

[0441] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 352, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 82, SEQ ID NO: 126, or SEQ ID NO: 144, maintains the HCDR2 sequence of SEQ ID NO: 83, SEQ ID NO: 127, or SEQ ID NO: 145, maintains the HCDR3 sequence of SEQ ID NO: 100 or SEQ ID NO: 155, maintains the LCDR1 sequence of SEQ ID NO: 85 or SEQ ID NO: 147, maintains the LCDR2 sequence of SEQ ID NO: 86 or SEQ ID NO: 148, and maintains the LCDR3 sequence of SEQ ID NO: 101.

[0442] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 353, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 82, SEQ ID NO: 126, or SEQ ID NO: 144, maintains the HCDR2 sequence of SEQ ID NO: 83, SEQ ID NO: 127, or SEQ ID NO: 145, maintains the HCDR3 sequence of SEQ ID NO: 100 or SEQ ID NO: 155, maintains the LCDR1 sequence of SEQ ID NO: 85 or SEQ ID NO: 147, maintains the LCDR2 sequence of SEQ ID NO: 86 or SEQ ID NO: 148, and maintains the LCDR3 sequence of SEQ ID NO: 102.

[0443] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 354, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 103, SEQ ID NO: 128, or SEQ ID NO: 156, maintains the HCDR2 sequence of SEQ ID NO: 104, SEQ ID NO: 129, or SEQ ID NO: 157, maintains the HCDR3 sequence of SEQ ID NO: 105 or SEQ ID NO: 158, maintains the LCDR1 sequence of SEQ ID NO: 106 or SEQ ID NO: 159, maintains the LCDR2 sequence of SEQ ID NO: 107 or SEQ ID NO: 160, and maintains the LCDR3 sequence of SEQ ID NO: 108.

[0444] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 355, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 103, SEQ ID NO: 128, or SEQ ID NO: 156, maintains the HCDR2 sequence of SEQ ID NO: 104, SEQ ID NO: 129, or SEQ ID NO: 157, maintains the HCDR3 sequence of SEQ ID NO: 109 or SEQ ID NO: 161, maintains the LCDR1 sequence of SEQ ID NO: 106 or SEQ ID NO: 159, maintains the LCDR2 sequence of SEQ ID NO: 107 or SEQ ID NO: 160, and maintains the LCDR3 sequence of SEQ ID NO: 110.

[0445] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 356, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 103, SEQ ID NO: 128, or SEQ ID NO: 156, maintains the HCDR2 sequence of SEQ ID NO: 104, SEQ ID NO: 129, or SEQ ID NO: 157, maintains the HCDR3 sequence of SEQ ID NO: 111 or SEQ ID NO: 162, maintains the LCDR1 sequence of SEQ ID NO: 106 or SEQ ID NO: 159, maintains the LCDR2 sequence of SEQ ID NO: 107 or SEQ ID NO: 160, and maintains the LCDR3 sequence of SEQ ID NO: 112.

[0446] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 357, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 103, SEQ ID NO: 128, or SEQ ID NO: 156, maintains the HCDR2 sequence of SEQ ID NO: 104, SEQ ID NO: 129, or SEQ ID NO: 157, maintains the HCDR3 sequence of SEQ ID NO: 105 or SEQ ID NO: 158, maintains the LCDR1 sequence of SEQ ID NO: 106 or SEQ ID NO: 159, maintains the LCDR2 sequence of SEQ ID NO: 107 or SEQ ID NO: 160, and maintains the LCDR3 sequence of SEQ ID NO: 113.

[0447] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 358, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 103, SEQ ID NO: 128, or SEQ ID NO: 156, maintains the HCDR2 sequence of SEQ ID NO: 104, SEQ ID NO: 129, or SEQ ID NO: 157, maintains the HCDR3 sequence of SEQ ID NO: 114 or SEQ ID NO: 163, maintains the LCDR1 sequence of SEQ ID NO: 106 or SEQ ID NO: 159, maintains the LCDR2 sequence of SEQ ID NO: 107 or SEQ ID NO: 160, and maintains the LCDR3 sequence of SEQ ID NO: 115.

[0448] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 359, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 103, SEQ ID NO: 128, or SEQ ID NO: 156, maintains the HCDR2 sequence of SEQ ID NO: 104, SEQ ID NO: 129, or SEQ ID NO: 157, maintains the HCDR3 sequence of SEQ ID NO: 116 or SEQ ID NO: 164, maintains the LCDR1 sequence of SEQ ID NO: 106 or SEQ ID NO: 159, maintains the LCDR2 sequence of SEQ ID NO: 107 or SEQ ID NO: 160, and maintains the LCDR3 sequence of SEQ ID NO: 113.

[0449] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 360, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 103, SEQ ID NO: 128, or SEQ ID NO: 156, maintains the HCDR2 sequence of SEQ ID NO: 104, SEQ ID NO: 129, or SEQ ID NO: 157, maintains the HCDR3 sequence of SEQ ID NO: 117 or SEQ ID NO: 165, maintains the LCDR1 sequence of SEQ ID NO: 106 or SEQ ID NO: 159, maintains the LCDR2 sequence of SEQ ID NO: 107 or SEQ ID NO: 160, and maintains the LCDR3 sequence of SEQ ID NO: 118.

[0450] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 361, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 103, SEQ ID NO: 128, or SEQ ID NO: 156, maintains the HCDR2 sequence of SEQ ID NO: 104, SEQ ID NO: 129, or SEQ ID NO: 157, maintains the HCDR3 sequence of SEQ ID NO: 116 or SEQ ID NO: 164, maintains the LCDR1 sequence of SEQ ID NO: 106 or SEQ ID NO: 159, maintains the LCDR2 sequence of SEQ ID NO: 107 or SEQ ID NO: 160, and maintains the LCDR3 sequence of SEQ ID NO: 119.

[0451] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 362, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 103, SEQ ID NO: 128, or SEQ ID NO: 156, maintains the HCDR2 sequence of SEQ ID NO: 104, SEQ ID NO: 129, or SEQ ID NO: 157, maintains the HCDR3 sequence of SEQ ID NO: 120 or SEQ ID NO: 166, maintains the LCDR1 sequence of SEQ ID NO: 106 or SEQ ID NO: 159, maintains the LCDR2 sequence of SEQ ID NO: 107 or SEQ ID NO: 160, and maintains the LCDR3 sequence of SEQ ID NO: 121.

[0452] In some embodiments, the heavy chain of the antibody or antigen-binding fragment thereof comprises a heavy chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 363, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 103, SEQ ID NO: 128, or SEQ ID NO: 156, maintains the HCDR2 sequence of SEQ ID NO: 104, SEQ ID NO: 129, or SEQ ID NO: 157, maintains the HCDR3 sequence of SEQ ID NO: 122 or SEQ ID NO: 167, maintains the LCDR1 sequence of SEQ ID NO: 106 or SEQ ID NO: 159, maintains the LCDR2 sequence of SEQ ID NO: 107 or SEQ ID NO: 160, and maintains the LCDR3 sequence of SEQ ID NO: 123.

[0453] In some embodiments, the light chain of the antibody or antigen-binding fragment thereof comprises a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:2, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:61, SEQ ID NO:124, or SEQ ID NO:130, maintains the HCDR2 sequence of SEQ ID NO:62, SEQ ID NO:125, or SEQ ID NO:131, maintains the HCDR3 sequence of SEQ ID NO:63 or SEQ ID NO:132, maintains the LCDR1 sequence of SEQ ID NO:64 or SEQ ID NO:133, maintains the LCDR2 sequence of SEQ ID NO:65 or SEQ ID NO:134, and maintains the LCDR3 sequence of SEQ ID NO:66.

[0454] In some embodiments, the light chain of the antibody or antigen-binding fragment thereof comprises a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:4, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:61, SEQ ID NO:124, or SEQ ID NO:130, maintains the HCDR2 sequence of SEQ ID NO:62, SEQ ID NO:125, or SEQ ID NO:131, maintains the HCDR3 sequence of SEQ ID NO:67 or SEQ ID NO:135, maintains the LCDR1 sequence of SEQ ID NO:64 or SEQ ID NO:1339, maintains the LCDR2 sequence of SEQ ID NO:65 or SEQ ID NO:134, and maintains the LCDR3 sequence of SEQ ID NO:68.

[0455] In some embodiments, the light chain of the antibody or antigen-binding fragment thereof comprises a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:6, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:61, SEQ ID NO:124, or SEQ ID NO:130, maintains the HCDR2 sequence of SEQ ID NO:62, SEQ ID NO:125, or SEQ ID NO:131, maintains the HCDR3 sequence of SEQ ID NO:69 or SEQ ID NO:136, maintains the LCDR1 sequence of SEQ ID NO:64 or SEQ ID NO:133, maintains the LCDR2 sequence of SEQ ID NO:65 or SEQ ID NO:134, and maintains the LCDR3 sequence of SEQ ID NO:68.

[0456] In some embodiments, the light chain of the antibody or antigen-binding fragment thereof comprises a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:8, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:61, SEQ ID NO:124, or SEQ ID NO:130, maintains the HCDR2 sequence of SEQ ID NO:62, SEQ ID NO:125, or SEQ ID NO:131, maintains the HCDR3 sequence of SEQ ID NO:70 or SEQ ID NO:137, maintains the LCDR1 sequence of SEQ ID NO:64 or SEQ ID NO:133, maintains the LCDR2 sequence of SEQ ID NO:65 or SEQ ID NO:134, and maintains the LCDR3 sequence of SEQ ID NO:71.

[0457] In some embodiments, the light chain of the antibody or antigen-binding fragment thereof comprises a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 10, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 61, SEQ ID NO: 124, or SEQ ID NO: 130, maintains the HCDR2 sequence of SEQ ID NO: 62, SEQ ID NO: 125, or SEQ ID NO: 131, maintains the HCDR3 sequence of SEQ ID NO: 72 or SEQ ID NO: 138, maintains the LCDR1 sequence of SEQ ID NO: 64 or SEQ ID NO: 133, maintains the LCDR2 sequence of SEQ ID NO: 65 or SEQ ID NO: 134, and maintains the LCDR3 sequence of SEQ ID NO: 71.

[0458] In some embodiments, the light chain of the antibody or antigen-binding fragment thereof comprises a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 12, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 61, SEQ ID NO: 124, or SEQ ID NO: 130, maintains the HCDR2 sequence of SEQ ID NO: 62, SEQ ID NO: 125, or SEQ ID NO: 131, maintains the HCDR3 sequence of SEQ ID NO: 73 or SEQ ID NO: 139, maintains the LCDR1 sequence of SEQ ID NO: 64 or SEQ ID NO: 133, maintains the LCDR2 sequence of SEQ ID NO: 65 or SEQ ID NO: 134, and maintains the LCDR3 sequence of SEQ ID NO: 71.

[0459] In some embodiments, the light chain of the antibody or antigen-binding fragment thereof comprises a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 14, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 61, SEQ ID NO: 124, or SEQ ID NO: 130, maintains the HCDR2 sequence of SEQ ID NO: 62, SEQ ID NO: 125, or SEQ ID NO: 131, maintains the HCDR3 sequence of SEQ ID NO: 74 or SEQ ID NO: 140, maintains the LCDR1 sequence of SEQ ID NO: 64 or SEQ ID NO: 133, maintains the LCDR2 sequence of SEQ ID NO: 65 or SEQ ID NO: 134, and maintains the LCDR3 sequence of SEQ ID NO: 75.

[0460] In some embodiments, the light chain of the antibody or antigen-binding fragment thereof comprises a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 16, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 61, SEQ ID NO: 124, or SEQ ID NO: 130, maintains the HCDR2 sequence of SEQ ID NO: 62, SEQ ID NO: 125, or SEQ ID NO: 131, maintains the HCDR3 sequence of SEQ ID NO: 76 or SEQ ID NO: 141, maintains the LCDR1 sequence of SEQ ID NO: 64 or SEQ ID NO: 133, maintains the LCDR2 sequence of SEQ ID NO: 65 or SEQ ID NO: 134, and maintains the LCDR3 sequence of SEQ ID NO: 77.

[0461] In some embodiments, the light chain of the antibody or antigen-binding fragment thereof comprises a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 18, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 61, SEQ ID NO: 124, or SEQ ID NO: 130, maintains the HCDR2 sequence of SEQ ID NO: 62, SEQ ID NO: 125, or SEQ ID NO: 131, maintains the HCDR3 sequence of SEQ ID NO: 78 or SEQ ID NO: 142, maintains the LCDR1 sequence of SEQ ID NO: 64 or SEQ ID NO: 133, maintains the LCDR2 sequence of SEQ ID NO: 65 or SEQ ID NO: 134, and maintains the LCDR3 sequence of SEQ ID NO: 79.

[0462] In some embodiments, the light chain of the antibody or antigen-binding fragment thereof comprises a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:20, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:61, SEQ ID NO:124, or SEQ ID NO:130, maintains the HCDR2 sequence of SEQ ID NO:62, SEQ ID NO:125, or SEQ ID NO:131, maintains the HCDR3 sequence of SEQ ID NO:80 or SEQ ID NO:143, maintains the LCDR1 sequence of SEQ ID NO:64 or SEQ ID NO:133, maintains the LCDR2 sequence of SEQ ID NO:65 or SEQ ID NO:134, and maintains the LCDR3 sequence of SEQ ID NO:81.

[0463] In some embodiments, the light chain of the antibody or antigen-binding fragment thereof comprises a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 22, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 82, SEQ ID NO: 126, or SEQ ID NO: 144, maintains the HCDR2 sequence of SEQ ID NO: 83, SEQ ID NO: 127, or SEQ ID NO: 145, maintains the HCDR3 sequence of SEQ ID NO: 84 or SEQ ID NO: 146, maintains the LCDR1 sequence of SEQ ID NO: 85 or SEQ ID NO: 147, maintains the LCDR2 sequence of SEQ ID NO: 86 or SEQ ID NO: 148, and maintains the LCDR3 sequence of SEQ ID NO: 87.

[0464] In some embodiments, the light chain of the antibody or antigen-binding fragment thereof comprises a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:24, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:82, SEQ ID NO:126, or SEQ ID NO:144, maintains the HCDR2 sequence of SEQ ID NO:83, SEQ ID NO:127, or SEQ ID NO:145, maintains the HCDR3 sequence of SEQ ID NO:88 or SEQ ID NO:149, maintains the LCDR1 sequence of SEQ ID NO:85 or SEQ ID NO:147, maintains the LCDR2 sequence of SEQ ID NO:86 or SEQ ID NO:148, and maintains the LCDR3 sequence of SEQ ID NO:89.

[0465] In some embodiments, the light chain of the antibody or antigen-binding fragment thereof comprises a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:26, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:82, SEQ ID NO:126, or SEQ ID NO:144, maintains the HCDR2 sequence of SEQ ID NO:83, SEQ ID NO:127, or SEQ ID NO:145, maintains the HCDR3 sequence of SEQ ID NO:90 or SEQ ID NO:150, maintains the LCDR1 sequence of SEQ ID NO:85 or SEQ ID NO:147, maintains the LCDR2 sequence of SEQ ID NO:86 or SEQ ID NO:148, and maintains the LCDR3 sequence of SEQ ID NO:89.

[0466] In some embodiments, the light chain of the antibody or antigen-binding fragment thereof comprises a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:28, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:82, SEQ ID NO:126, or SEQ ID NO:144, maintains the HCDR2 sequence of SEQ ID NO:83, SEQ ID NO:127, or SEQ ID NO:145, maintains the HCDR3 sequence of SEQ ID NO:91 or SEQ ID NO:151, maintains the LCDR1 sequence of SEQ ID NO:85 or SEQ ID NO:147, maintains the LCDR2 sequence of SEQ ID NO:86 or SEQ ID NO:148, and maintains the LCDR3 sequence of SEQ ID NO:92.

[0467] In some embodiments, the light chain of the antibody or antigen-binding fragment thereof comprises a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:30, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:82, SEQ ID NO:126, or SEQ ID NO:144, maintains the HCDR2 sequence of SEQ ID NO:83, SEQ ID NO:127, or SEQ ID NO:145, maintains the HCDR3 sequence of SEQ ID NO:93 or SEQ ID NO:152, maintains the LCDR1 sequence of SEQ ID NO:85 or SEQ ID NO:147, maintains the LCDR2 sequence of SEQ ID NO:86 or SEQ ID NO:148, and maintains the LCDR3 sequence of SEQ ID NO:94.

[0468] In some embodiments, the light chain of the antibody or antigen-binding fragment thereof comprises a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 32, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 82, SEQ ID NO: 126, or SEQ ID NO: 144, maintains the HCDR2 sequence of SEQ ID NO: 83, SEQ ID NO: 127, or SEQ ID NO: 145, maintains the HCDR3 sequence of SEQ ID NO: 84 or SEQ ID NO: 146, maintains the LCDR1 sequence of SEQ ID NO: 85 or SEQ ID NO: 147, maintains the LCDR2 sequence of SEQ ID NO: 86 or SEQ ID NO: 148, and maintains the LCDR3 sequence of SEQ ID NO: 95.

[0469] In some embodiments, the light chain of the antibody or antigen-binding fragment thereof comprises a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 34, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 82, SEQ ID NO: 126, or SEQ ID NO: 144, maintains the HCDR2 sequence of SEQ ID NO: 83, SEQ ID NO: 127, or SEQ ID NO: 145, maintains the HCDR3 sequence of SEQ ID NO: 96 or SEQ ID NO: 153, maintains the LCDR1 sequence of SEQ ID NO: 85 or SEQ ID NO: 147, maintains the LCDR2 sequence of SEQ ID NO: 86 or SEQ ID NO: 148, and maintains the LCDR3 sequence of SEQ ID NO: 97.

[0470] In some embodiments, the light chain of the antibody or antigen-binding fragment thereof comprises a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 36, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 82, SEQ ID NO: 126, or SEQ ID NO: 144, maintains the HCDR2 sequence of SEQ ID NO: 83, SEQ ID NO: 127, or SEQ ID NO: 145, maintains the HCDR3 sequence of SEQ ID NO: 98 or SEQ ID NO: 154, maintains the LCDR1 sequence of SEQ ID NO: 85 or SEQ ID NO: 147, maintains the LCDR2 sequence of SEQ ID NO: 86 or SEQ ID NO: 148, and maintains the LCDR3 sequence of SEQ ID NO: 99.

[0471] In some embodiments, the light chain of the antibody or antigen-binding fragment thereof comprises a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 38, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 82, SEQ ID NO: 126, or SEQ ID NO: 144, maintains the HCDR2 sequence of SEQ ID NO: 83, SEQ ID NO: 127, or SEQ ID NO: 145, maintains the HCDR3 sequence of SEQ ID NO: 100 or SEQ ID NO: 155, maintains the LCDR1 sequence of SEQ ID NO: 85 or SEQ ID NO: 147, maintains the LCDR2 sequence of SEQ ID NO: 86 or SEQ ID NO: 148, and maintains the LCDR3 sequence of SEQ ID NO: 101.

[0472] In some embodiments, the light chain of the antibody or antigen-binding fragment thereof comprises a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:40, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:82, SEQ ID NO:126, or SEQ ID NO:144, maintains the HCDR2 sequence of SEQ ID NO:83, SEQ ID NO:127, or SEQ ID NO:145, maintains the HCDR3 sequence of SEQ ID NO:100 or SEQ ID NO:155, maintains the LCDR1 sequence of SEQ ID NO:85 or SEQ ID NO:147, maintains the LCDR2 sequence of SEQ ID NO:86 or SEQ ID NO:148, and maintains the LCDR3 sequence of SEQ ID NO:102.

[0473] In some embodiments, the light chain of the antibody or antigen-binding fragment thereof comprises a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:42, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:103, SEQ ID NO:128, or SEQ ID NO:156, maintains the HCDR2 sequence of SEQ ID NO:104, SEQ ID NO:129, or SEQ ID NO:157, maintains the HCDR3 sequence of SEQ ID NO:105 or SEQ ID NO:158, maintains the LCDR1 sequence of SEQ ID NO:106 or SEQ ID NO:159, maintains the LCDR2 sequence of SEQ ID NO:107 or SEQ ID NO:160, and maintains the LCDR3 sequence of SEQ ID NO:108.

[0474] In some embodiments, the light chain of the antibody or antigen-binding fragment thereof comprises a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:44, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:103, SEQ ID NO:128, or SEQ ID NO:156, maintains the HCDR2 sequence of SEQ ID NO:104, SEQ ID NO:129, or SEQ ID NO:157, maintains the HCDR3 sequence of SEQ ID NO:109 or SEQ ID NO:161, maintains the LCDR1 sequence of SEQ ID NO:106 or SEQ ID NO:159, maintains the LCDR2 sequence of SEQ ID NO:107 or SEQ ID NO:160, and maintains the LCDR3 sequence of SEQ ID NO:110.

[0475] In some embodiments, the light chain of the antibody or antigen-binding fragment thereof comprises a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:46, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:103, SEQ ID NO:128, or SEQ ID NO:156, maintains the HCDR2 sequence of SEQ ID NO:104, SEQ ID NO:129, or SEQ ID NO:157, maintains the HCDR3 sequence of SEQ ID NO:111 or SEQ ID NO:162, maintains the LCDR1 sequence of SEQ ID NO:106 or SEQ ID NO:159, maintains the LCDR2 sequence of SEQ ID NO:107 or SEQ ID NO:160, and maintains the LCDR3 sequence of SEQ ID NO:112.

[0476] In some embodiments, the light chain of the antibody or antigen-binding fragment thereof comprises a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:48, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:103, SEQ ID NO:128, or SEQ ID NO:156, maintains the HCDR2 sequence of SEQ ID NO:104, SEQ ID NO:129, or SEQ ID NO:157, maintains the HCDR3 sequence of SEQ ID NO:105 or SEQ ID NO:158, maintains the LCDR1 sequence of SEQ ID NO:106 or SEQ ID NO:159, maintains the LCDR2 sequence of SEQ ID NO:107 or SEQ ID NO:160, and maintains the LCDR3 sequence of SEQ ID NO:113.

[0477] In some embodiments, the light chain of the antibody or antigen-binding fragment thereof comprises a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:50, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:103, SEQ ID NO:128, or SEQ ID NO:156, maintains the HCDR2 sequence of SEQ ID NO:104, SEQ ID NO:129, or SEQ ID NO:157, maintains the HCDR3 sequence of SEQ ID NO:114 or SEQ ID NO:163, maintains the LCDR1 sequence of SEQ ID NO:106 or SEQ ID NO:159, maintains the LCDR2 sequence of SEQ ID NO:107 or SEQ ID NO:160, and maintains the LCDR3 sequence of SEQ ID NO:115.

[0478] In some embodiments, the light chain of the antibody or antigen-binding fragment thereof comprises a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:52, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:103, SEQ ID NO:128, or SEQ ID NO:156, maintains the HCDR2 sequence of SEQ ID NO:104, SEQ ID NO:129, or SEQ ID NO:157, maintains the HCDR3 sequence of SEQ ID NO:116 or SEQ ID NO:164, maintains the LCDR1 sequence of SEQ ID NO:106 or SEQ ID NO:159, maintains the LCDR2 sequence of SEQ ID NO:107 or SEQ ID NO:160, and maintains the LCDR3 sequence of SEQ ID NO:113.

[0479] In some embodiments, the light chain of the antibody or antigen-binding fragment thereof comprises a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:54, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:103, SEQ ID NO:128, or SEQ ID NO:156, maintains the HCDR2 sequence of SEQ ID NO:104, SEQ ID NO:129, or SEQ ID NO:157, maintains the HCDR3 sequence of SEQ ID NO:117 or SEQ ID NO:165, maintains the LCDR1 sequence of SEQ ID NO:106 or SEQ ID NO:159, maintains the LCDR2 sequence of SEQ ID NO:107 or SEQ ID NO:160, and maintains the LCDR3 sequence of SEQ ID NO:118.

[0480] In some embodiments, the light chain of the antibody or antigen-binding fragment thereof comprises a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:56, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:103, SEQ ID NO:128, or SEQ ID NO:156, maintains the HCDR2 sequence of SEQ ID NO:104, SEQ ID NO:129, or SEQ ID NO:157, maintains the HCDR3 sequence of SEQ ID NO:116 or SEQ ID NO:164, maintains the LCDR1 sequence of SEQ ID NO:106 or SEQ ID NO:159, maintains the LCDR2 sequence of SEQ ID NO:107 or SEQ ID NO:160, and maintains the LCDR3 sequence of SEQ ID NO:119.

[0481] In some embodiments, the light chain of the antibody or antigen-binding fragment thereof comprises a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:58, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:103, SEQ ID NO:128, or SEQ ID NO:156, maintains the HCDR2 sequence of SEQ ID NO:104, SEQ ID NO:129, or SEQ ID NO:157, maintains the HCDR3 sequence of SEQ ID NO:120 or SEQ ID NO:166, maintains the LCDR1 sequence of SEQ ID NO:106 or SEQ ID NO:159, maintains the LCDR2 sequence of SEQ ID NO:107 or SEQ ID NO:160, and maintains the LCDR3 sequence of SEQ ID NO:121.

[0482] In some embodiments, the light chain of the antibody or antigen-binding fragment thereof comprises a light chain variable region having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:60, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:103, SEQ ID NO:128, or SEQ ID NO:156, maintains the HCDR2 sequence of SEQ ID NO:104, SEQ ID NO:129, or SEQ ID NO:157, maintains the HCDR3 sequence of SEQ ID NO:122 or SEQ ID NO:167, maintains the LCDR1 sequence of SEQ ID NO:106 or SEQ ID NO:159, maintains the LCDR2 sequence of SEQ ID NO:107 or SEQ ID NO:160, and maintains the LCDR3 sequence of SEQ ID NO:123.

[0483] The VH and VL sequences can be in any format, including, but not limited to, an scFv format in which the VH and VL regions are linked by a peptide linker. Peptide linkers that can be used to link the various peptides provided herein include, for example, (GGGGS) n (SEQ ID NO: 266, (GGGGA) n(SEQ ID NO: 267, or any combination thereof, where each n is independently 1 to 5. In some embodiments, each n is independently 1. In some embodiments, each n is independently 2. In some embodiments, each n is independently 3. In some embodiments, each n is independently 4. In some embodiments, each n is independently 5. In some embodiments, the variable regions are not linked with a peptide linker.

[0484] In some embodiments, the antibody comprises SEQ ID NO:1 and SEQ ID NO:2. In some embodiments, the antibody comprises SEQ ID NO:3 and SEQ ID NO:4. In some embodiments, the antibody comprises SEQ ID NO:5 and SEQ ID NO:6. In some embodiments, the antibody comprises SEQ ID NO:7 and SEQ ID NO:8. In some embodiments, the antibody comprises SEQ ID NO:9 and SEQ ID NO:10. In some embodiments, the antibody comprises SEQ ID NO:11 and SEQ ID NO:12. In some embodiments, the antibody comprises SEQ ID NO:13 and SEQ ID NO:14. In some embodiments, the antibody comprises SEQ ID NO:15 and SEQ ID NO:16. In some embodiments, the antibody comprises SEQ ID NO:17 and SEQ ID NO:18. In some embodiments, the antibody comprises SEQ ID NO:19 and SEQ ID NO:20. In some embodiments, the antibody comprises SEQ ID NO:21 and SEQ ID NO:22. In some embodiments, the antibody comprises SEQ ID NO:23 and SEQ ID NO:24. In some embodiments, the antibody comprises SEQ ID NO:25 and SEQ ID NO:26. In some embodiments, the antibody comprises SEQ ID NO:27 and SEQ ID NO:28. In some embodiments, the antibody comprises SEQ ID NO:29 and SEQ ID NO:30. In some embodiments, the antibody comprises SEQ ID NO:31 and SEQ ID NO:32. In some embodiments, the antibody comprises SEQ ID NO:33 and SEQ ID NO:34. In some embodiments, the antibody comprises SEQ ID NO:35 and SEQ ID NO:36. In some embodiments, the antibody comprises SEQ ID NO:37 and SEQ ID NO:38. In some embodiments, the antibody comprises SEQ ID NO:39 and SEQ ID NO:40. In some embodiments, the antibody comprises SEQ ID NO:41 and SEQ ID NO:42. In some embodiments, the antibody comprises SEQ ID NO:43 and SEQ ID NO:44. In some embodiments, the antibody comprises SEQ ID NO:45 and SEQ ID NO:46. In some embodiments, the antibody comprises SEQ ID NO:47 and SEQ ID NO:48. In some embodiments, the antibody comprises SEQ ID NO:49 and SEQ ID NO:50. In some embodiments, the antibody comprises SEQ ID NO:51 and SEQ ID NO:52. In some embodiments, the antibody comprises SEQ ID NO:53 and SEQ ID NO:54. In some embodiments, the antibody comprises SEQ ID NO:55 and SEQ ID NO:56. In some embodiments, the antibody comprises SEQ ID NO:57 and SEQ ID NO:58.In some embodiments, the antibody comprises SEQ ID NO:59 and SEQ ID NO:60. In some embodiments, the antibody comprises SEQ ID NO:334 and SEQ ID NO:2. In some embodiments, the antibody comprises SEQ ID NO:335 and SEQ ID NO:4. In some embodiments, the antibody comprises SEQ ID NO:336 and SEQ ID NO:6. In some embodiments, the antibody comprises SEQ ID NO:337 and SEQ ID NO:8. In some embodiments, the antibody comprises SEQ ID NO:338 and SEQ ID NO:10. In some embodiments, the antibody comprises SEQ ID NO:339 and SEQ ID NO:12. In some embodiments, the antibody comprises SEQ ID NO:340 and SEQ ID NO:14. In some embodiments, the antibody comprises SEQ ID NO:341 and SEQ ID NO:16. In some embodiments, the antibody comprises SEQ ID NO:342 and SEQ ID NO:18. In some embodiments, the antibody comprises SEQ ID NO:343 and SEQ ID NO:20. In some embodiments, the antibody comprises SEQ ID NO:344 and SEQ ID NO:22. In some embodiments, the antibody comprises SEQ ID NO:345 and SEQ ID NO:24. In some embodiments, the antibody comprises SEQ ID NO:346 and SEQ ID NO:26. In some embodiments, the antibody comprises SEQ ID NO:347 and SEQ ID NO:28. In some embodiments, the antibody comprises SEQ ID NO:348 and SEQ ID NO:30. In some embodiments, the antibody comprises SEQ ID NO:349 and SEQ ID NO:32. In some embodiments, the antibody comprises SEQ ID NO:350 and SEQ ID NO:34. In some embodiments, the antibody comprises SEQ ID NO:351 and SEQ ID NO:36. In some embodiments, the antibody comprises SEQ ID NO:352 and SEQ ID NO:38. In some embodiments, the antibody comprises SEQ ID NO:353 and SEQ ID NO:40. In some embodiments, the antibody comprises SEQ ID NO:354 and SEQ ID NO:42. In some embodiments, the antibody comprises SEQ ID NO:355 and SEQ ID NO:44. In some embodiments, the antibody comprises SEQ ID NO:356 and SEQ ID NO:46. In some embodiments, the antibody comprises SEQ ID NO:357 and SEQ ID NO:48. In some embodiments, the antibody comprises SEQ ID NO:358 and SEQ ID NO:50. In some embodiments, the antibody comprises SEQ ID NO:359 and SEQ ID NO:52. In some embodiments, the antibody comprises SEQ ID NO:360 and SEQ ID NO:54.In some embodiments, the antibody comprises SEQ ID NO: 361 and SEQ ID NO: 56. In some embodiments, the antibody comprises SEQ ID NO: 362 and SEQ ID NO: 58. In some embodiments, the antibody comprises SEQ ID NO: 363 and SEQ ID NO: 60.

[0485] As provided herein, the different peptides described herein (V H or V L ) may be linked by a peptide linker or may not be linked by a peptide linker, instead forming a contiguous sequence. In some embodiments, the heavy chain variable region and the light chain variable region are not linked by a linker. In some embodiments, the heavy chain variable region and the light chain variable region are linked via a peptide linker. In some embodiments, the peptide linker is (GGGGS) n (SEQ ID NO: 266), (GGGGA) n (SEQ ID NO: 267), or any combination thereof, wherein each n is independently 1 to 5. In some embodiments, each n is independently 1. In some embodiments, each n is independently 2. In some embodiments, each n is independently 3. In some embodiments, each n is independently 4. In some embodiments, each n is independently 5. Linked peptide formats include V H -ZV L or V L -ZV H wherein Z is a peptide linker. In some embodiments, Z is represented by the formula: (GGGGS) n (SEQ ID NO: 266), (GGGGA) n (SEQ ID NO: 267), or any combination thereof, wherein each n is independently 1 to 5. In some embodiments, each n is independently 1. In some embodiments, each n is independently 2. In some embodiments, each n is independently 3. In some embodiments, each n is independently 4. In some embodiments, each n is independently 5.

[0486] In some embodiments, the VH and VL polypeptides are linked to an Fc region such as "IgG4 S228P L235E LS" or "IgG4 S228P L235E YTE". In some embodiments, the Fc region is provided herein. In some embodiments, the Fc region is "IgG4 S228P L235E LS". In some embodiments, the Fc region is "IgG4 S228 L235E YTE".

[0487] In some embodiments, the antibody or antigen-binding fragment thereof comprises a V H Peptides and V L In some embodiments, VH and VL each independently comprise one, two, three, four, or five conservative amino acid substitutions. In some embodiments, the CDRs of VH and VL comprise no more than one conservative amino acid substitution. Thus, in some embodiments, HCDR1, HCDR2, or HCDR3 can comprise one or no conservative amino acid substitutions. Additionally, in some embodiments, LCDR1, LCDR2, or LCDR3 can comprise one or no conservative amino acid substitutions.

[0488] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region of the light chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:2, and the heavy chain variable region of the heavy chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:1. %, 98%, 99%, or 100% identity to the antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 61, SEQ ID NO: 124, or SEQ ID NO: 130, maintains the HCDR2 sequence of SEQ ID NO: 62, SEQ ID NO: 125, or SEQ ID NO: 131, maintains the HCDR3 sequence of SEQ ID NO: 63 or SEQ ID NO: 132, maintains the LCDR1 sequence of SEQ ID NO: 64 or SEQ ID NO: 133, maintains the LCDR2 sequence of SEQ ID NO: 65 or SEQ ID NO: 134, and maintains the LCDR3 sequence of SEQ ID NO: 66.

[0489] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region of the light chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:4, and the heavy chain variable region of the heavy chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:3. %, 98%, 99% or 100% identity to the antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 61, SEQ ID NO: 124 or SEQ ID NO: 130, maintains the HCDR2 sequence of SEQ ID NO: 62, SEQ ID NO: 125 or SEQ ID NO: 131, maintains the HCDR3 sequence of SEQ ID NO: 67 or SEQ ID NO: 135, maintains the LCDR1 sequence of SEQ ID NO: 64 or SEQ ID NO: 1339, maintains the LCDR2 sequence of SEQ ID NO: 65 or SEQ ID NO: 134, and maintains the LCDR3 sequence of SEQ ID NO: 68.

[0490] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region of the light chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:6, and the heavy chain variable region of the heavy chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:5. %, 98%, 99% or 100% identity to the antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 61, SEQ ID NO: 124 or SEQ ID NO: 130, maintains the HCDR2 sequence of SEQ ID NO: 62, SEQ ID NO: 125 or SEQ ID NO: 131, maintains the HCDR3 sequence of SEQ ID NO: 69 or SEQ ID NO: 136, maintains the LCDR1 sequence of SEQ ID NO: 64 or SEQ ID NO: 133, maintains the LCDR2 sequence of SEQ ID NO: 65 or SEQ ID NO: 134, and maintains the LCDR3 sequence of SEQ ID NO: 68.

[0491] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region of the light chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:8, and the heavy chain variable region of the heavy chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:7. %, 98%, 99% or 100% identity to the antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 61, SEQ ID NO: 124 or SEQ ID NO: 130, maintains the HCDR2 sequence of SEQ ID NO: 62, SEQ ID NO: 125 or SEQ ID NO: 131, maintains the HCDR3 sequence of SEQ ID NO: 70 or SEQ ID NO: 137, maintains the LCDR1 sequence of SEQ ID NO: 64 or SEQ ID NO: 133, maintains the LCDR2 sequence of SEQ ID NO: 65 or SEQ ID NO: 134, and maintains the LCDR3 sequence of SEQ ID NO: 71.

[0492] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region of the light chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 10, and the heavy chain variable region of the heavy chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 9. The antibody or antigen-binding fragment thereof has 7%, 98%, 99%, or 100% identity, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 61, SEQ ID NO: 124, or SEQ ID NO: 130, maintains the HCDR2 sequence of SEQ ID NO: 62, SEQ ID NO: 125, or SEQ ID NO: 131, maintains the HCDR3 sequence of SEQ ID NO: 72 or SEQ ID NO: 138, maintains the LCDR1 sequence of SEQ ID NO: 64 or SEQ ID NO: 133, maintains the LCDR2 sequence of SEQ ID NO: 65 or SEQ ID NO: 134, and maintains the LCDR3 sequence of SEQ ID NO: 71.

[0493] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region of the light chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 12, and the heavy chain variable region of the heavy chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 11. The antibody or antigen-binding fragment thereof has 7%, 98%, 99%, or 100% identity, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 61, SEQ ID NO: 124, or SEQ ID NO: 130, maintains the HCDR2 sequence of SEQ ID NO: 62, SEQ ID NO: 125, or SEQ ID NO: 131, maintains the HCDR3 sequence of SEQ ID NO: 73 or SEQ ID NO: 139, maintains the LCDR1 sequence of SEQ ID NO: 64 or SEQ ID NO: 133, maintains the LCDR2 sequence of SEQ ID NO: 65 or SEQ ID NO: 134, and maintains the LCDR3 sequence of SEQ ID NO: 71.

[0494] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region of the light chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 14, and the heavy chain variable region of the heavy chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 13. The antibody or antigen-binding fragment thereof has 7%, 98%, 99%, or 100% identity, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 61, SEQ ID NO: 124, or SEQ ID NO: 130, maintains the HCDR2 sequence of SEQ ID NO: 62, SEQ ID NO: 125, or SEQ ID NO: 131, maintains the HCDR3 sequence of SEQ ID NO: 74 or SEQ ID NO: 140, maintains the LCDR1 sequence of SEQ ID NO: 64 or SEQ ID NO: 133, maintains the LCDR2 sequence of SEQ ID NO: 65 or SEQ ID NO: 134, and maintains the LCDR3 sequence of SEQ ID NO: 75.

[0495] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region of the light chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 16, and the heavy chain variable region of the heavy chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 15. The antibody or antigen-binding fragment thereof has 7%, 98%, 99%, or 100% identity, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 61, SEQ ID NO: 124, or SEQ ID NO: 130, maintains the HCDR2 sequence of SEQ ID NO: 62, SEQ ID NO: 125, or SEQ ID NO: 131, maintains the HCDR3 sequence of SEQ ID NO: 76 or SEQ ID NO: 141, maintains the LCDR1 sequence of SEQ ID NO: 64 or SEQ ID NO: 133, maintains the LCDR2 sequence of SEQ ID NO: 65 or SEQ ID NO: 134, and maintains the LCDR3 sequence of SEQ ID NO: 77.

[0496] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region of the light chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 18, and the heavy chain variable region of the heavy chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 17. The antibody or antigen-binding fragment thereof has 7%, 98%, 99%, or 100% identity, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 61, SEQ ID NO: 124, or SEQ ID NO: 130, maintains the HCDR2 sequence of SEQ ID NO: 62, SEQ ID NO: 125, or SEQ ID NO: 131, maintains the HCDR3 sequence of SEQ ID NO: 78 or SEQ ID NO: 142, maintains the LCDR1 sequence of SEQ ID NO: 64 or SEQ ID NO: 133, maintains the LCDR2 sequence of SEQ ID NO: 65 or SEQ ID NO: 134, and maintains the LCDR3 sequence of SEQ ID NO: 79.

[0497] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region of the light chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:20, and the heavy chain variable region of the heavy chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:19. The antibody or antigen-binding fragment thereof has 7%, 98%, 99%, or 100% identity, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 61, SEQ ID NO: 124, or SEQ ID NO: 130, maintains the HCDR2 sequence of SEQ ID NO: 62, SEQ ID NO: 125, or SEQ ID NO: 131, maintains the HCDR3 sequence of SEQ ID NO: 80 or SEQ ID NO: 143, maintains the LCDR1 sequence of SEQ ID NO: 64 or SEQ ID NO: 133, maintains the LCDR2 sequence of SEQ ID NO: 65 or SEQ ID NO: 134, and maintains the LCDR3 sequence of SEQ ID NO: 81.

[0498] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region of the light chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:22, and the heavy chain variable region of the heavy chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:21. The antibody or antigen-binding fragment thereof has 7%, 98%, 99%, or 100% identity, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 82, SEQ ID NO: 126, or SEQ ID NO: 144, maintains the HCDR2 sequence of SEQ ID NO: 83, SEQ ID NO: 127, or SEQ ID NO: 145, maintains the HCDR3 sequence of SEQ ID NO: 84 or SEQ ID NO: 146, maintains the LCDR1 sequence of SEQ ID NO: 85 or SEQ ID NO: 147, maintains the LCDR2 sequence of SEQ ID NO: 86 or SEQ ID NO: 148, and maintains the LCDR3 sequence of SEQ ID NO: 87.

[0499] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region of the light chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:24, and the heavy chain variable region of the heavy chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:23. and has 7%, 98%, 99%, or 100% identity, wherein the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 82, SEQ ID NO: 126, or SEQ ID NO: 144, maintains the HCDR2 sequence of SEQ ID NO: 83, SEQ ID NO: 127, or SEQ ID NO: 145, maintains the HCDR3 sequence of SEQ ID NO: 88 or SEQ ID NO: 149, maintains the LCDR1 sequence of SEQ ID NO: 85 or SEQ ID NO: 147, maintains the LCDR2 sequence of SEQ ID NO: 86 or SEQ ID NO: 148, and maintains the LCDR3 sequence of SEQ ID NO: 89.

[0500] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region of the light chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:26, and the heavy chain variable region of the heavy chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:25. The antibody or antigen-binding fragment thereof has 7%, 98%, 99%, or 100% identity, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 82, SEQ ID NO: 126, or SEQ ID NO: 144, maintains the HCDR2 sequence of SEQ ID NO: 83, SEQ ID NO: 127, or SEQ ID NO: 145, maintains the HCDR3 sequence of SEQ ID NO: 90 or SEQ ID NO: 150, maintains the LCDR1 sequence of SEQ ID NO: 85 or SEQ ID NO: 147, maintains the LCDR2 sequence of SEQ ID NO: 86 or SEQ ID NO: 148, and maintains the LCDR3 sequence of SEQ ID NO: 89.

[0501] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region of the light chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:28, and the heavy chain variable region of the heavy chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:27. and the antibody or antigen-binding fragment thereof has 7%, 98%, 99%, or 100% identity, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 82, SEQ ID NO: 126, or SEQ ID NO: 144, maintains the HCDR2 sequence of SEQ ID NO: 83, SEQ ID NO: 127, or SEQ ID NO: 145, maintains the HCDR3 sequence of SEQ ID NO: 91 or SEQ ID NO: 151, maintains the LCDR1 sequence of SEQ ID NO: 85 or SEQ ID NO: 147, maintains the LCDR2 sequence of SEQ ID NO: 86 or SEQ ID NO: 148, and maintains the LCDR3 sequence of SEQ ID NO: 92.

[0502] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region of the light chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 30, and the heavy chain variable region of the heavy chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 29. and the antibody or antigen-binding fragment thereof has 7%, 98%, 99%, or 100% identity, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 82, SEQ ID NO: 126, or SEQ ID NO: 144, maintains the HCDR2 sequence of SEQ ID NO: 83, SEQ ID NO: 127, or SEQ ID NO: 145, maintains the HCDR3 sequence of SEQ ID NO: 93 or SEQ ID NO: 152, maintains the LCDR1 sequence of SEQ ID NO: 85 or SEQ ID NO: 147, maintains the LCDR2 sequence of SEQ ID NO: 86 or SEQ ID NO: 148, and maintains the LCDR3 sequence of SEQ ID NO: 94.

[0503] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region of the light chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 32, and the heavy chain variable region of the heavy chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 31. and has 7%, 98%, 99%, or 100% identity, wherein the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:82, SEQ ID NO:126, or SEQ ID NO:144, maintains the HCDR2 sequence of SEQ ID NO:83, SEQ ID NO:127, or SEQ ID NO:145, maintains the HCDR3 sequence of SEQ ID NO:84 or SEQ ID NO:146, maintains the LCDR1 sequence of SEQ ID NO:85 or SEQ ID NO:147, maintains the LCDR2 sequence of SEQ ID NO:86 or SEQ ID NO:148, and maintains the LCDR3 sequence of SEQ ID NO:95.

[0504] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region of the light chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 34, and the heavy chain variable region of the heavy chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 33. and the antibody or antigen-binding fragment thereof has 7%, 98%, 99%, or 100% identity, and the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 82, SEQ ID NO: 126, or SEQ ID NO: 144, maintains the HCDR2 sequence of SEQ ID NO: 83, SEQ ID NO: 127, or SEQ ID NO: 145, maintains the HCDR3 sequence of SEQ ID NO: 96 or SEQ ID NO: 153, maintains the LCDR1 sequence of SEQ ID NO: 85 or SEQ ID NO: 147, maintains the LCDR2 sequence of SEQ ID NO: 86 or SEQ ID NO: 148, and maintains the LCDR3 sequence of SEQ ID NO: 97.

[0505] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region of the light chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 36, and the heavy chain variable region of the heavy chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 35. and has 7%, 98%, 99%, or 100% identity, wherein the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO: 82, SEQ ID NO: 126, or SEQ ID NO: 144, maintains the HCDR2 sequence of SEQ ID NO: 83, SEQ ID NO: 127, or SEQ ID NO: 145, maintains the HCDR3 sequence of SEQ ID NO: 98 or SEQ ID NO: 154, maintains the LCDR1 sequence of SEQ ID NO: 85 or SEQ ID NO: 147, maintains the LCDR2 sequence of SEQ ID NO: 86 or SEQ ID NO: 148, and maintains the LCDR3 sequence of SEQ ID NO: 99.

[0506] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region of the light chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 38, and the heavy chain variable region of the heavy chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 37. %, 98%, 99% or 100% identity to the antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:82, SEQ ID NO:126 or SEQ ID NO:144, maintains the HCDR2 sequence of SEQ ID NO:83, SEQ ID NO:127 or SEQ ID NO:145, maintains the HCDR3 sequence of SEQ ID NO:100 or SEQ ID NO:155, maintains the LCDR1 sequence of SEQ ID NO:85 or SEQ ID NO:147, maintains the LCDR2 sequence of SEQ ID NO:86 or SEQ ID NO:148, and maintains the LCDR3 sequence of SEQ ID NO:101.

[0507] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region of the light chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:40, and the heavy chain variable region of the heavy chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:39. %, 98%, 99% or 100% identity to the antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof maintains the HCDR1 sequence of SEQ ID NO:82, SEQ ID NO:126 or SEQ ID NO:144, maintains the HCDR2 sequence of SEQ ID NO:83, SEQ ID NO:127 or SEQ ID NO:145, maintains the HCDR3 sequence of SEQ ID NO:100 or SEQ ID NO:155, maintains the LCDR1 sequence of SEQ ID NO:85 or SEQ ID NO:147, maintains the LCDR2 sequence of SEQ ID NO:86 or SEQ ID NO:148, and maintains the LCDR3 sequence of SEQ ID NO:102.

[0508] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region of the light chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 44, and the heavy chain variable region of the heavy chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 41. The antibody or antigen-binding fragment thereof has 98%, 99%, or 100% identity, and maintains the HCDR1 sequence of SEQ ID NO: 103, SEQ ID NO: 128, or SEQ ID NO: 156, maintains the HCDR2 sequence of SEQ ID NO: 104, SEQ ID NO: 129, or SEQ ID NO: 157, maintains the HCDR3 sequence of SEQ ID NO: 105 or SEQ ID NO: 158, maintains the LCDR1 sequence of SEQ ID NO: 106 or SEQ ID NO: 159, maintains the LCDR2 sequence of SEQ ID NO: 107 or SEQ ID NO: 160, and maintains the LCDR3 sequence of SEQ ID NO: 108.

[0509] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region of the light chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 44, and the heavy chain variable region of the heavy chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 43. The antibody or antigen-binding fragment thereof has 98%, 99%, or 100% identity, and maintains the HCDR1 sequence of SEQ ID NO: 103, SEQ ID NO: 128, or SEQ ID NO: 156, maintains the HCDR2 sequence of SEQ ID NO: 104, SEQ ID NO: 129, or SEQ ID NO: 157, maintains the HCDR3 sequence of SEQ ID NO: 109 or SEQ ID NO: 161, maintains the LCDR1 sequence of SEQ ID NO: 106 or SEQ ID NO: 159, maintains the LCDR2 sequence of SEQ ID NO: 107 or SEQ ID NO: 160, and maintains the LCDR3 sequence of SEQ ID NO: 110.

[0510] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region of the light chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 46, and the heavy chain variable region of the heavy chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 45. The antibody or antigen-binding fragment thereof has 98%, 99%, or 100% identity, and maintains the HCDR1 sequence of SEQ ID NO: 103, SEQ ID NO: 128, or SEQ ID NO: 156, maintains the HCDR2 sequence of SEQ ID NO: 104, SEQ ID NO: 129, or SEQ ID NO: 157, maintains the HCDR3 sequence of SEQ ID NO: 111 or SEQ ID NO: 162, maintains the LCDR1 sequence of SEQ ID NO: 106 or SEQ ID NO: 159, maintains the LCDR2 sequence of SEQ ID NO: 107 or SEQ ID NO: 160, and maintains the LCDR3 sequence of SEQ ID NO: 112.

[0511] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region of the light chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:48, and the heavy chain variable region of the heavy chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO:47. The antibody or antigen-binding fragment thereof has 98%, 99%, or 100% identity, and maintains the HCDR1 sequence of SEQ ID NO: 103, SEQ ID NO: 128, or SEQ ID NO: 156, maintains the HCDR2 sequence of SEQ ID NO: 104, SEQ ID NO: 129, or SEQ ID NO: 157, maintains the HCDR3 sequence of SEQ ID NO: 105 or SEQ ID NO: 158, maintains the LCDR1 sequence of SEQ ID NO: 106 or SEQ ID NO: 159, maintains the LCDR2 sequence of SEQ ID NO: 107 or SEQ ID NO: 160, and maintains the LCDR3 sequence of SEQ ID NO: 113.

[0512] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region of the light chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 50, and the heavy chain variable region of the heavy chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 49. The antibody or antigen-binding fragment thereof has 98%, 99%, or 100% identity, and maintains the HCDR1 sequence of SEQ ID NO: 103, SEQ ID NO: 128, or SEQ ID NO: 156, maintains the HCDR2 sequence of SEQ ID NO: 104, SEQ ID NO: 129, or SEQ ID NO: 157, maintains the HCDR3 sequence of SEQ ID NO: 114 or SEQ ID NO: 163, maintains the LCDR1 sequence of SEQ ID NO: 106 or SEQ ID NO: 159, maintains the LCDR2 sequence of SEQ ID NO: 107 or SEQ ID NO: 160, and maintains the LCDR3 sequence of SEQ ID NO: 115.

[0513] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region of the light chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 52, and the heavy chain variable region of the heavy chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 51. The antibody or antigen-binding fragment thereof has 98%, 99%, or 100% identity, and maintains the HCDR1 sequence of SEQ ID NO: 103, SEQ ID NO: 128, or SEQ ID NO: 156, maintains the HCDR2 sequence of SEQ ID NO: 104, SEQ ID NO: 129, or SEQ ID NO: 157, maintains the HCDR3 sequence of SEQ ID NO: 116 or SEQ ID NO: 164, maintains the LCDR1 sequence of SEQ ID NO: 106 or SEQ ID NO: 159, maintains the LCDR2 sequence of SEQ ID NO: 107 or SEQ ID NO: 160, and maintains the LCDR3 sequence of SEQ ID NO: 113.

[0514] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region of the light chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 54, and the heavy chain variable region of the heavy chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 55. The antibody or antigen-binding fragment thereof has 98%, 99%, or 100% identity, and maintains the HCDR1 sequence of SEQ ID NO: 103, SEQ ID NO: 128, or SEQ ID NO: 156, maintains the HCDR2 sequence of SEQ ID NO: 104, SEQ ID NO: 129, or SEQ ID NO: 157, maintains the HCDR3 sequence of SEQ ID NO: 117 or SEQ ID NO: 165, maintains the LCDR1 sequence of SEQ ID NO: 106 or SEQ ID NO: 159, maintains the LCDR2 sequence of SEQ ID NO: 107 or SEQ ID NO: 160, and maintains the LCDR3 sequence of SEQ ID NO: 118.

[0515] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region of the light chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 56, and the heavy chain variable region of the heavy chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 55. The antibody or antigen-binding fragment thereof has 98%, 99%, or 100% identity, and maintains the HCDR1 sequence of SEQ ID NO: 103, SEQ ID NO: 128, or SEQ ID NO: 156, maintains the HCDR2 sequence of SEQ ID NO: 104, SEQ ID NO: 129, or SEQ ID NO: 157, maintains the HCDR3 sequence of SEQ ID NO: 116 or SEQ ID NO: 164, maintains the LCDR1 sequence of SEQ ID NO: 106 or SEQ ID NO: 159, maintains the LCDR2 sequence of SEQ ID NO: 107 or SEQ ID NO: 160, and maintains the LCDR3 sequence of SEQ ID NO: 119.

[0516] In some embodiments, the antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region of the light chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 58, and the heavy chain variable region of the heavy chain has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 57. The antibody or antigen-binding fragment thereof has 98%, 99%, or 100%...

Claims

1. An antibody or antigen-binding fragment thereof, said antibody or antibody fragment comprising: a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the HCDR1 has the amino acid sequence of SEQ ID NO: 61, the HCDR2 has the amino acid sequence of SEQ ID NO: 62, and the HCDR3 has the amino acid sequence of SEQ ID NO: 78; an antibody or antigen-binding fragment thereof comprising: a light chain variable region comprising a light chain LCDR1, an LCDR3, and an LCDR3 sequence, wherein the LCDR1 has the amino acid sequence of SEQ ID NO: 64, the LCDR2 has the amino acid sequence of SEQ ID NO: 65, and the LCDR3 has the amino acid sequence of SEQ ID NO:

79.

2. The antibody or antigen-binding fragment thereof of claim 1, wherein the heavy chain variable region comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO:

342.

3. The antibody or antigen-binding fragment thereof of claim 1, wherein the heavy chain variable region comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:

342.

4. The antibody or antigen-binding fragment thereof of claim 1, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:

342.

5. The antibody or antigen-binding fragment thereof of claim 1, wherein the heavy chain variable region comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO:

17.

6. The antibody or antigen-binding fragment thereof of claim 1, wherein the heavy chain variable region comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:

17.

7. The antibody or antigen-binding fragment thereof of claim 1, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:

17.

8. The antibody or antigen-binding fragment thereof of claim 1, wherein the heavy chain variable region comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO:

454.

9. The antibody or antigen-binding fragment thereof of claim 1, wherein the heavy chain variable region comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:

454.

10. The antibody or antigen-binding fragment thereof of claim 1, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO:

454.

11. The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody comprises a heavy chain that is at least 90% identical to the amino acid sequence of SEQ ID NO:

381.

12. The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody comprises a heavy chain that is at least 95% identical to the amino acid sequence of SEQ ID NO:

381.

13. The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody comprises a heavy chain having the amino acid sequence of SEQ ID NO:

381.

14. The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody comprises a heavy chain that is at least 90% identical to the amino acid sequence of SEQ ID NO:

185.

15. The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody comprises a heavy chain that is at least 95% identical to the amino acid sequence of SEQ ID NO:

185.

16. The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody comprises a heavy chain having the amino acid sequence of SEQ ID NO:

185.

17. The antibody or antigen-binding fragment thereof of any one of claims 1 to 16, wherein the light chain variable region comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO:

18.

18. The antibody or antigen-binding fragment thereof of any one of claims 1 to 16, wherein the light chain variable region comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:

18.

19. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 16, wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO:

18.

20. The antibody or antigen-binding fragment thereof of any one of claims 1 to 16, wherein the antibody comprises a light chain that is at least 90% identical to the amino acid sequence of SEQ ID NO:

236.

21. The antibody or antigen-binding fragment thereof of any one of claims 1 to 16, wherein the antibody comprises a light chain that is at least 95% identical to the amino acid sequence of SEQ ID NO:

236.

22. The antibody or antigen-binding fragment thereof of any one of claims 1 to 16, wherein the antibody comprises a heavy chain having the amino acid sequence of SEQ ID NO:

236.

23. 2. The antibody of claim 1, wherein the antibody or antigen-binding fragment thereof comprises a variable heavy chain region having the amino acid sequence of SEQ ID NO: 342 and a light chain variable region having the sequence of SEQ ID NO:

18.

24. 24. The antibody of claim 23, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain having the sequence of SEQ ID NO: 381 and a light chain having the sequence of SEQ ID NO:

236.

25. The antibody of claim 1, wherein the antibody or antigen-binding fragment thereof comprises a variable heavy chain region having the amino acid sequence of SEQ ID NO: 17 and a light chain variable region having the sequence of SEQ ID NO:

18.

26. 24. The antibody of claim 23, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain having the sequence of SEQ ID NO: 185 and a light chain having the sequence of SEQ ID NO:

236.

27. An antibody or antigen-binding fragment thereof, said antibody or antibody fragment comprising: (a) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has an amino acid sequence selected from SEQ ID NO: 61, SEQ ID NO: 124, or SEQ ID NO: 130; the heavy chain HCDR2 has the amino acid sequence of SEQ ID NO: 62, SEQ ID NO: 125, or SEQ ID NO: 131; and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO: 63 or SEQ ID NO: 132, or a variant or conventional equivalent of any one of the foregoing; and (ii) a light chain variable region comprising light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 has the amino acid sequence of SEQ ID NO: 64 or SEQ ID NO: 133; the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 65 or SEQ ID NO: 134; and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO: 66, or a variant or conventional equivalent of any one of the foregoing; (b) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO:61, SEQ ID NO:124, or SEQ ID NO:130, the heavy chain HCDR2 sequence has the amino acid sequence of SEQ ID NO:62, SEQ ID NO:125, or SEQ ID NO:131, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO:67 or SEQ ID NO:135, or a variant or conventional equivalent of any one of the foregoing; and (ii) a light chain variable region comprising light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 sequence has the amino acid sequence of SEQ ID NO:64 or SEQ ID NO:133, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO:65 or SEQ ID NO:134, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO:68, or a variant or conventional equivalent of any one of the foregoing; (c) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO:61, SEQ ID NO:124, or SEQ ID NO:130, the heavy chain HCDR2 sequence has the amino acid sequence of SEQ ID NO:62, SEQ ID NO:125, or SEQ ID NO:131, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO:69 or SEQ ID NO:136, or a variant or conventional equivalent of any one of the foregoing; and (ii) a light chain variable region comprising light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 sequence has the amino acid sequence of SEQ ID NO:64 or SEQ ID NO:133, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO:65 or SEQ ID NO:134, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO:68, or a variant or conventional equivalent of any one of the foregoing; (d) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO:61, SEQ ID NO:124, or SEQ ID NO:130, the heavy chain HCDR2 has the amino acid sequence of SEQ ID NO:62, SEQ ID NO:125, or SEQ ID NO:131, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO:70 or SEQ ID NO:137, or a variant or conventional equivalent of any one of the foregoing; and (ii) a light chain variable region comprising light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 sequence has the amino acid sequence of SEQ ID NO:64 or SEQ ID NO:133, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO:65 or SEQ ID NO:134, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO:71, or a variant or conventional equivalent of any one of the foregoing; (e) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO:61, SEQ ID NO:124, or SEQ ID NO:130, the heavy chain HCDR2 sequence has the amino acid sequence of SEQ ID NO:62, SEQ ID NO:125, or SEQ ID NO:131, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO:72 or SEQ ID NO:138, or a variant or conventional equivalent of any one of the foregoing; and (ii) a light chain variable region comprising light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 sequence has the amino acid sequence of SEQ ID NO:64 or SEQ ID NO:133, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO:65 or SEQ ID NO:134, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO:71, or a variant or conventional equivalent of any one of the foregoing; (f) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO:61, SEQ ID NO:124, or SEQ ID NO:130, the heavy chain HCDR2 sequence has the amino acid sequence of SEQ ID NO:62, SEQ ID NO:125, or SEQ ID NO:131, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO:73 or SEQ ID NO:139, or a variant or conventional equivalent of any one of the foregoing; and (ii) a light chain variable region comprising light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 has the amino acid sequence of SEQ ID NO:64 or SEQ ID NO:133, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO:65 or SEQ ID NO:134, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO:71, or a variant or conventional equivalent of any one of the foregoing; (g) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO:61, SEQ ID NO:124, or SEQ ID NO:130, the heavy chain HCDR2 sequence has the amino acid sequence of SEQ ID NO:62, SEQ ID NO:125, or SEQ ID NO:131, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO:74 or SEQ ID NO:140, or a variant or conventional equivalent of any one of the foregoing; and (ii) a light chain variable region comprising light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 has the amino acid sequence of SEQ ID NO:64 or SEQ ID NO:133, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO:65 or SEQ ID NO:134, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO:75, or a variant or conventional equivalent of any one of the foregoing; (h) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO:61, SEQ ID NO:124, or SEQ ID NO:130, the heavy chain HCDR2 sequence has the amino acid sequence of SEQ ID NO:62, SEQ ID NO:125, or SEQ ID NO:131, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO:76 or SEQ ID NO:141, or a variant or conventional equivalent of any one of the foregoing; and (ii) a light chain variable region comprising light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 has the amino acid sequence of SEQ ID NO:64 or SEQ ID NO:133, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO:65 or SEQ ID NO:134, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO:77, or a variant or conventional equivalent of any one of the foregoing; (i) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO:61, SEQ ID NO:124, or SEQ ID NO:130, the heavy chain HCDR2 sequence has the amino acid sequence of SEQ ID NO:62, SEQ ID NO:125, or SEQ ID NO:131, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO:78 or SEQ ID NO:142, or a variant or conventional equivalent of any one of the foregoing; and (ii) a light chain variable region comprising light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 sequence has the amino acid sequence of SEQ ID NO:64 or SEQ ID NO:133, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO:65 or SEQ ID NO:134, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO:79, or a variant or conventional equivalent of any one of the foregoing; (j) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO:61, SEQ ID NO:124, or SEQ ID NO:130, the heavy chain HCDR2 sequence has the amino acid sequence of SEQ ID NO:62, SEQ ID NO:125, or SEQ ID NO:131, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO:80 or SEQ ID NO:143, or a variant or conventional equivalent of any one of the foregoing; and (ii) a light chain variable region comprising light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 has the amino acid sequence of SEQ ID NO:64 or SEQ ID NO:133, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO:65 or SEQ ID NO:134, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO:81, or a variant or conventional equivalent of any one of the foregoing; (k) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO:82, SEQ ID NO:126, or SEQ ID NO:144, the heavy chain HCDR2 sequence has the amino acid sequence of SEQ ID NO:83, SEQ ID NO:127, or SEQ ID NO:145, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO:84 or SEQ ID NO:146, or a variant or conventional equivalent of any one of the foregoing; and (ii) a light chain variable region comprising light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 sequence has the amino acid sequence of SEQ ID NO:85 or SEQ ID NO:147, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO:86 or SEQ ID NO:148, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO:87, or a variant or conventional equivalent of any one of the foregoing; (l) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO:82, SEQ ID NO:126, or SEQ ID NO:144, the heavy chain HCDR2 sequence has the amino acid sequence of SEQ ID NO:83, SEQ ID NO:127, or SEQ ID NO:145, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO:88 or SEQ ID NO:149, or a variant or conventional equivalent of any one of the foregoing; and (ii) a light chain variable region comprising light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 sequence has the amino acid sequence of SEQ ID NO:85 or SEQ ID NO:147, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO:86 or SEQ ID NO:148, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO:89, or a variant or conventional equivalent of any one of the foregoing; (m) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO:82, SEQ ID NO:126, or SEQ ID NO:144, the heavy chain HCDR2 has the amino acid sequence of SEQ ID NO:83, SEQ ID NO:127, or SEQ ID NO:145, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO:90 or SEQ ID NO:150, or a variant or conventional equivalent of any one of the foregoing; and (ii) a light chain variable region comprising light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 has the amino acid sequence of SEQ ID NO:85 or SEQ ID NO:147, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO:86 or SEQ ID NO:148, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO:89, or a variant or conventional equivalent of any one of the foregoing; (n) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO:82, SEQ ID NO:126, or SEQ ID NO:144, the heavy chain HCDR2 has the amino acid sequence of SEQ ID NO:83, SEQ ID NO:127, or SEQ ID NO:145, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO:91 or SEQ ID NO:151, or a variant or conventional equivalent of any one of the foregoing; and (ii) a light chain variable region comprising light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 sequence has the amino acid sequence of SEQ ID NO:85 or SEQ ID NO:147, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO:86 or SEQ ID NO:148, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO:92, or a variant or conventional equivalent of any one of the foregoing; (o) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO:82, SEQ ID NO:126, or SEQ ID NO:144, the heavy chain HCDR2 sequence has the amino acid sequence of SEQ ID NO:83, SEQ ID NO:127, or SEQ ID NO:145, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO:93 or SEQ ID NO:152, or a variant or conventional equivalent of any one of the foregoing; and (ii) a light chain variable region comprising light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 sequence has the amino acid sequence of SEQ ID NO:85 or SEQ ID NO:147, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO:86 or SEQ ID NO:148, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO:94, or a variant or conventional equivalent of any one of the foregoing; (p) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO:82, SEQ ID NO:126, or SEQ ID NO:144, the heavy chain HCDR2 sequence has the amino acid sequence of SEQ ID NO:83, SEQ ID NO:127, or SEQ ID NO:145, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO:84 or SEQ ID NO:146, or a variant or conventional equivalent of any one of the foregoing; and (ii) a light chain variable region comprising light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 sequence has the amino acid sequence of SEQ ID NO:85 or SEQ ID NO:147, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO:86 or SEQ ID NO:148, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO:95, or a variant or conventional equivalent of any one of the foregoing; (q) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO:82, SEQ ID NO:126, or SEQ ID NO:144, the heavy chain HCDR2 sequence has the amino acid sequence of SEQ ID NO:83, SEQ ID NO:127, or SEQ ID NO:145, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO:96 or SEQ ID NO:153, or a variant or conventional equivalent of any one of the foregoing; and (ii) a light chain variable region comprising light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 sequence has the amino acid sequence of SEQ ID NO:85 or SEQ ID NO:147, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO:86 or SEQ ID NO:148, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO:97, or a variant or conventional equivalent of any one of the foregoing; (r) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO:82, SEQ ID NO:126, or SEQ ID NO:144, the heavy chain HCDR2 sequence has the amino acid sequence of SEQ ID NO:83, SEQ ID NO:127, or SEQ ID NO:145, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO:98 or SEQ ID NO:154, or a variant or conventional equivalent of any one of the foregoing; and (ii) a light chain variable region comprising light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 sequence has the amino acid sequence of SEQ ID NO:85 or SEQ ID NO:147, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO:86 or SEQ ID NO:148, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO:99, or a variant or conventional equivalent of any one of the foregoing; (s) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO:82, SEQ ID NO:126, or SEQ ID NO:144, the heavy chain HCDR2 sequence has the amino acid sequence of SEQ ID NO:83, SEQ ID NO:127, or SEQ ID NO:145, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO:100 or SEQ ID NO:155, or a variant or conventional equivalent of any one of the foregoing; and (ii) a light chain variable region comprising light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 sequence has the amino acid sequence of SEQ ID NO:85 or SEQ ID NO:147, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO:86 or SEQ ID NO:148, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO:101, or a variant or conventional equivalent of any one of the foregoing; (t) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO:82, SEQ ID NO:126, or SEQ ID NO:144, the heavy chain HCDR2 has the amino acid sequence of SEQ ID NO:83, SEQ ID NO:127, or SEQ ID NO:145, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO:100 or SEQ ID NO:155, or a variant or conventional equivalent of any one of the foregoing; and (ii) a light chain variable region comprising light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 sequence has the amino acid sequence of SEQ ID NO:85 or SEQ ID NO:147, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO:86 or SEQ ID NO:148, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO:102, or a variant or conventional equivalent of any one of the foregoing; (u) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO: 103, SEQ ID NO: 128, or SEQ ID NO: 156; the heavy chain HCDR2 has the amino acid sequence of SEQ ID NO: 104, SEQ ID NO: 129, or SEQ ID NO: 157; and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO: 105 or SEQ ID NO: 158, or a variant or conventional equivalent of any one of the foregoing. and (ii) a light chain variable region comprising light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 sequence has the amino acid sequence of SEQ ID NO: 106 or SEQ ID NO: 159, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 107 or SEQ ID NO: 160, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO: 108, or a variant or conventional equivalent of any one of the foregoing; (v) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO: 103, SEQ ID NO: 128, or SEQ ID NO: 156, the heavy chain HCDR2 sequence has the amino acid sequence of SEQ ID NO: 104, SEQ ID NO: 129, or SEQ ID NO: 157, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO: 109 or SEQ ID NO: 161, or a variant or conventional equivalent of any one of the foregoing; and (ii) a light chain variable region comprising light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 sequence has the amino acid sequence of SEQ ID NO: 106 or SEQ ID NO: 159, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 107 or SEQ ID NO: 160, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO: 110, or a variant or conventional equivalent of any one of the foregoing; (w) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO: 103, SEQ ID NO: 128, or SEQ ID NO: 156, the heavy chain HCDR2 sequence has the amino acid sequence of SEQ ID NO: 104, SEQ ID NO: 129, or SEQ ID NO: 157, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO: 111 or SEQ ID NO: 162, or a variant or conventional equivalent of any one of the foregoing; and (ii) a light chain variable region comprising light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 sequence has the amino acid sequence of SEQ ID NO: 106 or SEQ ID NO: 159, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 107 or SEQ ID NO: 160, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO: 112, or a variant or conventional equivalent of any one of the foregoing; (x) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO: 103, SEQ ID NO: 128, or SEQ ID NO: 156, the heavy chain HCDR2 sequence has the amino acid sequence of SEQ ID NO: 104, SEQ ID NO: 129, or SEQ ID NO: 157, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO: 105 or SEQ ID NO: 158, or a variant or conventional equivalent of any one of the foregoing; and (ii) a light chain variable region comprising light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 sequence has the amino acid sequence of SEQ ID NO: 106 or SEQ ID NO: 159, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 107 or SEQ ID NO: 160, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO: 113, or a variant or conventional equivalent of any one of the foregoing; (y) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO: 103, SEQ ID NO: 128, or SEQ ID NO: 156, the heavy chain HCDR2 sequence has the amino acid sequence of SEQ ID NO: 104, SEQ ID NO: 129, or SEQ ID NO: 157, and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO: 114 or SEQ ID NO: 163, or a variant or conventional equivalent of any one of the foregoing; and (ii) a light chain variable region comprising light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 has the amino acid sequence of SEQ ID NO: 106 or SEQ ID NO: 159, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 107 or SEQ ID NO: 160, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO: 115, or a variant or conventional equivalent of any one of the foregoing; (z) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO: 103, SEQ ID NO: 128, or SEQ ID NO: 156; the heavy chain HCDR2 has the amino acid sequence of SEQ ID NO: 104, SEQ ID NO: 129, or SEQ ID NO: 157; and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO: 116 or SEQ ID NO: 164, or a variant or conventional equivalent of any one of the foregoing. and (ii) a light chain variable region comprising light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 sequence has the amino acid sequence of SEQ ID NO: 106 or SEQ ID NO: 159, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 107 or SEQ ID NO: 160, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO: 113, or a variant or conventional equivalent of any one of the foregoing; (aa) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO: 103, SEQ ID NO: 128, or SEQ ID NO: 156; the heavy chain HCDR2 has the amino acid sequence of SEQ ID NO: 104, SEQ ID NO: 129, or SEQ ID NO: 157; and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO: 117 or SEQ ID NO: 165, or a variant or conventional equivalent of any one of the foregoing. and (ii) a light chain variable region comprising light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 sequence has the amino acid sequence of SEQ ID NO: 106 or SEQ ID NO: 159, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 107 or SEQ ID NO: 160, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO: 118, or a variant or conventional equivalent of any one of the foregoing; (ab) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO: 103, SEQ ID NO: 128, or SEQ ID NO: 156; the heavy chain HCDR2 has the amino acid sequence of SEQ ID NO: 104, SEQ ID NO: 129, or SEQ ID NO: 157; and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO: 116 or SEQ ID NO: 164, or a variant or conventional equivalent of any one of the foregoing. and (ii) a light chain variable region comprising light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 has the amino acid sequence of SEQ ID NO: 106 or SEQ ID NO: 159, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 107 or SEQ ID NO: 160, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO: 119, or a variant or conventional equivalent of any one of the foregoing; (ac) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO: 103, SEQ ID NO: 128, or SEQ ID NO: 156; the heavy chain HCDR2 has the amino acid sequence of SEQ ID NO: 104, SEQ ID NO: 129, or SEQ ID NO: 157; and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO: 120 or SEQ ID NO: 166, or a variant or conventional equivalent of any one of the foregoing. and (ii) a light chain variable region comprising light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 has the amino acid sequence of SEQ ID NO: 106 or SEQ ID NO: 159, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 107 or SEQ ID NO: 160, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO: 121, or a variant or conventional equivalent of any one of the foregoing; (ad) a heavy chain variable region comprising heavy chain HCDR1, HCDR2, and HCDR3 sequences, wherein the heavy chain HCDR1 sequence has the amino acid sequence of SEQ ID NO: 103, SEQ ID NO: 128, or SEQ ID NO: 156; the heavy chain HCDR2 has the amino acid sequence of SEQ ID NO: 104, SEQ ID NO: 129, or SEQ ID NO: 157; and the heavy chain HCDR3 sequence has the amino acid sequence of SEQ ID NO: 122 or SEQ ID NO: 167, or a variant or conventional equivalent of any one of the foregoing. and (ii) a light chain variable region comprising light chain LCDR1, LCDR2, and LCDR3 sequences, wherein the light chain LCDR1 has the amino acid sequence of SEQ ID NO: 106 or SEQ ID NO: 159, the light chain LCDR2 sequence has the amino acid sequence of SEQ ID NO: 107 or SEQ ID NO: 160, and the light chain LCDR3 sequence has the amino acid sequence of SEQ ID NO: 123, or a variant or conventional equivalent of any one of the foregoing.

28. The antibody or antigen-binding fragment thereof (a) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO:2 and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO:1, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart a of claim 1; or (b) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO:4 and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO:3, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart b of claim 1; or (c) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO:6 and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO:5, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart c of claim 1; or (d) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO:8 and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO:7, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart d of claim 1; or (e) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 10, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 9, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart e of claim 1; or (f) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 12 and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 11, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart f of claim 1; or (g) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 14, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 13, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart g of claim 1; or (h) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 16, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 15, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart h of claim 1; or (i) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 18, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 17, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart i of claim 1; or (j) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO:20, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO:19, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart j of claim 1; or (k) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 22 and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 21, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart k of claim 1; or (l) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO:24, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO:23, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart l of claim 1; or (m) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO:26, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO:25, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart m of claim 1; or (n) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO:28, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO:27, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart n of claim 1; or (o) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 30, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 29, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart o of claim 1; or (p) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 32, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 31, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart p of claim 1; or (q) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 34, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 33, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart q of claim 1; or (r) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 36, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 35, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart r of claim 1; or (s) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 38, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 37, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart s of claim 1; or (t) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO:40, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO:39, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart t of claim 1; or (u) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 42, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 41, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart u of claim 1; or (v) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 44, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 43, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart v of claim 1; or (w) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 46, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 45, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart w of claim 1; or (x) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 48, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 47, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart x of claim 1; or (y) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 50, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 49, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 according to subpart y of claim 1; or (z) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 52, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 51, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart z of claim 1; or (aa) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 54, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 53, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart ab of claim 1; or (ab) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 56, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 55, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart ac of claim 1; or (ac) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 58, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 57, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart ad of claim 1; or (ad) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 60, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 59, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart ae of claim 1; or (ae) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO:2 and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO:334, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart a of claim 1; or (af) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO:4, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO:335, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart b of claim 1; or (ag) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO:6 and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO:336, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart c of claim 1; or (ah) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO:8 and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO:337, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart d of claim 1; or (ai) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 10, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 338, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart e of claim 1; or (aj) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 12 and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 339, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart f of claim 1; or (ak) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 14, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 340, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart g of claim 1; or (a1) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 16, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 341, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart h of claim 1; or (am) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 18, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 342, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 according to subpart i of claim 1; or (an) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO:20, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO:343, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart j of claim 1; or (ao) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 22 and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 344, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart k of claim 1; or (ap) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO:24 and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO:345, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 according to subpart 1 of claim 1; or (aq) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO:26, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO:346, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart m of claim 1; or (ar) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO:28 and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO:347, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart n of claim 1; or (as) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 30, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 348, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart o of claim 1; or (at) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 32, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 349, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart p of claim 1; or (au) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 34, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 350, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart q of claim 1; or (av) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 36, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 351, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart r of claim 1; or (aw) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 38, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 352, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart s of claim 1; or (ax) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 40, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 353, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 according to subpart t of claim 1; or (ay) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 42, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 354, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart u of claim 1; or (az) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 44, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 355, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart v of claim 1; or (ba) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 46, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 356, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart w of claim 1; or (bb) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO:48, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO:357, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart x of claim 1; or (bc) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 50, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 358, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart y of claim 1; or (bd) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 52, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 359, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart z of claim 1; or (be) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 54, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 360, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart ab of claim 1; or (bf) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 56, and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 361, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart ac of claim 1; or (bg) a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO:58 and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO:362, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart ad of claim 1; or (bh) The antibody or antigen-binding fragment thereof of claim 26, comprising a light chain variable region of the light chain having at least 90% sequence identity to SEQ ID NO: 60 and a heavy chain variable region of the heavy chain having at least 90% sequence identity to SEQ ID NO: 363, wherein the antibody or antigen-binding fragment thereof maintains the sequences of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 set forth in subpart ae of claim 1.

29. (a) the light chain variable region comprises SEQ ID NO:2 and the heavy chain variable region comprises SEQ ID NO:1; (b) the light chain variable region comprises SEQ ID NO:4 and the heavy chain variable region comprises SEQ ID NO:3; (c) the light chain variable region comprises SEQ ID NO: 6 and the heavy chain variable region comprises SEQ ID NO: 5; (d) the light chain variable region comprises SEQ ID NO: 8 and the heavy chain variable region comprises SEQ ID NO: 7; (e) the light chain variable region comprises SEQ ID NO: 10 and the heavy chain variable region comprises SEQ ID NO: 9; (f) the light chain variable region comprises SEQ ID NO: 12 and the heavy chain variable region comprises SEQ ID NO: 11; (g) the light chain variable region comprises SEQ ID NO: 14 and the heavy chain variable region comprises SEQ ID NO: 13; (h) the light chain variable region comprises SEQ ID NO: 16 and the heavy chain variable region comprises SEQ ID NO: 15; (i) the light chain variable region comprises SEQ ID NO: 18 and the heavy chain variable region comprises SEQ ID NO: 17; (j) the light chain variable region comprises SEQ ID NO: 20 and the heavy chain variable region comprises SEQ ID NO: 19; (k) the light chain variable region comprises SEQ ID NO: 22 and the heavy chain variable region comprises SEQ ID NO: 21; (l) the light chain variable region comprises SEQ ID NO: 24 and the heavy chain variable region comprises SEQ ID NO: 23; (m) the light chain variable region comprises SEQ ID NO: 26 and the heavy chain variable region comprises SEQ ID NO: 25; (n) the light chain variable region comprises SEQ ID NO: 28 and the heavy chain variable region comprises SEQ ID NO: 27; (o) the light chain variable region comprises SEQ ID NO: 30 and the heavy chain variable region comprises SEQ ID NO: 29; (p) the light chain variable region comprises SEQ ID NO: 32 and the heavy chain variable region comprises SEQ ID NO: 31; (q) the light chain variable region comprises SEQ ID NO: 34 and the heavy chain variable region comprises SEQ ID NO: 33; (r) the light chain variable region comprises SEQ ID NO: 36 and the heavy chain variable region comprises SEQ ID NO: 35; (s) the light chain variable region comprises SEQ ID NO: 38 and the heavy chain variable region comprises SEQ ID NO: 37; (t) the light chain variable region comprises SEQ ID NO: 40 and the heavy chain variable region comprises SEQ ID NO: 39; (u) the light chain variable region comprises SEQ ID NO: 42 and the heavy chain variable region comprises SEQ ID NO: 41; (v) the light chain variable region comprises SEQ ID NO: 44 and the heavy chain variable region comprises SEQ ID NO: 43; (w) the light chain variable region comprises SEQ ID NO: 46 and the heavy chain variable region comprises SEQ ID NO: 45; (x) the light chain variable region comprises SEQ ID NO: 48 and the heavy chain variable region comprises SEQ ID NO: 47; (y) the light chain variable region comprises SEQ ID NO: 50 and the heavy chain variable region comprises SEQ ID NO: 49; (z) the light chain variable region comprises SEQ ID NO: 52 and the heavy chain variable region comprises SEQ ID NO: 51; (aa) the light chain variable region comprises SEQ ID NO: 54 and the heavy chain variable region comprises SEQ ID NO: 53; (ab) the light chain variable region comprises SEQ ID NO: 56 and the heavy chain variable region comprises SEQ ID NO: 55; (ac) the light chain variable region comprises SEQ ID NO: 58 and the heavy chain variable region comprises SEQ ID NO: 57; (ad) the light chain variable region comprises SEQ ID NO: 60 and the heavy chain variable region comprises SEQ ID NO: 59; or (ae) the light chain variable region comprises SEQ ID NO: 2 and the heavy chain variable region comprises SEQ ID NO: 334; (af) the light chain variable region comprises SEQ ID NO: 4 and the heavy chain variable region comprises SEQ ID NO: 335; (ag) the light chain variable region comprises SEQ ID NO: 6 and the heavy chain variable region comprises SEQ ID NO: 336; (ah) the light chain variable region comprises SEQ ID NO: 8 and the heavy chain variable region comprises SEQ ID NO: 337; (ai) the light chain variable region comprises SEQ ID NO: 10 and the heavy chain variable region comprises SEQ ID NO: 338; (aj) the light chain variable region comprises SEQ ID NO: 12 and the heavy chain variable region comprises SEQ ID NO: 339; (ak) the light chain variable region comprises SEQ ID NO: 14 and the heavy chain variable region comprises SEQ ID NO: 340; (a1) the light chain variable region comprises SEQ ID NO: 16 and the heavy chain variable region comprises SEQ ID NO: 341; (am) the light chain variable region comprises SEQ ID NO: 18 and the heavy chain variable region comprises SEQ ID NO: 342; (an) the light chain variable region comprises SEQ ID NO: 20 and the heavy chain variable region comprises SEQ ID NO: 343; (ao) the light chain variable region comprises SEQ ID NO: 22 and the heavy chain variable region comprises SEQ ID NO: 344; (ap) the light chain variable region comprises SEQ ID NO: 24 and the heavy chain variable region comprises SEQ ID NO: 345; (aq) the light chain variable region comprises SEQ ID NO: 26 and the heavy chain variable region comprises SEQ ID NO: 346; (ar) the light chain variable region comprises SEQ ID NO: 28 and the heavy chain variable region comprises SEQ ID NO: 347; (as) the light chain variable region comprises SEQ ID NO: 30 and the heavy chain variable region comprises SEQ ID NO: 348; (at) the light chain variable region comprises SEQ ID NO: 32 and the heavy chain variable region comprises SEQ ID NO: 349; (au) the light chain variable region comprises SEQ ID NO: 34 and the heavy chain variable region comprises SEQ ID NO: 350; (av) the light chain variable region comprises SEQ ID NO: 36 and the heavy chain variable region comprises SEQ ID NO: 351; (aw) the light chain variable region comprises SEQ ID NO: 38 and the heavy chain variable region comprises SEQ ID NO: 352; (ax) the light chain variable region comprises SEQ ID NO: 40 and the heavy chain variable region comprises SEQ ID NO: 353; (ay) the light chain variable region comprises SEQ ID NO: 42 and the heavy chain variable region comprises SEQ ID NO: 354; (az) the light chain variable region comprises SEQ ID NO: 44 and the heavy chain variable region comprises SEQ ID NO: 355; (ba) the light chain variable region comprises SEQ ID NO: 46 and the heavy chain variable region comprises SEQ ID NO: 356; (bb) the light chain variable region comprises SEQ ID NO: 48 and the heavy chain variable region comprises SEQ ID NO: 357; (bc) the light chain variable region comprises SEQ ID NO: 50 and the heavy chain variable region comprises SEQ ID NO: 358; (bd) the light chain variable region comprises SEQ ID NO: 52 and the heavy chain variable region comprises SEQ ID NO: 359; (be) the light chain variable region comprises SEQ ID NO: 54 and the heavy chain variable region comprises SEQ ID NO: 360; (bf) the light chain variable region comprises SEQ ID NO: 56 and the heavy chain variable region comprises SEQ ID NO: 361; (bg) the light chain variable region comprises SEQ ID NO: 58 and the heavy chain variable region comprises SEQ ID NO: 362; or (bh) The antibody or antigen-binding fragment thereof of claim 28, wherein the light chain variable region comprises SEQ ID NO: 60 and the heavy chain variable region comprises SEQ ID NO:

363.

30. (a) the light chain comprises SEQ ID NO: 228 and the heavy chain comprises SEQ ID NO: 168 or SEQ ID NO: 169; or (b) the light chain comprises SEQ ID NO: 229 and the heavy chain comprises SEQ ID NO: 170 or SEQ ID NO: 171; or (c) the light chain comprises SEQ ID NO: 230 and the heavy chain comprises SEQ ID NO: 172 or SEQ ID NO: 173; or (d) the light chain comprises SEQ ID NO: 231 and the heavy chain comprises SEQ ID NO: 174 or SEQ ID NO: 175; or (e) the light chain comprises SEQ ID NO: 232 and the heavy chain comprises SEQ ID NO: 176 or SEQ ID NO: 177; or (f) the light chain comprises SEQ ID NO: 233 and the heavy chain comprises SEQ ID NO: 178 or SEQ ID NO: 179; or (g) the light chain comprises SEQ ID NO: 234 and the heavy chain comprises SEQ ID NO: 180 or SEQ ID NO: 181; or (h) the light chain comprises SEQ ID NO: 235 and the heavy chain comprises SEQ ID NO: 182 or SEQ ID NO: 183; or (i) the light chain comprises SEQ ID NO: 236 and the heavy chain comprises SEQ ID NO: 184 or SEQ ID NO: 185; or (j) the light chain comprises SEQ ID NO: 237 and the heavy chain comprises SEQ ID NO: 186 or SEQ ID NO: 187; or (k) the light chain comprises SEQ ID NO: 238 and the heavy chain comprises SEQ ID NO: 188 or SEQ ID NO: 189; or (l) the light chain comprises SEQ ID NO: 239 and the heavy chain comprises SEQ ID NO: 190 or SEQ ID NO: 191; or (m) the light chain comprises SEQ ID NO: 240 and the heavy chain comprises SEQ ID NO: 192 or SEQ ID NO: 193; or (n) the light chain comprises SEQ ID NO: 241 and the heavy chain comprises SEQ ID NO: 194 or SEQ ID NO: 195; or (o) the light chain comprises SEQ ID NO: 242 and the heavy chain comprises SEQ ID NO: 196 or SEQ ID NO: 197; or (p) the light chain comprises SEQ ID NO: 243 and the heavy chain comprises SEQ ID NO: 198 or SEQ ID NO: 199; or (q) the light chain comprises SEQ ID NO: 244 and the heavy chain comprises SEQ ID NO: 200 or SEQ ID NO: 201; or (r) the light chain comprises SEQ ID NO: 245 and the heavy chain comprises SEQ ID NO: 202 or SEQ ID NO: 203; or (s) the light chain comprises SEQ ID NO: 246 and the heavy chain comprises SEQ ID NO: 204 or SEQ ID NO: 205; or (t) the light chain comprises SEQ ID NO: 247 and the heavy chain comprises SEQ ID NO: 206 or SEQ ID NO: 207; or (u) the light chain comprises SEQ ID NO: 248 and the heavy chain comprises SEQ ID NO: 208 or SEQ ID NO: 209; or (v) the light chain comprises SEQ ID NO: 249 and the heavy chain comprises SEQ ID NO: 210 or SEQ ID NO: 211; or (w) the light chain comprises SEQ ID NO: 250 and the heavy chain comprises SEQ ID NO: 212 or SEQ ID NO: 213; or (x) the light chain comprises SEQ ID NO: 251 and the heavy chain comprises SEQ ID NO: 214 or SEQ ID NO: 215; or (y) the light chain comprises SEQ ID NO: 252 and the heavy chain comprises SEQ ID NO: 216 or SEQ ID NO: 217; or (z) the light chain comprises SEQ ID NO: 253 and the heavy chain comprises SEQ ID NO: 218 or SEQ ID NO: 219; or (aa) the light chain comprises SEQ ID NO: 254 and the heavy chain comprises SEQ ID NO: 220 or SEQ ID NO: 221; or (ab) the light chain comprises SEQ ID NO: 255 and the heavy chain comprises SEQ ID NO: 222 or SEQ ID NO: 223; or (ac) the light chain comprises SEQ ID NO: 256 and the heavy chain comprises SEQ ID NO: 224 or SEQ ID NO: 225; or (ad) the light chain comprises SEQ ID NO: 257 and the heavy chain comprises SEQ ID NO: 226 or SEQ ID NO: 227; or (ae) the light chain comprises SEQ ID NO: 228 and the heavy chain comprises SEQ ID NO: 364 or SEQ ID NO: 365; or (af) the light chain comprises SEQ ID NO: 229 and the heavy chain comprises SEQ ID NO: 366 or SEQ ID NO: 367; or (ag) the light chain comprises SEQ ID NO: 230 and the heavy chain comprises SEQ ID NO: 368 or SEQ ID NO: 369; or (ah) the light chain comprises SEQ ID NO: 231 and the heavy chain comprises SEQ ID NO: 370 or SEQ ID NO: 371; or (ai) the light chain comprises SEQ ID NO: 232 and the heavy chain comprises SEQ ID NO: 372 or SEQ ID NO: 373; or (aj) the light chain comprises SEQ ID NO: 233 and the heavy chain comprises SEQ ID NO: 374 or SEQ ID NO: 375; or (ak) the light chain comprises SEQ ID NO: 234 and the heavy chain comprises SEQ ID NO: 376 or SEQ ID NO: 377; or (a1) the light chain comprises SEQ ID NO: 235 and the heavy chain comprises SEQ ID NO: 378 or SEQ ID NO: 379; or (am) the light chain comprises SEQ ID NO: 236 and the heavy chain comprises SEQ ID NO: 380 or SEQ ID NO: 381; or (an) the light chain comprises SEQ ID NO: 237 and the heavy chain comprises SEQ ID NO: 382 or SEQ ID NO: 383; or (ao) the light chain comprises SEQ ID NO: 238 and the heavy chain comprises SEQ ID NO: 384 or SEQ ID NO: 385; or (ap) the light chain comprises SEQ ID NO: 239 and the heavy chain comprises SEQ ID NO: 386 or SEQ ID NO: 387; or (aq) the light chain comprises SEQ ID NO: 240 and the heavy chain comprises SEQ ID NO: 388 or SEQ ID NO: 389; or (ar) the light chain comprises SEQ ID NO: 241 and the heavy chain comprises SEQ ID NO: 390 or SEQ ID NO: 391; or (as) the light chain comprises SEQ ID NO: 242 and the heavy chain comprises SEQ ID NO: 392 or SEQ ID NO: 393; or (at) the light chain comprises SEQ ID NO: 243 and the heavy chain comprises SEQ ID NO: 394 or SEQ ID NO: 395; or (au) the light chain comprises SEQ ID NO: 244 and the heavy chain comprises SEQ ID NO: 396 or SEQ ID NO: 397; or (av) the light chain comprises SEQ ID NO: 245 and the heavy chain comprises SEQ ID NO: 398 or SEQ ID NO: 399; or (aw) the light chain comprises SEQ ID NO: 246 and the heavy chain comprises SEQ ID NO: 400 or SEQ ID NO: 401; or (ax) the light chain comprises SEQ ID NO: 247 and the heavy chain comprises SEQ ID NO: 402 or SEQ ID NO: 403; or (ay) the light chain comprises SEQ ID NO: 248 and the heavy chain comprises SEQ ID NO: 404 or SEQ ID NO: 405; or (az) the light chain comprises SEQ ID NO: 249 and the heavy chain comprises SEQ ID NO: 406 or SEQ ID NO: 407; or (ba) the light chain comprises SEQ ID NO: 250 and the heavy chain comprises SEQ ID NO: 408 or SEQ ID NO: 409; or (bb) the light chain comprises SEQ ID NO: 251 and the heavy chain comprises SEQ ID NO: 410 or SEQ ID NO: 411; or (bc) the light chain comprises SEQ ID NO: 252 and the heavy chain comprises SEQ ID NO: 412 or SEQ ID NO: 413; or (bd) the light chain comprises SEQ ID NO: 253 and the heavy chain comprises SEQ ID NO: 414 or SEQ ID NO: 415; or (be) the light chain comprises SEQ ID NO: 254 and the heavy chain comprises SEQ ID NO: 416 or SEQ ID NO: 417; or (bf) the light chain comprises SEQ ID NO: 255 and the heavy chain comprises SEQ ID NO: 418 or SEQ ID NO: 419; or (bg) the light chain comprises SEQ ID NO: 256 and the heavy chain comprises SEQ ID NO: 420 or SEQ ID NO: 421; or (bh) The antibody or antigen-binding fragment thereof of claim 29, wherein the light chain comprises SEQ ID NO: 257 and the heavy chain comprises SEQ ID NO: 422 or SEQ ID NO:

423.

31. The antibody HCDR1 of SEQ ID NO: 61, HCDR2 of SEQ ID NO: 62, and DX １０ X １１ X １２ YX １３ X １４ DX １５ (SEQ ID NO: 329), wherein X １０ is E, Q, or N, and X １１ is T, E, S, or N, and X １２ is D or Q, and X １３ is A or G, and X １４ is L, W, F, or Y, and X １５ is Y, E, L, N, F, or W; and LCDR1 of SEQ ID NO: 64, LCDR2 of SEQ ID NO: 65, and X １６ X １７ X １８ EDX １９ X ２０ X ２１ X ２２ (SEQ ID NO: 328), wherein X １６ is Q, E, K, or H, and X １７ is Q or H, and X １８ is Y or H, and X １９ is L or Y, and X ２０ is P or I, and X ２１ is L or P, and X ２２ and a variable light chain, wherein is T or V.

32. An isolated nucleic acid molecule encoding the antibody or antigen-binding fragment thereof, heavy chain variable region, light chain variable region, heavy chain, or light chain of any one of the preceding claims.

33. 33. An expression vector comprising the nucleic acid molecule of claim 32.

34. 34. A host cell comprising the nucleic acid molecule of claim 32 or the vector of claim 33.

35. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof according to any one of claims 1 to 17 and a pharmaceutically acceptable excipient.

36. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of claim 18 and a pharmaceutically acceptable excipient.

37. 20. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of claim 19 and a pharmaceutically acceptable excipient.

38. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof according to any one of claims 20 to 31 and a pharmaceutically acceptable excipient.

39. The pharmaceutical composition of any one of claims 35 to 38, wherein the composition is formulated for intravenous or subcutaneous injection.

40. 1. A method for producing a polypeptide comprising a heavy chain variable region or a light chain variable region, comprising: (a) growing the host cell of claim 34 under conditions such that the host cell expresses the polypeptide comprising the heavy chain variable region or the light chain variable region; (b) purifying the polypeptide comprising the heavy chain variable region and / or the light chain variable region.

41. 20. A method of treating a subject having a C1s-mediated disorder, comprising administering to the subject an antibody or antigen-binding fragment thereof according to any one of claims 1 to 17, or a pharmaceutical composition comprising said antibody or antigen-binding fragment thereof.

42. 32. A method of treating a subject having a C1s-mediated disorder, comprising administering to the subject an antibody or antigen-binding fragment thereof according to any one of claims 18 to 31, or a pharmaceutical composition comprising said antibody or antigen-binding fragment thereof.

43. 43. The method of claim 41 or 42, wherein the disorder is myasthenia gravis, hemolysis, cold agglutinin disease, immune thrombocytopenia (ITP), glomerulopathy, atypical hemolytic uremic syndrome, antiphospholipid syndrome, graft rejection, chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN), dermatomyositis, or anti-MAG neuropathy.

44. 20. A method of treating a subject having myasthenia gravis or cold agglutinin disease, comprising administering to the subject an antibody or antigen-binding fragment thereof according to any one of claims 1 to 17, or a pharmaceutical composition comprising said antibody or antigen-binding fragment thereof.

45. 45. The method of claim 44, wherein the antibody or antigen-binding fragment thereof comprises a variable heavy chain region having the amino acid sequence of SEQ ID NO: 342 and a light chain variable region having the sequence of SEQ ID NO:

18.

46. 46. ​​The method of claim 45, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain having the sequence of SEQ ID NO: 381 and a light chain having the sequence of SEQ ID NO:

236.

47. 32. A method of inhibiting membrane attack complex (MAC) formation or deposition in a subject in need thereof (such as a patient with myasthenia gravis), comprising administering to the subject an antibody or antigen-binding fragment thereof according to any one of claims 1 to 31, or a pharmaceutical composition comprising said antibody or antigen-binding fragment thereof.

48. 32. A method of inhibiting or preventing impaired neurotransmission in a subject in need thereof (such as a patient with myasthenia gravis), the method comprising administering to the subject an antibody or antigen-binding fragment thereof according to any one of claims 1 to 31, or a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof.

49. 32. A method of enhancing, tolerating or permitting muscle contractions in a subject in need thereof (such as a patient with myasthenia gravis), the method comprising administering to the subject an antibody or antigen-binding fragment thereof according to any one of claims 1 to 31, or a pharmaceutical composition comprising said antibody or antigen-binding fragment thereof.

50. 32. A method of ameliorating or alleviating muscle paralysis in a subject in need thereof (such as a patient with myasthenia gravis), comprising administering to the subject an antibody or antigen-binding fragment thereof according to claims 1 to 31, or a pharmaceutical composition comprising said antibody or antigen-binding fragment thereof.

51. 32. A method of inhibiting loss of muscle tone or muscle mass in a subject in need thereof (such as a patient with myasthenia gravis), comprising administering to the subject an antibody or antigen-binding fragment thereof of any one of claims 1 to 31, or a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof.

52. 32. A method of reducing a muscle fatigue index in a subject in need thereof (such as a patient with myasthenia gravis), comprising administering to the subject an antibody or antigen-binding fragment thereof according to any one of claims 1 to 31, or a pharmaceutical composition comprising said antibody or antigen-binding fragment thereof.

Images